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1
CHAPTER I
I.

INTRODUCTION AND MOTIVATION

1.1. Introduction
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the
world [1]. Oxidative stress and endothelial dysfunction are reported as hallmarks for onset and
progression of CVD such as diabetes, atherosclerosis, hypertension, etc [2-5]. Endothelial
dysfunction is integral to the pathogenesis of CVDs and is mainly characterized by limited
bioavailability of nitric oxide (NO) [6]. Increase in the levels of reactive oxygen (ROS) and
nitrogen species (RNS) occur in oxidative stress [7]. ROS and RNS directly inactivate NO, act as
signaling molecules and promote protein dysfunction. Such events contribute to the initiation and
progression of endothelial dysfunction [8]. Further, in oxidative stress, the capacity of antioxidant
defense systems is hampered [9]. The therapeutic potential of the antioxidants in circumventing
the oxidative stress to improve endothelial dysfunction have reported mixed results. The relative
importance of the underlying mechanisms of oxidative stress mediated endothelial dysfunction
remain to be determined. The primary focus of this dissertation is to quantitatively understand the
interactions of ROS/RNS with the antioxidants and provide mechanistic basis for endothelial
dysfunction.
1.2. Motivation
ROS are the intermediates of molecular oxygen (O2) that are formed during cellular
physiological processes [10]. At physiological concentrations, ROS act as important secondary
messengers that transduce intracellular signals involved in various biological process [11, 12]. The
levels of ROS are kept in check by the antioxidant defense system of the cell such as enzymatic

2
antioxidants including superoxide dismutase (SOD), glutathione peroxidase (GPX), catalase,
peroxiredoxin (Prx) and thioredoxin etc. or the nonenzymatic antioxidants including ascorbate
(ASC) and glutathione (GSH) [13, 14]. When an aberrant production of ROS exceeds the buffering
capacity of these antioxidants, oxidative stress occurs [13]. Figure 1 below provides the general
impression of oxidative stress.

Figure 1: Oxidative stress overview
Endothelium is a single layer of cells that lines the lumen of blood vessels and plays an
important physiological role in vascular homeostasis [15]. The endothelial cells are also known to
mediate several other functions, including modulation of vascular tone, maintenance of blood
fluidity, regulation of inflammation and immune response, and neovascularization [15]. In
endothelial cells a major vasodilator, NO, is synthesized by a constitutive enzyme, endothelial

3
nitric

oxide

synthase

(eNOS).

eNOS

requires

an

essential

cofactor

(6R-)5,6,7,8-

tetrahydrobiopterin (BH4) for producing NO [16].
The increase in oxidative stress leads to a cascade of events that hampers the endothelial
cell functionality. These include decreased NO bioavailability [17]; increased O2•− production
from ROS producing enzymes [8]; reduction in the activity of antioxidant enzyme including ASC
and GSH enzyme system [18]; oxidation of BH4 [19]; reduction in expression and activity of eNOS
[20]; increased expression and enzymatic activity of arginase that break down eNOS substrate LArginine; decrease in the guanosine triphosphate cyclohydrolase 1 (GTPCH) activity which leads
to reduction in de novo synthesis of BH4; production of ONOO- which leads to increased oxidation
of BH4, decrease in SOD activity, tyrosine nitration and apoptosis [7]. Although studies have
recognized the association of endothelial dysfunction with oxidative stress, the underlying
mechanisms are still unclear.
The therapeutic potential of the antioxidants in circumventing the oxidative stress and/or
improve endothelial dysfunction has been studied largely. However, years of clinical research on
oxidative stress in animal models of cardiovascular disease and dysfunction reported inconsistent
results on the effective of antioxidants therapies in treating CVDs [7]. Putative reasons for these
inconsistencies could be due to; (i) relatively weak nature of the antioxidants used in clinical trials,
(ii) an incomplete understanding of the complex molecular mechanisms whereby ROS cause
pathological changes, (iii) the difficulty in extrapolating findings from experimental models to
clinical scenarios, and (iv) the methodological challenges relating to accurate measurement of ROS
in the cardiovascular system [21]. Computational modeling, which involves the use of
mathematical models, can be used as an effective method to identify the underlying principles of
operation in biological systems [22]. The work presented in this dissertation uses computational
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modeling-based approaches to circumvent the limitation of using experimental methods such as
simultaneous measurement of reactive species involved in oxidative stress. In this context,
computational modeling is used as a valuable tool to provide insights on the dynamics of the
complex interactions amongst reactive species in oxidative stress.
This work presented in this dissertation addresses the lack of systems level understanding
of oxidative stress mediated endothelial dysfunction and helps establish the mechanistic basis of
the role of cofactors and antioxidants in endothelial dysfunction. The improved quantitative
understanding of the role of oxidative stress in the progression of CVDs may allow for effective
treatment as well as earlier intervention in treating vascular diseases.
1.3. Research objectives and specific aims
There is a substantial evidence for the presence of complex interactions of ROS/RNS in
oxidative stress mediated endothelial dysfunction. However, we lack quantitative understanding
of these interactions due to technical limitations in experimental work. Thus, the overall objective
of this dissertation is to provide quantitative analyses of oxidative stress in endothelial cells and
deepen the understanding of the mechanistic basis of endothelial dysfunction. We used
computational modeling approaches to tackle the experimental complexities in analyzing reactive
species by simulating the concurrent dynamics of many variables. The central hypothesis of this
dissertation is oxidative stress can lead to uncoupling of eNOS and presence of BH4 and
antioxidants can improve NO bioavailability in endothelial cells. To test this hypothesis, we
developed following specific aims.
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1.3.1. AIM 1: Develop a detailed mathematical model for biopterin dependent eNOS
biochemical pathway
Oxidative stress levels can dynamically change the biopterin ratio (ratio of BH4 to the total
biopterin levels, (TBP)) by oxidative depletion of BH4 and causes uncoupling of eNOS. The
uncoupling of eNOS shifts the eNOS production of NO to O2•- [23, 24]. The extent of eNOS
uncoupling is predominantly determined by the availability of BH4, an essential cofactor of eNOS
that plays an important role in maintaining normal endothelial function [25-27]. The enhancement
of BH4 bioavailability holds therapeutic potential for improvement of endothelial dysfunction [16,
28, 29], whereas other studies have shown limited [30] or no improvement [31, 32] in endothelial
function. Our understanding of the complex interactions of eNOS uncoupling, oxidative stress and
BH4 availability are not complete and a quantitative understanding of these interactions is required.
To study this, we have developed a computational model for eNOS uncoupling that considers the
temporal changes in biopterin ratio in the oxidative stress conditions. Using the model, we have
studied the effects of cellular oxidative stress and BH4 synthesis on the eNOS NO production and
biopterin ratio.
1.3.2. AIM 2: Develop mathematical model to analyze the role of ascorbate in oxidative stress
mediated endothelial dysfunction
ASC, the reduced form of vitamin C, is an essential intracellular and circulatory antioxidant
which has been suggested to play an important role in maintaining endothelial function. ASC
deficiency has been associated with an increased risk of CVD [33]. The synthesis and
bioavailability of NO are sensitive to cellular antioxidant status and redox balance. ASC plays an
important role in maintaining this redox balance. Exogenous treatment with ASC is considered to
be of therapeutic potential [34, 35], however the potential mechanism of ASC in the mitigation of
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endothelial dysfunction is not clear [36]. In this study, we extended our computational model of
eNOS uncoupling developed in AIM 1 and studied the interactions of oxidative stress and biopterin
ratio in the presence of ASC and GSH. This model provides important quantitative insights on the
protective role of ASC in endothelial dysfunction.
1.3.3. AIM 3: Develop a mathematical model to analyze the interactions of ROS/RNS with
glutathione enzyme system
GSH and GPX enzyme system is essential for normal intracellular homeostasis and gets
disturbed under several pathophysiological conditions including endothelial dysfunction [37, 38].
The GSH/GPX system plays an important role in eliminating ROS/RNS. Studies have provided
important information regarding the interactions of ROS/RNS with the GSH/GPX in biological
systems. However, it is not clear how this cross talk affects these reactive species and GSH/GPX
enzyme system, under physiologic and oxidative/nitrosative stress conditions [39, 40]. In this
study, we developed a detailed endothelial cell kinetic model to understand the relationship
amongst the key enzyme systems including GSH, GPX, Prx and reactive species, such as H2O2,
ONOO-, and dinitrogen trioxide (N2O3). The analysis presented in this study would help us
interpret the complex interactions amongst reactive species and enzyme systems under physiologic
and oxidative/nitrosative stress conditions.
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CHAPTER II
II.

LITERATURE REVIEW

CVDs are regarded as the number one cause of deaths globally according to the World
Health Organization (WHO) fact sheet for September 2016 [1]. An estimated 17.5 million people
died from CVDs in 2012, which represents 31% of all global deaths [1]. According to the American
Heart Association and American Stroke Association, the cost estimates for all aspects of CVD
totaled $318 billion in 2015 and spending for all cardiovascular conditions is projected to continue
to rise with just the indirect cost projected to $368 billion by 2035 [41]. Although the mortality
rate of the disease has been brought down tremendously, we still lack the mechanistic basis behind
the onset and progression of the CVDs, despite of decades of research in this area. The different
forms of CVDs are complex in their etiology, however, risk factors common to all forms include
smoking, diabetes, hypertension, hypercholesteremia, obesity and aging [42]. The risk factors for
CVDs are associated with significant increases in ROS in the vascular wall [9, 43]. High level of
ROS can dynamically change the redox homeostasis of the endothelial cell. Cardiovascular risk
factors also negatively influence the bioavailability of NO and cause endothelial dysfunction [6].
2.1. Oxidative stress and cardiovascular diseases
Oxidative stress has been associated with the pathogenesis of several diseases including
vascular diseases, neurodegenerative diseases, diabetes, atherosclerosis, cancer, aging and obesity
[4, 44-49]. The term ‘oxidative stress’ is frequently used in redox biology and medicine. It was
first formulated in 1985 and as of today, approximately 219,225 PubMed entries show this term
[50]. Oxidative stress has been defined as an imbalance between generation of reactive oxygen
species (ROS) and their elimination by antioxidant defense capacity of the cell. This imbalance is
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caused due to elevated levels of ROS or reduced levels of antioxidants [51]. The ROS produced
include free oxygen radicals such as O2•-, oxygen ions, and peroxides [9]. The ROS-producing
enzymes contributing to vascular oxidative stress include, nicotinamide adenine dinucleotide
phosphate oxidase (NADPH) oxidase, xanthine oxidase (XO), enzymes of the mitochondrial
respiratory chain, and dysfunctional enzyme endothelial nitric oxide synthase (eNOS) that produce
vasodilator, nitric oxide (NO) [52]. The antioxidant defense that gets hampered in oxidative stress
include including SOD, GPX, catalase, Prx and thioredoxin etc. or the non-enzymatic one
including ASC and GSH [13, 53]
In endothelial cells reduced NO bioavailability because of increased NO degradation by
ROS marks the onset of endothelial dysfunction. For instance, O2•- reacts with NO to form
peroxynitrite (ONOO-). Formation of ONOO- promotes protein nitration and has deleterious
consequences on endothelial cells [54]. Studies on animal experimental models to analyze the
effect of genetic deletion or overexpression of ROS producing enzymes and the antioxidant
enzymes on the disease phenotype, provides the molecular proof for the involvement of oxidative
stress in CVDs. The extent of cells/tissue exposed to and the severity of the oxidative stress
determines the consequences of oxidative stress [55].
2.2. Endothelial dysfunction as an early detector of cardiovascular diseases
Endothelium forms a semipermeable barrier between the vascular wall and the blood
stream, which is both mechanical and biological in nature. It not only regulates the transport of
macromolecules between the vascular lumen and vascular smooth muscle but can also secret
relaxing and contracting molecules. The important functions of the endothelium are vasodilation
and modulating vascular tone by synthesizing and releasing vasoactive substances. In addition,
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endothelium is involved in regulation of platelet function, inflammatory responses, vascular
smooth muscle cell growth and migration. The maintenance of vascular tone is done by endothelial
derived relaxing factor, nitric oxide (NO). In endothelial cells, NO is synthesized by a constitutive
enzyme eNOS and NO can diffuse freely across biological membranes. It stimulates soluble
guanynyl cyclase in the smooth muscle cells that leads to increase in intracellular cyclic guanosine
monophosphate levels and results in vasodilation [15, 56].
The term endothelial dysfunction refers to several pathological conditions, including
altered anticoagulant and anti-inflammatory properties of the endothelium, impaired modulation
of vascular growth, and dysregulation of vascular remodeling [3]. In literature this term is most
often used to characterize impairment in vasorelaxation caused due to reduction in NO
bioavailability [3, 42, 57]. Accumulating evidence has demonstrated that endothelial functions are
essential to ensure proper maintenance of vascular homeostasis [15]. The pathogenesis of the
vascular disease is attributed to the alterations in the vascular endothelium [58]. The endothelium
lining the arteries is especially subjected to harmful stimuli including oscillatory shear stress,
disturbed turbulent flow and oxidative stress among others [59]. Endothelial dysfunction is the
hallmark of a wide range of CVDs including atherosclerosis, diabetes, smoking, aging, obesity,
hyperhomocysteinemia, hypertension and others. [56, 57, 60-64]. The general schematic for the
development and progression of cardiovascular diseases from the risk factors has been summarized
in Figure 2 (modified from [42]) below.
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Figure 2: General schematic of development and progression of vascular diseases
2.3. Intracellular sources of reactive oxygen species
Mammalian cells utilize aerobic respiration, which requires molecular oxygen (O2) for
biochemical conversion, to produce adenosine triphosphate (ATP) from food. As a side effect of
this process, ROS are generated [10]. These ROS have unpaired electrons and are considered as
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free radicals such as superoxide ion (O2•−) and hydroxyl radical (•OH), which are unstable and
have short biological half-lives. As well as, nonradical oxidizing ROS such as hydrogen peroxide
(H2O2), NO etc. These are comparatively stable and have longer half-lives [65, 66]. The one
electron reduction of O2 generates O2•−, which is a highly reactive radical with rapid spontaneous
(8×104 M−1·s−1) or enzymatic (2×109 M−1·s−1) dismutation rates. O2•− is also considered as a
precursor for converting to other forms of ROS/RNS through a series of reactions [67]. O2•− is
mainly produced in the inner mitochondrial membrane space as it is rich in O2 and electrons. O2•−
is ineffective at permeating through lipid membranes, hence considered as poor signaling molecule
[68]. The majority of O2•− generated is rapidly converted to H2O2. H2O2 can diffuse through
organelle as well as cell membranes and is considered as more stable ROS, than O2•−. H2O2 is also
considered as an ideal secondary messenger for mediating downstream cell signaling mechanisms
[69]. H2O2 decomposition produces highly reactive •OH radical, which is associated with oxidative
damage due to its mostly nonselective and irreversible reactivity [70]. In addition to ROS, RNS
such as NO, nitrogen dioxide (NO2•), ONOO-, dinitrogen trioxide (N2O3), and nitrous acid (HNO2)
also contribute to the oxidative stress [71]. These RNS have deleterious effects on the cell mostly
due to oxidative damage to proteins and DNA [72].
2.3.1. NADPH oxidase (NOX)
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases are the family enzymes
whose primary function is ROS production and are considered as re critical mediators of
cardiovascular physiology and pathophysiology [73, 74]. NOX has two membrane bound subunits
(gp91phox and p22phox) and several cytoplasmic subunits (p47phox, p67phox, p40phox and G
protein) [75, 76]. There are seven isoforms of NOX in mammals, amongst which the NOX1,
NOX2, NOX4 and NOX5. are variably expressed in the endothelial cells [73-75]. The various
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NOX isoforms are differentiated based on their specific type of ROS generation. NOX1 and NOX2
primarily produce O2•− from O2; NOX4 has been reported to generate H2O2 rather than O2•−; and
NOX5 produces both O2•− and H2O2 [77, 78]. NOX1 expression is residual under basal conditions
and after stimuli increases considerably. NOX2 affects both NO bioavailability as well as
contractile properties of vasculature [79]. NOX4 expression exerts vasoprotective effects [80] as
well as detrimental effect [81], depending on the stimuli. NOX5 is calcium sensitive isoform
important in redox-sensitive contractions. Recent study has described a novel function for vascular
NOX5 that links calcium and ROS to the pro-contractile molecular machinery in vasculature [82].
Various risk factors including hypertension, obesity, hypercholesterolaemia, atherosclerosis,
diabetes mellitus and dementia, can activate NOX, resulting in an enhanced production of ROS
[45, 46, 83-85].
2.3.2. Xanthine oxidase (XO)
XO is another enzyme largely concentrated in endothelial cells that mediates oxidation of
hypoxanthine and xanthine and produces O2•− and H2O2 as by‐products. In humans, unstimulated
cells have a relatively low basal expression of XO, yet upon cellular activation by cytokines, the
transcription of XO is rapidly upregulated and its activity increased [86]. Endothelial dysfunction
is linked with increment in endothelial XO [51]. Conditions like hypoxia or hyperoxia, which have
changes in the intracellular or extracellular O2 content can also alter the transcriptional regulation
of XO and lead to the intracellular accumulation of O2•- [86, 87]. The activity of XO is increased
in patients with coronary artery disease [88] and inhibitors of this enzyme reduce endothelial
dysfunction in both humans and animal models [89-91].
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2.3.3. Endothelial nitric oxide synthase (eNOS)
NO is produced by three different isoforms of nitric oxide synthases (NOS), NOS1 are
neuronal NOS (nNOS), NOS2 are inducible NOS (iNOS) and NOS3 are endothelial NOS isoform.
They all utilize L-arginine and molecular O2 as substrates and require cofactors such as; reduced
nicotinamide-adenine-dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD),
flavin mononucleotide (FMN), and (6R-)5,6,7,8-tetrahydrobiopterin (BH4) for producing NO. The
central and peripheral neurons and some other cell types constitutively express nNOS. Important
functions of nNOS include, maintaining synaptic plasticity in the central nervous system,
regulating blood pressure in CNS, smooth muscle relaxation, and vasodilatation via peripheral
nitrergic nerves. iNOS is expressed in many cell types in response to stimuli from
lipopolysaccharide, cytokines, or other agents. Large concentration of NO is generated from iNOS
compared to nNOS and eNOS that have cytostatic effects on parasitic target cells. iNOS
contributes to the pathophysiology of inflammatory diseases and septic shock. eNOS is mostly
expressed in endothelial cells. Under physiological conditions, eNOS produces NO and exerts
vasoprotective effects on the endothelium [92]. However, under pathological conditions,
uncoupling of eNOS occurs which produces O2•−, instead of NO. This further aggravates oxidative
stress [9, 92]. Particularly, ONOO- promote eNOS uncoupling [52].
2.3.3.1. eNOS catalyzed NO and O2•- production
The catalysis of eNOS is shown in Figure 3. In the endothelial cells, the active form of
eNOS exists as a dimer with two domains, oxygenase and reductase. The reductase domain has
the binding sites for the flavin co-factors FAD, FMN; the substrate NADPH and; calcium (Ca2+)
and calmodulin which is required for the electron flow through the reductase domain and to keep
the two domains bound to each other [24]. The oxygenase domain has the binding sites for heme,
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the co-factor tetrahydrobiopterin (BH4) and the substrate L-Arginine (L-Arg) [24]. In the reductase
domain NADPH oxidizes to NADP+ and the electrons (e−) donated proceed via FAD and FMN
redox carriers to the oxygenase domain. In the oxygenase domain the e- interact with the heme and
BH4 at the active site to catalyse the reaction of oxygen (O2) with L-Arg to generate citrulline and
NO as products through a series of biochemical reactions. An increase in the production of ROS
(including O2•-, •OH and CO3•-) and RNS (including ONOO- and •NO2) leads to oxidation of BH4
to dihydrobiopterin (BH2) [93, 94]. Both BH2 and BH4 can compete with similar affinity for
binding to eNOS [95]. The binding of BH2 to eNOS leads to the uncoupling of eNOS resulting in
O2•- production [93, 94, 96, 97].

Figure 3: Reaction catalyzed by eNOS and the production of NO and O2•−
2.3.4. Mitochondrial electron transport chain
Mitochondria utilize molecular O2 for energy production and oxidative phosphorylation.
During this process, consumed O2 is converted to O2•−, predominantly at complexes I, II and III.
Mitochondrial respiratory chain has been considered as the main source of ROS in vascular cells
[98, 99]. In addition to leak from respiratory chain, the mitochondrial growth factor adaptor Shc
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and monoamine oxidases are also responsible for ROS production in the vascular system [100].
Importantly, the overproduction of ROS in mitochondria results in changed mitochondrial
permeability, phenomenon called ‘ROS‐induced ROS release’ that triggers ROS burst and has a
pathological impact [101].
2.4. Antioxidant defense system
Antioxidants can counteract ROS/RNS and neutralize oxidants. The general endogenous
antioxidants system consists of (i) enzymatic antioxidants including superoxide dismutase (SOD),
catalase, glutathione peroxidase (GPX), peroxiredoxin (Prx) and thioredoxin (Trx); (ii) hydrophilic
antioxidants including urate, ASC, GSH and flavonoids and (iii) lipophilic anitioxidants including
tocopherol, carotenoid and ubiquinol [13, 14, 102].
2.4.1. Superoxide dismutase (SOD)
SOD is one of the most potent intracellular enzymatic antioxidants responsible for
catalyzing the dismutation of O2•- into H2O2 as shown below:
+
O2•− + O•−
2 + 2H → H2 O2 + O2

There are three different isoforms of SOD localized in different cellular compartments: a cytosolic
copper-zinc superoxide dismutase (SOD1 or CuZnSOD), a predominantly mitochondrial
manganese superoxide dismutase (SOD2 or MnSOD), and an extracellular CuZnSOD (SOD3)
with affinity for cell surface heparin sulfate proteoglycans. In endothelial cells, under
physiological conditions, SOD1-derived H2O2 has been shown to act as an endothelium-dependent
hyperpolarization factor in vivo and SOD2 derived H2O2 promoted endothelial cells sprouting and
new blood vessel formation. The reduced levels of SOD were associated with increased O2•- levels,
inhibited angiogenesis and impaired relaxation to acetylcholine. Deficiency of SOD has also been
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found in pulmonary hypertension, diabetes. Also, overexpression of SOD has been shown to
improve endothelial function in rate models of hypertension and heart failure [4]. The H2O2 is
reduced to molecular O2 and water by antioxidant enzymes, catalase, peroxidases.
2.4.2. Catalase
Catalase was the first antioxidant enzyme to be characterized and catalyzes conversion of
H2O2 to water and O2 as below:
2H2 O2 → 2H2 O + O2
Catalase consists of four subunits each containing is a heme- group and NADPH molecule. The
rate constant for the reactions described above is extremely high (~107 M.s-1). Catalase also has
one of the highest turnover rates of all enzymes, where one molecule of catalase can convert
approximately 6 million molecules of H2O2 to water and O2 each minute [103]. Catalases are
exclusively located in the peroxisome of cells. It is abundantly expressed in liver, lungs, and
kidneys. Catalase is known to efficiently clear exogenous H2O2 [102]. The role of catalase in
endothelial is uncertain, as under normal conditions, its activity seems to be not essential.
However, under oxidative stress, catalase activity increases in endothelial cells [4].
2.4.3. Glutathione peroxidase (GPX)
GPX catalyze the oxidation of GSH at direction of a hydroperoxide, which may be H2O2,
ONOO- or another species such as a lipid hydroperoxide as below:
ROOH + 2GSH → GSSG + H2 O + ROH
GPX is the selenium-dependent protein antioxidant that catalyzes the reduction of H2O2 to
molecular O2 and water by using GSH as a reducing equivalent. GPX is known to clear endogenous
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H2O2 [102]. In mammals eight different isoforms of GPX has been identified. Five of these
isoforms (GPX1, GPX2, GPX3, GPX4 and GPX6) contain selenocysteine residue in their active
site and three isoforms (GPX5, GPX7 and GPX8) have cysteine residues [104]. GPX-1 isoform is
most abundantly expressed in endothelial cells. GPX-1 is located both in the mitochondria and
cytoplasm of endothelial cells. Increased GPX-1 expressions have been reported to protect
endothelial cells from H2O2 induced apoptosis. While GPX-1 gene knockout was found to augment
leukocyte adhesion to endothelial cells, induce pro-inflammatory phenotype in aging, impair
vasodilation through decreased NO levels and increase oxidative stress [4]. GPX is also involved
in clearing ONOO- and are known to protect cells from ONOO- mediated cytotoxicity [105].
Cellular GPX deficiency has been implicated in endothelial dysfunction and pro-inflammation [38,
106, 107].
2.4.4. Peroxiredoxin (Prx)
Prx are thiol-specific enzymes that use cysteine residues for inactivating H2O2 to water. In
mammals six isoforms of Prx has been identified. Prx1-5 isoforms require two cysteine residues
whereas Prx6 requires one cysteine residue for their catalytic activity. These isoforms are
distributed across various cellular sites of ROS production, such as cytosol, mitochondria and
peroxisomes. Prx1-5 uses thioredoxin as reducing equivalent, while Prx6 does not use thioredoxin
[108]. As like GPX, Prx can also inactivate ONOO- [109, 110]. Increased expression of Prx6 has
been observed under conditions of increased ROS generation in various models of injury, as well
as patients with peripheral arterial disease show marked increase in circulating levels of Prx1, 2,
4, and 6 [108]. Prx1 is reported to protect mice against excessive endothelial activation and
atherosclerosis, and the Prdx1−/− mice are reported susceptible to chronic inflammation [111].
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2.4.5. Ascorbate (ASC) – reduced form of Vitamin C
Vitamin C, also known as ascorbic acid or ascorbate (ASC), is a water-soluble molecule
that cannot be synthesized endogenously in humans, monkeys, guinea pigs, and several other
animal species. Humans normally acquire vitamin C from dietary sources through a substratesaturable transporting mechanism. Two sodium-dependent transporters are specific for ASC, and
its oxidation product dehydroascorbic acid (DHA) is transported by glucose transporters [112].
Ascorbic acid is differentially accumulated by most tissues and body fluids. Plasma and tissue
vitamin C concentrations are dependent on amount consumed, bioavailability, renal excretion, and
utilization [113]. Low levels of plasma ASC are associated several diseases including cancer,
diabetes, HIV, sepsis and cardiovascular diseases [53, 114-116]. The systemic or localized cellular
ASC deficiency has been reported as a cause for endothelial dysfunction in cardiovascular disease
[117]. For instance, supplementation of ASC has shown improvement in patients with obstructive
sleep apnea which is a condition associated with oxidative stress, endothelial dysfunction and
increased cardiovascular morbidity and mortality [35].
2.4.6. Glutathione (GSH) antioxidant system
GSH is the most thiol antioxidant, abundant in cytosol, nuclei and mitochondria is a major
soluble antioxidant found in cells. Because of its high intracellular concentration (1 – 10 mM),
GSH is considered as a major thiol-disulfide redox buffer of the cell. GSH is mostly present in its
reduced form, when oxidized it forms glutathione disulfide (GSSG). The ratio of GSH/GSSG is a
good measure of oxidative stress of an organism. GSSG is reduced by the NADPH-dependent
flavoenzyme glutathione reductase (GR), and this enzyme is critical to the maintenance of a proper
GSH redox potential in mammalian cells [118]. The protective roles of GSH against
oxidative/nitrosative stress includes, GSH acting as a cofactor or reducing equivalent for enzymes,
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participate in amino acid transport across plasma membrane, scavenge reactive species and
regenerate vitamins C and E. Depletion in GSH has been implicated in several diseases including
arthritis, AIDS, Parkinson’s disease, alcoholic liver diseases, cancer, cardiovascular and brain
disorders [103].
2.5. Oxidative stress mediated endothelial dysfunction as a therapeutic target for treating
cardiovascular diseases
In CVDs, the increase in oxidative stress leads to a cascade of events that hampers the
endothelial cell functionality. Table 1 summarizes the recent literature that establishes the
association of oxidative stress in endothelial dysfunction. Researchers have been studying different
ways to treat endothelial dysfunction for long time. Potentiation of the antioxidant pathways has
been suggested as an effective strategy to improve endothelial dysfunction and a potential target
to reduce the cardiovascular risk [119]. For instance, studies reported therapeutic potential of
replenishing BH4 bioavailability to increase NO bioavailability [25] or supplementing antioxidants
[117] such as SOD and ASC to reduce the oxidative stress. Although being known for having
therapeutic potential, studies using BH4 and ASC have shown mixed results [33, 120]. In fact,
most of the clinical trials on antioxidant therapy have hardly shown positive clinical outcome [5].
Further, the GSH/GPX enzyme system is known to participate in numerous physiological and
pathophysiological processes including endothelial cell function and dysfunction [37, 38, 107,
121]. Supplementation of GSH and selenium compound, known to improve GPX expression and
activity, has been shown to protect endothelial cells and improve endothelial dysfunction in vivo,
in vitro as well as clinical studies [122-124]. In the present dissertation, the dynamic interactions
of ROS/RNS with cofactors, substrates and antioxidants has been analyzed as shown in Figure 4
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below. Specifically, the role of BH4, ASC and GSH/GPX in oxidative stress and cardiovascular
health and disease are presented.
Table 1: Association of oxidative stress and endothelial dysfunction

Causes
Decrease in NO
bioavailability
Increase O2•- production
Decrease in SOD, ASC,
GSH and GPX

Implications
Endothelial
dysfunction

References
Incalza et al. [4], Chen et al. [125],
Satitthummanid et al. [126]

Oxidative stress

Daiber et al. [7], Sena et al. [51], Di Meo
et al. [8]

Oxidative stress

He et al. [13], Kurutas et al. [103],
Gabryel et al. [127], Likidlilid et al.
[128]

Increase in eNOS
activity/expression

eNOS uncoupling

Santhanam et al. [27], Karbach et al. [2],

Decrease in BH4
bioavailability

eNOS uncoupling

Wang et al. [28], Chen and Ding et al.
[129]

Increase in ONOOlevels

Tyrosine nitration and Radi et al. [130], Ferrer-Sueta et al. [54]
apoptosis
Pacher et al. [131]
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Figure 4: Overview of interactions of ROS/RNS with cofactors, substrates and antioxidants
presented in the dissertation
2.5.1. Role of tetrahydrobiopterin in endothelial dysfunction
In endothelial cells, biopterin is primarily present in reduced form (6R-)5,6,7,8tetrahydrobiopterin (BH4) because of low levels of oxidative stress under normal physiologic
conditions [132]. BH4 is considered as an essential cofactor of eNOS that plays an important role
in maintaining normal endothelial function. Increase in oxidative stress can cause uncoupling of
the eNOS. The uncoupling of eNOS shifts the eNOS production of NO to superoxide (O2•-) [23,
24]. The extent of eNOS uncoupling is predominantly determined by the availability of BH4, [25,
26]. However, more recently it has been determined that the extent of oxidative stress is dependent
on the biopterin ratio which is the ratio of BH4 to the total biopterin levels (TBP) [93, 95].

22
In addition, oxidative stress can alter the activity of GTPCH. GTPCH is a key enzyme in
de novo synthesis pathway for the endogenous production of BH4 [94, 133]. The activity of
GTPCH is reported to increase [134, 135] or reduce [136] in oxidative stress conditions. Shimizu
et al. [134, 135] reported that the long exposures of endothelial cells to H2O2, •OH and ONOOinduced GTPCH mRNA expression and resulted in an increase of only BH4 levels and not the
oxidized forms of biopterin. The GTPCH inhibitor reduced the BH4 levels in ROS and RNS
exposed vascular endothelial cells. Meininger et al. [136] reported a decrease in GTPCH activity
with a proportional decrease in the BH4 levels in diabetic rats. The endothelial cell NO synthesis
from the diabetic rats was only 18% compared to that of normal animals.
Several experimental studies have reported changes in biopterin ratio and NO levels
because of BH4 enhancement in endothelial dysfunction [95, 137, 138]. Crabtree et al. [95]
reported a decrease in the biopterin ratio from 1:1 (BH4:BH2) in non-supplemented cells to 1:6 in
10 μM BH4 supplemented hyperglycemic endothelial cells. They also reported a 40% decrease in
NO production for BH4 supplemented hyperglycemic endothelial cells. Alp et al. [138] reported
that BH4 comprised only 10% of the total biopterin content in diabetic-GTPCH overexpressing
transgenic mice as compared to 80% in control GTPCH overexpressing transgenic mice. This
decrease in the biopterin ratio was attributed to a 2 to 3–fold increase in O2•- production in diabeticGTPCH overexpressing transgenic mice. Sasaki et al. [137] reported that O2•- production increased
1.6-fold in diabetic mice as compared to non-diabetic control mice and BH4 supplementation
suppressed O2•- production in diabetic mice. These studies demonstrate the presence of complex
biochemical interactions between BH4, oxidized biopterins, ROS and RNS that ultimately
modulate eNOS uncoupling in endothelial dysfunction. In Chapter III the analysis of these
interactions is elucidated.

23
2.5.2. Ascorbate and endothelial dysfunction
Low levels of ascorbate (ASC, reduced form of vitamin C) are associated with diseases
such as cancer, diabetes, HIV, sepsis and cardiovascular diseases [53, 114-116]. The systemic or
localized cellular ASC deficiency has been reported as a cause for endothelial dysfunction in
cardiovascular disease [117]. It is well established that endothelial dysfunction is primarily caused
due to a reduction in NO and an increase in oxidative stress [20, 55, 139, 140]. The synthesis and
bioavailability of NO are sensitive to cellular antioxidant status and redox balance. ASC plays an
important role in maintaining this redox balance [35, 116, 117, 141, 142]. Exogenous treatment
with ASC is considered to be of therapeutic potential [34], however the potential mechanism of
ASC in the mitigation of endothelial dysfunction is not clear [36].
Individual experimental studies have reported several putative mechanisms by which ASC
may improve endothelial dysfunction. These mechanisms include: i) increasing or maintaining
intracellular levels of BH4 bioavailability in the reduced form [143, 144]; ii) scavenging of
ROS/RNS including O2•- and ONOO- [145]; and iii) increasing eNOS activity through promoting
eNOS phosphorytion [116] or reducing eNOS S-nitrosylation [146]. To better decipher the role of
ASC in improving endothelial dysfunction, a quantitative understating of intracellular ASC
interactions in endothelial cells is needed.
Many clinical and experimental studies provide evidence for the therapeutic potential of
ASC. Akolkar et al. [147] reported that doxorubicin-induced oxidative and nitrosative stress in
cardiac tissues was mitigated by the supplementation of ASC. Mullan et al. [148] showed an
improvement in the arterial- blood pressure and stiffness in patients with type 2 diabetes after 1
month of oral dose of ASC. Studies also reported a reversal of NO-dependent endothelial
dysfunction in coronary or peripheral arteries of atherosclerotic patients following the
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supplementation of ASC [149, 150]. However, other studies reported ASC as pro-oxidant and
increased oxidative stress. Varadhraj et al. [151] showed that the pharmacological ASC
concentrations in the range of 10 mM or higher induced oxidative stress and led to a loss of redoxdependent cell viability in microvascular endothelial cells. It is evident that we lack the
understanding of how ASC attenuates oxidative stress in health and disease. In chapter IV, the
analysis the role of ASC in endothelial dysfunction is provided by integrating these potential
mechanisms.
2.5.3. Role of glutathione and glutathione peroxidase in alleviating oxidative stress
GSH acts as a reducing agent in biological processes such as antioxidant defense,
detoxification, signal transduction regulation, and cell apoptosis and proliferation [40, 152, 153].
GSH/GPX enzyme system removes ROS and RNS [39]. Deleterious consequences of excess
ROS/RNS include, increased oxidative/nitrosative stress, NO degradation, protein nitration, DNA
damage, lipid and protein structure modification, and mitochondria failure [4, 154]. GSH depletion
can lead to an increase in ROS and RNS generation, an increase in mitochondrial complex I
activity and NADPH oxidation, a decrease in cell viability, and an impairment of ATP generation
[155-157]. The GPX catalyzes reduction of many oxidative species including H2O2 and ONOOand uses GSH as a substrate [105, 158]. GPX depletion potentiates oxidative stress and leads to
endothelial dysfunction [38] and apoptosis [159].
Several studies have reported the importance of GSH in alleviating oxidative stress. Ehrhart
et al. [160] reported that GSH played a more important role than catalase in oxidative stress
defense. Canals et al. [161] reported that NO changed from being anti-apoptotic to pro-apoptotic
agent upon GSH depletion. GSH gets oxidized to glutathione disulfide (GSSG) and regenerated
by the action of glutathione reductase and NADPH system. Yeh et al. [162] reported that GSH and
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GSSG levels were significantly associated with increased oxidative stress in patients receiving
hemodialysis treatment. Prasai et al. [163] reported that a reduction in [GSH]/[GSSG] ratio led to
an increase in ROS and activated vascular endothelial growth factor receptor (VEGFR2).
GSH and GPX play an important role in modulating ROS and RNS levels in biological
systems. GSH participates in recycling of GPX. GPX can deplete or maintain H2O2 as well as
ONOO- at base level [104, 106]. Marc et al. [38] reported that GPX detoxifies nearly 70% H2O2
in endothelial cells. Gabryel et al. [127] reported that GPX and SOD activity increase protected
ischemic endothelial cells. Fu et al. [164] showed that GPX removed ROS and protected against
lipid peroxidation and protein oxidation from injuries mediated by only ROS, but not RNS.
Maraldi et al. [165] showed that an increase in GPX activity was not sufficient to scavenge RNSinduced oxidative stress. In addition to the GSH/GPX system, studies have reported a role of Prx
in the removal of H2O2 and ONOO- in many cell types [109, 166-168]. All these studies suggest
that there is a cross talk of ROS and RNS with GSH/GPX system. In chapter V the interactions of
ROS/RNS with GSH/GPX system are analyzed.
2.6. Use of computational modeling analysis
Extensive literature points that oxidative stress mediated endothelial dysfunction plays a
central role in the pathogenesis of various CVDs and neurovascular diseases. Even though the
therapeutic potential of essential eNOS cofactor and antioxidants including BH4, ASC and GSH
and its related enzyme system has been shown in experimental studies, the clinical outcomes are
not reflected. The reason for this being we lack the quantitative understanding at the molecular
level inside the endothelial cells in health and disease. The experimental studies mostly provide
the qualitative data for the mechanisms involving reactive species in health and diseases. However,
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the endothelial cell is a dynamic system and a delicate balance is present amongst many processes
inside which are disrupted in the disease state. Several challenges are involved for evaluating the
quantitative assessment of reactive species in experimental settings. These include i) free radical
are short-lived intermediate species making them difficult to quantify, ii) different species have
complex roles in different processes, thus multiple species analysis is required, iii) difficult to
develop cellular models that mimic in vivo conditions, iv) there exists spatial heterogeneity
between different chemical species amongst the different compartments of the cell.
Most of these challenges could be overcome by mathematical modeling approaches, which
can help to elucidate behavior of these interactions for a particular system. Computational systems
biology uses mathematical and computational methods to understand how biological systems
work, with a secondary goal of manipulating and optimizing biomedical systems, guided by
mathematics. Development of mathematical models, using mass action and reaction kinetics that
are deterministic in nature, can provide ample information about the system under study. Such a
study is important it is difficult to gather dynamics interactions of short lived reactive species using
traditional experimental approaches. Also, implementation of computational model is perceived
as a necessary methodological step for systems biologists. Such a model would be used to provide
an in silico numerical evaluation of hypotheses, guidelines for designing future experiments, as
well as avoid the use of complex analytical methods. This would considerably reduce the costs of
expensive in vivo or in vitro experiments [169].
Mathematical modeling has proven insightful in providing mechanistic roles of ROS/RNS
as well as antioxidants previously. Endothelial cell based computational model were developed to
investigate eNOS uncoupling related NO and O2•- production. These models showed that the extent
of eNOS uncoupling is dependent on the biopterin ratio [93, 170]. Computational modeling was
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used to gain mechanistic insights on the role of ASC. Kuiper et al. [171] developed the
pharmacokinetic model of ASC diffusion through tumor tissue to study the penetration of ASC
through tissues. Their model predicted cellular ASC levels are dependent on the plasma supply.
Ponte et al. [172] provided insights in the mechanism of ASC activation of anticancer drugs. Hu
et al. [173] developed a dynamic system of coexisting NO and O2•- and studied the effect of ASC
on the nitrosation kinetics of the model system by including the reactions of ASC on free radical
scavenging and repairing in the model.
Several computational modeling studies investigated quantitative and mechanistic roles of
GSH/GPX system in oxidative stress [174-176]. Keszler et al. [177] proposed various pathways
for the reaction amongst GSH, NO and oxygen (O2) and reported the reaction between GSH with
N2O3 as a potential mechanisms of S-nitrosothiol (GSNO) formation. Hu et al. [175] and Bagci et
al. [178] reported that GSH depletion resulted in an increased levels of ROS and RNS including,
dinitrogen trioxide (N2O3) and ONOO-. Ng et al. [176] examined the removal rate of H2O2 with
respect to the kinetic behavior of GSH and GPX and reported H2O2 removal is a function of both
GSH and GPX. While, Adimora et al. [179] modeled intracellular H2O2 clearance pathways
including Prx and GSH/GPX and reported that the Prx was one of the major H2O2 clearance
pathway.
The results from both experimental and modeling studies provide evidence for the presence
of complex interactions amongst oxidative stress and endothelial dysfunction. This also establishes
the need for the quantitative understanding of these interactions which will help in identifying
intricate molecular determinants governing endothelial function and dysfunction. Identification of
the underlying mechanisms is essential to develop novel clinical breakthroughs and improve
knowledge [5].
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CHAPTER III
III.

COMPUTATIONAL ANALYSIS OF INTERACTIONS OF OXIDATIVE STRESS
AND TETRAHYDROBIOPTERIN SYNTHESIS1 IN ENOS COUPLING

3.1. Introduction
An increase in oxidative stress causes endothelial dysfunction in several CVDs. Increase
in oxidative stress results in the reduction in BH4 and eNOS uncoupling. Several experimental
studies have examined the interactions of oxidative stress and BH4 enhancement on the biopterin
ratio and endothelial dysfunction [95, 137, 138]. The results from these studies demonstrates the
presence of complex biochemical interactions between BH4, oxidized biopterins, ROS and RNS
that modulates eNOS uncoupling. Our understanding of the complex interactions of eNOS
uncoupling, oxidative stress and BH4 availability is not complete and a quantitative understanding
of these interactions is required. In the present study, we developed a computational model for
eNOS uncoupling that considers the temporal changes in biopterin ratio in the oxidative stress
conditions. Using the model, we studied the effects of cellular oxidative stress (Qsupcell)
representing the non-eNOS based oxidative stress sources and BH4 synthesis (QBH4) on eNOS NO
production and biopterin ratio (BH4/total biopterins (TBP)). The results from the present study
will be helpful in guiding the experimentation in this high priority area of cardiovascular research.
In order to do so, the first step is to develop the computational model for eNOS uncoupling that
considers the temporal changes in biopterin ratio in the cellular oxidative stress conditions.

1

This work has been published: Joshi, S., S. Kar, and M. Kavdia, Computational analysis of interactions of
oxidative stress and tetrahydrobiopterin reveals instability in eNOS coupling. Microvasc Res, 2017. 114: p. 114128.
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3.2. Materials and methods
3.2.1. Model Description
Figure 5 shows an endothelial cell computational model for the eNOS biochemical
pathways that includes interactions of the cellular oxidative stress and BH4 synthesis. The eNOS
biochemical pathway related NO and O2•- production depends on the relative availability of BH4
and BH2, respectively, which is a function of the biopterin ratio. In this study, the biopterin ratio
is defined as the ratio of reduced biopterin to total biopterin ([BH4]/[TBP]). The concentration of
BH4 and BH2 depends on the rate of synthesis and oxidation of BH4 [180]. The sources of oxidative
stress in endothelial cells include NADPH oxidase, xanthine oxidase and mitochondrial electron
transport chain [181, 182]. Each of these distinctive oxidative stress sources produces O2•- at
different rates [183-185] and results in enhanced ROS and RNS production in endothelial cells
[181, 186]. Figure 6 represents the downstream reactions involving the products of eNOS
biochemical pathway, NO and O2•- with other ROS, RNS and biopterins (BH4, BH3 and BH2).
The eNOS biochemical pathway produces NO and O2•-, when eNOS is coupled (left) and
uncoupled (right), respectively. The enzymes-substrate complexes are denoted by orange rectangle
and respective rate constants for the reactions involved are indicated. QBH4 and Qsupcell are the rates
of biopterin synthesis and cellular oxidative stress, respectively. Shows the downstream reaction
of NO and O2•- and their mutual reaction product ONOO-. BH4 can be oxidized to BH3 by free
radicals including O2•-, ONOO-, •OH, •NO2 and NO3- to form BH3. The BH3 further oxidizes to
BH2 by molecular O2 (k36).
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Figure 5: Schematics of reaction pathway for computational model for interactions of
eNOS biochemical pathway, cellular oxidative stress and tetrahydrobiopterin synthesis.
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Figure 6: Schematic for interactions of NO and O2•- and their downstream reactions leading
to oxidation of BH4 to BH3 and ultimately to BH2.
The eNOS biochemical pathway and downstream reactions with the respective rate
constants modeled in this study are presented in Table 2 and Table 3. The nomenclature of enzymesubstrate complex involved in eNOS biochemical pathway denoted in Figure 5 can be found in the
parenthesis under species in Table 3. In brief, the key reactions from the eNOS biochemical
pathway for NO production include; (i) the binding of the co-factor BH4 and substrates (L-arginine
and O2) to eNOS, (ii) the oxidation of L-arginine to N-hydroxyl-L-arginine (NHA) through
enzyme substrate complexes (from eNOS-[FeIII-O2-]-BH4-Arg, E1 to eNOS-(FeIII)-BH4-NHA, E2)
and (iii) the oxidation of NHA to form NO and citrulline through enzyme substrate complexes
(from eNOS-(FeIII)-BH4-NHA, E2 to eNOS-(FeIII)-NO-BH4, E4) [93, 187]. The eNOS
biochemical pathway for O2•- production involves the binding of co-factor BH2 and substrates (Larginine and O2) to eNOS [188-191]. However, the inability of BH2 to transfer electron to the
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eNOS heme results in the dissociation of the eNOS-substrate complex eNOS-[FeIII-O2-]-BH2-Arg,
E5 to form O2•- [97, 190].
Table 2: Chemical reactions and rate constants involved in the eNOS biochemical pathway
for NO and O2•- production and their downstream reactions involving NO, ROS, RNS and
biopterins.
Reactions
eNOS − (FeIII ) + BH4 →

kc2

eNOS − (FeIII ) − BH4 →
+ BH4

kc−2

eNOS − (FeIII ) − BH4
eNOS − (FeIII )

ka1

eNOS − (FeIII ) − BH4 + L − Arg →
− (FeIII ) − BH4 − Arg

eNOS

Rate Constants

References

kc2 = 2.20x104 M-1.s-1

[188]

kc-2 = 0.005 s-1

[188]

ka1 = 1.19x106 M-1.s-1

[191]

ka-1 = 3.77 s-1

[191]

ka2 = 0.474 s-1

[192]

ka3 = 8.20x105 M-1.s-1

[97]

ka-3 = 48.3 s-1

[97]

ka5 = 7.68 s-1

[97]

ka6 = 7.68 s-1

[193]

ka−1

eNOS − (FeIII ) − BH4 − Arg →
eNOS
III
− (Fe ) − BH4 + L − Arg
eNOS − (FeIII ) − BH4 − Arg + FMNH2
ka2

+ e− →
eNOS − (FeII ) − BH4
− Arg + FMNH −
ka3

eNOS − (FeII ) − BH4 − Arg + O2 →
eNOS
−
III
− [Fe − O2 ] − BH4 − Arg
ka-3

eNOS − [FeIII − O−
eNOS
2 ] − BH4 − Arg →
II
− (Fe ) − BH4 − Arg + O2
ka5

eNOS − (FeII ) − BH4 − Arg + O2 + e− →
eNOS
− [FeIII − OOH] − BH3 − Arg
ka6

eNOS − [FeIII − OOH] − BH3 − Arg →
eNOS
IV
− [Fe − O] − BH3 − Arg
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ka7

eNOS − [FeIV − O] − BH3 − Arg →
eNOS
III
− (Fe ) − BH3 − NHA

ka7 = 6.85 s-1

[194]

ka8 = 3.62 s-1

[195]

kb1 = 0.1 s-1

[191]

kb-1 = 1x105 M-1.s-1

[191]

kb2 = 0.474 s-1

[192]

kb3 = 9.19x105 M-1.s-1

[97]

kb-3 = 40.5 s-1

[97]

kb5 = 36.6 s-1

[196]

kb6 = 9.45 s-1

[196]

kb7 = 11.5 s-1

[192]

ka8

eNOS − (FeIII ) − BH3 − NHA →
eNOS
III
− (Fe ) − BH4 − NHA
kb1

eNOS − (FeIII ) − BH4 − NHA →
eNOS
− (FeIII ) − BH4 + NHA
kb−1

eNOS − (FeIII ) − BH4 + NHA →
eNOS
III
− (Fe ) − BH4 − NHA
eNOS − (FeIII ) − BH4 − NHA + FMNH2
kb2

+ e− →
eNOS − (FeII ) − BH4
− NHA + FMNH −
kb3

eNOS − (FeII ) − BH4 − NHA + O2 →
eNOS
−
III
− [Fe − O2 ] − BH4 − NHA
kb−3

eNOS − [FeIII − O−
eNOS
2 ] − BH4 − NHA →
II
− (Fe ) − BH4 − NHA + O2
eNOS − [FeIII − O−
2 ] − BH4 − NHA
kb5

+ e− →
eNOS − [FeIII − OOH]
− BH3 − NHA
kb6

eNOS − [FeIII − OOH] − BH3 − NHA →
eNOS
III
− (Fe ) − NO − BH4 + L − Cit
+ H2 O
eNOS − (FeIII ) − NO − BH4 →
− BH4 + NO

kb7

eNOS − (FeIII ) − BH4 + NO →
− NO − BH4

kb−7

eNOS − (FeIII )

eNOS − (FeIII ) kb-7 = 1.7x106 M-1.s-1

[197]
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eNOS − (FeIII ) − NO − BH4 + e− →
− (FeII ) − NO − BH4

kb8

eNOS

kb8 = 7.8x10-3 s-1

[192]

kb9 = 1.76 s-1

[192]

kb10 = 1.76x10-3 s-1

[192]

kb-10 = 3.07x106 M-1.s-1

[197]

kb9

eNOS − (FeII ) − NO − BH4 + O2 →
eNOS
−
III
− (Fe ) − BH4 + ONOO
kb10

eNOS − (FeII ) − NO − BH4 + NO →
− (FeII ) − BH4
kb−10

eNOS − (FeII ) − BH4 →
− BH4 + NO

eNOS

eNOS − (FeII ) − NO

eNOS − (FeII ) − BH4 − NHA →
− BH4 + NHA

kb12

eNOS − (FeII ) kb12 = 3.66 s-1

[191]

kb−12

eNOS − (FeII ) − BH4 + NHA →
eNOS
− (FeII ) − BH4 − NHA
k13

eNOS − (FeII ) − BH4 + L − Arg →
− (FeII ) − BH4 − Arg
k−13

eNOS − (FeII ) − BH4 − Arg →
− BH4 + L − Arg
eNOS − (FeIII ) + BH2 →

kc3

eNOS − (FeIII ) − BH2 →
+ BH2

kc−3

eNOS

eNOS − (FeII )

eNOS − (FeIII ) − BH2
eNOS − (FeIII )

kc4

eNOS − (FeIII ) − BH2 + L − Arg →
− (FeIII ) − BH2 − Arg

eNOS

kb-12 = 1.09x106 M-1.s-1

[191]

k13 = 1.19x106 M-1.s-1

[191]

k-13 = 3.77 s-1

[191]

kc3 = 2.20x104 M-1.s-1

[188]

kc-3 = 0.047 s-1

[188]

kc4 = 1.19x106 M-1.s-1

[191]

kc-4 = 3.77 s-1

[191]

kc−4

eNOS − (FeIII ) − BH2 − Arg →
eNOS
III
− (Fe ) − BH2 + L − Arg
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eNOS − (FeIII ) − BH2 − Arg + FMNH2
kc5

kc5 = 0.474 s-1

[198]

kc6 = 1.73x106 M-1.s-1

[190]

kc-6 = 14.2 s-1

[190]

kc8 = 0.375 s-1

[190]

k14 = 6.7x109 M-1. s-1

[199]

k15 = 2.4x106 M-2.s-1

[200]

k16 = 3.85x109 M-1.s-1

[199]

k17 = 0.6 M-1.s-1

[201]

k18 = 3.9x105 M-1.s-1

[201]

k19 = 4.65 x 104 M-1.s-1

[201]

k22 = 6 x 103 M-1.s-1

[202]

NO3 − + H +

k25 = 0.981 s-1

[200]

• NO2 +• OH

k26 = 0.401 s-1

[200]

k27 = 9.1 x 104 M-1.s-1

[199]

k28 = 3.57x105 M-1.s-1

[200]

+ e− →
eNOS − (FeII ) − BH2
− Arg + FMNH −
kc6

eNOS − (FeII ) − BH2 − Arg + O2 →
eNOS
− [FeIII − O−
]
−
BH
−
Arg
2
2
kc−6

eNOS − [FeIII − O−
eNOS
2 ] − BH2 − Arg →
II
− (Fe ) − BH2 − Arg + O2
kc8

eNOS − [FeIII − O−
eNOS
2 ] − BH2 − Arg →
III
− (Fe ) − BH2 − Arg + O−
2
k14

NO + O2 •− →

ONOO− ↔ ONOOH

4NO + O2 + 2H2 O →
O2 •− + H2 O →
2BH4 + O2 →

SOD, k16

k17

k19

ONOOH →

0.5O2 + 0.5H2 O2 + OH−

k18

BH3 + H2 O2

BH4 + BH2

BH4 + ONOO− →
ONOOH →

4NO2 − + 2H+

2BH2 + 2H2 O

BH4 + O2 •− + H + →
2BH3 →

k15

k25

k26

k22

BH3

ONOO− (ONOOH) + NO →
HO2 + O2 •− + H2 O →

k28

k27

• NO2 + NO2 −

O2 + H2 O2 + OH−
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ONOO− + CO2 →

k29

NO3 − + CO2

k29 = 3.886 x 104 M-1.s-1

[200]

ONOO− + CO2 →

k30

• NO2 + CO3 •−

k30 = 1.915 x 104 M-1.s-1

[200]

k31

HCO3 − + O2

k31 = 6.65 x 108 M-1.s-1

[200]

k32

HCO3 − + NO2 −

k32 = 5.82 x 109 M-1.s-1

[200]

k33 = 8.8 x 109 M-1.s-1

[144]

k34 = 9.4 x 108 M-1.s-1

[144]

k35 = 4.6 x 109 M-1.s-1

[144]

k36 = 3.2 x 103 M-1.s-1

[201]

k38 = 152.5 s-1

Text; [203205]

QBH4 = 0.5 nM.s-1

[206]

CO3 •− + O2 •− + H + →

CO3 •− + NO + OH− →
BH4 +• OH →

k33

BH4 +• NO2 →

k34

BH4 + CO3 •− →
BH3 + O2 →

k36

OH− + H + + BH3

k35

NO2 − + H + + BH3
CO3 2− + H + + BH3

BH2 + HO2 •

BH2 (Diffusion out of cell)

GTPCH →

QBH4

BH4

O2
+ e− (NADPH oxidase/Mitochondria) →

Qsupcell

O2 •−

Text; [183,
Qsupcell = 0.01, 0.1, 1, 10,
184,
207,
100, 1000, 10000 nM.s-1
208]

Table 3: Rate expression of various species involved in the eNOS biochemical pathway for
NO and O2•- production and their downstream reactions.
Species
eNOS-(FeIII)
(E-1)
eNOS-(FeIII)-BH2
(Ec1)

vi (M.s-1)
k c−3 [eNOS − (FeIII ) − BH2 ] − k c−2 [eNOS − (FeIII ) − BH4 ]
− k c3 [BH2 ][eNOS − (FeIII )] − k c2 [eNOS
− (FeIII )][BH4 ]
k c−4 [eNOS − (FeIII ) − BH2 − Arg] + k c3 [BH2 ][eNOS
− (FeIII )] − k c4 [eNOS − (FeIII ) − BH2 ][Arg]
− k c−3 [eNOS − (FeIII ) − BH2 ]
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eNOS-(FeIII)-BH2-Arg
(Ec2)
eNOS-(FeII)-BH2-Arg
(Ec3)

k c4 [eNOS − (FeIII ) − BH2 ][Arg] + k c8 [eNOS − [FeIII − O−
2]
III
− BH2 − Arg] − k c−4 [eNOS − (Fe ) − BH2
− Arg] − k c5 [eNOS − (FeIII ) − BH2 − Arg]
k c5 [eNOS − (FeIII ) − BH2 − Arg] + k c−6 [eNOS − [FeIII
II
− O−
2 ] − BH2 − Arg] − k c6 [eNOS − (Fe )
− BH2 − Arg][O2 ]

-

eNOS-[FeIII-O2 ]-BH2-Arg
or
eNOS-[FeII-O2]-BH2-Arg

k c6 [eNOS − (FeII ) − BH2 − Arg][O2 ] − k c8 [eNOS − [FeIII
III
− O−
2 ] − BH2 − Arg] − k c−6 [eNOS − [Fe
−
− O2 ] − BH2 − Arg]

(Ec4)

eNOS-(FeIII)-BH4
(E)

eNOS-(FeIII)-BH4-Arg
(Ea1)

eNOS-(FeII)-BH4-Arg
(Ea2)

k c2 [eNOS − (FeIII )][BH4 ] + k a−1 [eNOS − (FeIII ) − BH4
− Arg] + k b1 [eNOS − (FeIII ) − BH4 − NHA]
+ k b7 [eNOS − (FeIII ) − NO − BH4 ]
+ k b9 [eNOS − (FeIII ) − NO − BH4 ]
+ k b9 [eNOS − (FeII ) − NO − BH4 ]
− k c−2 [eNOS − (FeIII ) − BH4 ] − k a1 [eNOS
− (FeIII ) − BH4 ][Arg] − k b−1 [NHA][eNOS
− (FeIII ) − BH4 ] − k b−7 [eNOS − (FeIII )
− BH4 ][NO]
k a1 [eNOS − (FeIII ) − BH4 ][Arg] − k a−1 [eNOS − (FeIII )
− BH4 − Arg] − k a2 [eNOS − (FeIII ) − BH4
− Arg]
k a2 [eNOS − (FeIII ) − BH4 − Arg]
+ k a−3 [eNOS − [FeIII − O−
2 ] − BH4 − Arg]
II
+ k 13 [Arg][eNOS − (Fe ) − BH4 ]
− k −13 [eNOS − (FeII ) − BH4 − Arg]
− k a3 [eNOS − (FeII ) − BH4 − Arg][O2 ]

-

eNOS-[FeIII-O2 ]-BH4-Arg
or
eNOS-[FeII-O2]-BH4-Arg

k a3 [eNOS − (FeII ) − BH4 − Arg][O2 ] − k a5 [eNOS − [FeIII
III
− O−
2 ] − BH4 − Arg] − k a−3 [eNOS − [Fe
− O−
2 ] − BH4 − Arg]

(Ea3)
eNOS-[FeIII-OOH]-BH3Arg
(Ea4)

III
k a5 [eNOS − [FeIII − O−
2 ] − BH4 − Arg] − k a6 [eNOS − [Fe
− OOH] − BH3 − Arg]
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eNOS-[FeIV-O]-BH3-Arg
(Ea5)

eNOS-(FeIII)-BH3-NHA
(Ea6)
eNOS-(FeIII)-BH4-NHA
(Eb1)

eNOS-(FeII)-BH4-NHA
(Eb2)

[eNOS − (FeIII )] + [eNOS − (FeIII ) − BH2 ]
+ [eNOS − (FeIII ) − BH2 − Arg]
+ [eNOS − (FeII ) − BH2 − Arg]
+ [eNOS − [FeIII − O−
2 ] − BH2 − Arg]
+ [eNOS − (FeIII ) − BH4 ]
+ [eNOS − (FeIII ) − BH4 − Arg]
+ [eNOS − (FeII ) − BH4 − Arg] + [eNOS
III
− [FeIII − O−
2 ] − BH4 − Arg] + [eNOS − [Fe
− OOH] − BH3 − Arg] + [eNOS − [FeIV − O]
− BH3 − Arg] + [eNOS − (FeIII ) − BH3
− NHA] + [eNOS − (FeIII ) − BH4 − NHA]
+ [eNOS − (FeII ) − BH4 − NHA] + [eNOS
− [FeIII − O−
2 ] − BH4 − NHA] + [eNOS
III
− [Fe − OOH] − BH3 − NHA] + [eNOS
− (FeIII ) − NO − BH4 ] + [eNOS − (FeII )
− NO − BH4 ] + [eNOS − (FeII ) − BH4 ]
− [eNOS]
k a7 [eNOS − [FeIV − O] − BH3 − Arg] − k a8 [eNOS − (FeIII )
− BH3 − NHA]
k a8 [eNOS − (FeIII ) − BH3 − NHA] + k b−1 [NHA][eNOS
− (FeIII ) − BH4 ] − k b2 [eNOS − (FeIII ) − BH4
− NHA] − k b1 [eNOS − (FeIII ) − BH4 − NHA]
k b2 [eNOS − (FeIII ) − BH4 − NHA] + k b−3 [eNOS − [FeIII
II
− O−
2 ] − BH4 − NHA] + k b−12 [eNOS − (Fe )
− BH4 ][NHA] − k b3 [eNOS − (FeII ) − BH4
− NHA][O2 ] − k b12 [eNOS − (FeII ) − BH4
− NHA]

-

eNOS-[FeIII-O2 ]-BH4-NHA
or
eNOS-[FeII-O2]-BH4-NHA
(Eb3)
eNOS-[FeIII-OOH]-BH3NHA
(Eb4)
III

eNOS-(Fe )-NO-BH4
(Eb5)

k b3 [eNOS − (FeII ) − BH4 − NHA][O2 ] − k b−3 [eNOS
− [FeIII − O−
2 ] − BH4 − NHA] − k b5 [eNOS
III
− [Fe − O−
2 ] − BH4 − NHA]
k b5 [eNOS − [FeIII − O−
2 ] − BH4 − NHA] − k b6 [eNOS
III
− [Fe − OOH] − BH3 − NHA]
k b6 [eNOS − [FeIII − OOH] − BH3 − NHA] + k b−7 [eNOS
− (FeIII ) − BH4 ][NO] − k b8 [eNOS − (FeIII )
− NO − BH4 ] − k b7 [eNOS − (FeIII ) − NO
− BH4 ]

39

eNOS-(FeII)-NO-BH4
(Eb6)

eNOS-(FeII)-BH4
(Eb7)

k b8 [eNOS − (FeIII ) − NO − BH4 ] + k b−10 [NO][eNOS
− (FeII ) − BH4 ] − k b10 [eNOS − (FeII ) − NO
− BH4 ] − k b9 [eNOS − (FeII ) − NO − BH4 ]
k b10 [eNOS − (FeII ) − NO − BH4 ] + k −13 [eNOS − (FeII )
− BH4 − Arg] + k b12 [eNOS − (FeII ) − BH4
− NHA] − k b−10 [NO][eNOS − (FeII ) − BH4 ]
− k b−12 [eNOS − (FeII ) − BH4 ][NHA]
− k 13 [eNOS − (FeII ) − BH4 ][Arg]

NO

k b7 [eNOS − (FeIII ) − NO − BH4 ] + k b10 [eNOS − (FeII )
− NO − BH4 ] − k b−7 [NO][eNOS − (FeIII )
− BH4 ] − k b−10 [eNOS − (FeII ) − BH4 ][NO]
− 4k15 [NO]2 [O2 ] − k 14 [NO][O•−
2 ]
− 0.22k27 [ONOO− ][NO] − k 32 [NO][CO•−
3 ]

Citrulline

k b6 [eNOS − [FeIII − OOH] − BH3 − NHA]

NHA

k b1 [eNOS − (FeIII ) − BH4 − NHA] + k b12 [eNOS − (FeII )
− BH4 − NHA] − k b−1 [NHA][eNOS − (FeIII )
− BH4 ] − k b−12 [NHA][eNOS − (FeII ) − BH4 ]

NO3

-

k b9 [eNOS − (FeII ) − NO − BH4 ] + k 25 [ONOO− ]
+ k 29 [ONOO− ][CO2 ]

O2•-

•−
k c8 [eNOS − [FeIII − O−
2 ] − BH2 − Arg] − k 14 [NO][O2 ]
•− 2
− k 16 [SOD][O•−
2 ] − 0.0025k28 [O2 ]
•−
•−
− k 31 [O2 ][CO3 ] − k 18 [BH4 ][O•−
2 ]

H2O2

•− 2
•−
k 16 [SOD][O•−
2 ] + 0.0025k28 [O2 ] + k 18 [BH4 ][O2 ]

BH4

QBH4 + 2k19 [BH3 ]2 + k 20 [BH3 ] + k c−2 [eNOS − (FeIII )
− BH4 ] − k c2 [eNOS − (FeIII )][BH4 ] − k 33 [
• OH][BH4 ]-k34 [
• NO2 ][BH4 ]-k35 [CO•−
3 ][BH4 ]
−
− k 22 [BH4 ][ONOO ] − k 17 [BH4 ][O2 ]
− k18 [BH4 ][O2•− ]

BH3

k 33 [• OH][BH4 ] + k 34 [• NO2 ][BH4 ] + k 35 [CO•−
3 ][BH4 ]
+ k 22 [BH4 ][ONOO− ] + k 18 [BH4 ][O•−
2 ]
2
− 2k19 [BH3 ] − k 36 [BH3 ][O2 ]

BH2

k 17 [BH4 ][O2 ] + k 36 [BH3 ][O2 ] − k c−3 [eNOS − (FeIII )
− BH2 ] − k c−3 [eNOS − (FeIII ) − BH2 ]
− k 38 [BH2 ]

ONOO-

−
−
k 14 [NO][O•−
2 ] − k 25 [ONOO ] − k 26 [ONOO ]
−
− k 29 [ONOO ][CO2 ] − k 30 [ONOO− ][CO2 ]
− 0.22k27 [ONOO− ][NO]
− k 22 [BH4 ][ONOO− ]
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NO2

4k15 [NO]2 [O2 ] + 0.22k27 [NO][ONOO− ] + k 32 [CO•−
3 ][NO]
+ k 34 [• NO2 ][BH4 ]

-

•OH

k 26 [ONOO− ] − k 33 [• OH][BH4 ]

•NO2

k 26 [ONOO− ] + k 30 [ONOO− ][CO2 ] + 0.22k27 [ONOO− ][NO]
− k 34 [• NO2 ][BH4 ]

CO3•-

•−
•−
k 30 [ONOO− ][CO2 ] − k 31 [CO•−
3 ][O2 ] − k 32 [CO3 ][NO]
− k 35 [CO•−
3 ][BH4 ]

RNO
(NO Production)
RO2•(Superoxide Production)

k b7 [eNOS − (FeIII ) − NO − BH4 ] + k b10 [eNOS − (FeII )
− NO − BH4 ]
k c8 [eNOS − [FeIII − O−
2 ] − BH2 − Arg]

The cellular oxidative stress and BH4 synthesis are represented by production rate terms
for O2•- (Qsupcell) and BH4 (QBH4). Qsupcell (M.s-1) represent the sum of O2•- production rate from
non-eNOS based sources including NADPH and xanthine oxidase, and mitochondria, while QBH4
(M.s-1) represent the rate of BH4 synthesis by guanosine triphosphate cyclohydrolase I (GTPCH).
GTPCH is a key enzyme in de novo synthesis pathway for the endogenous production of BH4 [94,
133]. The activity of GTPCH is reported to increase [134, 135] or reduce [136] in oxidative stress
conditions. We have accounted for the extracellular diffusion of BH2 (k38) since BH4 is reported
to have very low permeability across the endothelial cell membrane [209] and BH3 has an
extremely short half-life [144]. The main downstream reactions include (i) the reaction between
NO and O2•- to form ONOO-, which is in an acid-base equilibrium with peroxynitrous acid
(ONOOH), (ii) the formation of RNS (•NO2) and ROS (•OH and CO3•-) from the interaction of
ONOO- with CO2 and NO, respectively and by dissociation of ONOOH, (iii) the self and SODcatalyzed dismutation of O2•- to form H2O2 , (iv) the oxidation of BH4 to biopterin radical (BH3)
by ROS (O2•-, •OH and CO3•-) and RNS (ONOO- and •NO2), and (v) the oxidation of BH4 and BH3
to BH2 by O2.
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3.2.2. Model Assumptions
The current model is developed for dimeric eNOS since O2•- generated from monomeric eNOS
is negligible compared to dimeric eNOS [23, 210].
1) The NO production rate is assumed to be independent of the geometrical location of eNOS
within the endothelial cell based on an earlier eNOS catalysis modeling study [187].
2) All chemical species involved in the eNOS biochemical pathways and downstream reactions
are assumed to have uniform concentration within the endothelial cell similar to earlier
modeling studies of eNOS catalysis [93, 170, 187].
3) The model accounts for eNOS uncoupling due to oxidative depletion of BH4 and binding of
BH2 to eNOS. Other molecular mechanisms for eNOS uncoupling including protein
phosphorylation, S-glutathionylation requires eNOS modification and are not considered in
this study [211].
3.2.3. Computational Model
The model equations are formulated by applying the law of mass action kinetics to the
chemical species involved in the eNOS biochemical pathways and the downstream reactions. A
total of 33 distinct chemical species are involved in the eNOS biochemical pathways and
downstream reactions. We have used 33 rate equations to model the temporal changes in
concentration of these species. Mathematically, the rate equations for 32 of these chemical species
including BH4 and BH2 can be represented as:
𝑑[𝑆𝑖 ]
= 𝑉𝑖
dt

(1)

In equation (1), [Si] (in M) represents the concentration of the ith chemical species. Vi (in
M.s-1) represents the rate expression of the ith chemical species. Mathematically, Vi represents the
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summation of the generation rates subtracted by the consumption rates of species i from its
participating reactions. To account for the mass conservation of eNOS, the rate equation of an
intermediate eNOS-substrate complex (33rd species) was set in the form of an algebraic equation
as follows:
[eNOS] = [𝐸] + [𝐸−1 ] + ∑[𝐸ai ] + ∑[𝐸bi ] + ∑[𝐸ci ]

(2)

In equation (2), [E] and [E-1] represent the different forms of native eNOS. [Eai], [Ebi] and
[Eci] represent the different forms of the eNOS-substrate complex while [eNOS] represents the
total eNOS concentration. In addition to the 33 rate equations described above, 2 other rate
equations were used to represent NO and O2•- production rates, respectively. The rate equations of
NO and O2•- production includes the summation of the generation terms for the respective species.
The expressions of Vi for the 35 different rate equations are shown in Table 2.
3.2.4. Model Parameters
The key model parameters in this study are the rate constants for the different reactions
involved, enzyme concentration, substrate concentration, co-factor concentration, rate of
extracellular diffusion of BH2 (k38), BH4 synthesis rate by GTPCH (QBH4) and O2•- production rate
from non-eNOS based sources (Qsupcell). The model parameters involving eNOS biochemical
pathway related NO and O2•- production and their downstream reactions are listed in Table 4. Most
of these parameters and reaction rate constants were adopted from literature based on the previous
computational modeling work on eNOS catalysis [93, 170]. The rate constants that were measured
at different temperatures were scaled up to the physiologically relevant temperature of 37ºC using
the Arrhenius equation as detailed in Kar and Kavdia [93]. Some of the rate constants used in our
model, as detailed in Table 1, were obtained from neuronal NOS (kc2, kc-2, kc3, kc-3) and inducible
NOS (kc5) isoforms. The [TBP] at t=0 minute was set at an initial value of 7 µM based on reported
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BH4 concentration of 2.6 pmol/106 cells in endothelial cells [212] and oxidized biopterin represents
a small amount (~5–10%) of total biopterin under normal physiologic conditions [95].
Table 4: Kinetic parameters related to eNOS biochemical pathways for NO and O 2•production
Variable/Constant

Values and Units

References

[eNOS]

0.097 µM

[93, 170, 187]

Vmax (eNOS)

0.585 µmol min-1.mg-1

[187, 213]

[NADPH]

166-295 µM

[214]

[CaM]

5 µM

[215]

[Ca2+]

0.013-0.280 µM

[214, 216]

[L-Arginine]

100 µM

[93, 170]

[O2]

140 µM

[93, 170]

[CO2]

1.1 mM

[93, 170]

[SOD]

10 µM

[93, 170]

Km (NADPH)

0.65 µM

[213]

Km (O2)

7.7 µM

[217]

Km (L-Arginine)

2.9-5 µM

[187, 213]

EC50 (Ca2+)

0.11 µM

[187, 213]

EC50 (CaM)

0.009 µM

[187, 213]

Endothelial cell volume

400 µm3

[187]

Endothelial cell radius

10-20 µm

[187]

Endothelial cell thickness

0.5-1.0 µm

[187]

BH2 diffusion coefficient

1×10-9 m2.s-1

[205, 209]

Under physiologic conditions, the reported activity of GTPCH was 7 pmoles.mg protein 1

.hr-1 [206]. This corresponds to QBH4 of 0.5 nM.s-1 based on reported values of endothelial cell

dimensions and total protein content [93, 187]. Hasegawa and co-workers [204, 205, 218]
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measured the transport parameters (diffusion coefficient and permeability) related to extracellular
diffusion of BH2. Based on their reported values and endothelial cell dimensions [93, 187], the
apparent first order rate constant [203] for extracellular BH2 diffusion (k38) was estimated to be
152.5 s-1. To assess the role of oxidative stress on eNOS catalysis, we used Qsupcell values of 0.01,
0.1, 1, 10, 100, 1000 and 10000 nM.s-1. This range was established based on the reported
endothelial O2•− production rates of 0.016 nM.s-1 to 6000 nM.s-1 under normal and oxidative stress
experimental conditions [93, 183, 199, 207, 219, 220]. To represent initial state of eNOS coupling
or uncoupling, we used a biopterin ratio ([BH4]/[TBP]) of 0.99, 0.7, 0.25 and 0.05 at t=0 minute
[170, 221].
3.2.5. Numerical Solution
The rate equations in the form of equation (1) or (2) as listed in Table 2 were solved
numerically with the appropriate initial conditions using the MATLAB (Mathworks Inc, Natick,
MA) ordinary differential equation solver ode15s. The relative and absolute error tolerance values
were set at 1×10-10 and 1×10-15 respectively. The simulations were run for 5×105 s (8333 minutes)
such that all the chemical species participating in the eNOS biochemical pathways and downstream
reactions attain steady state.
3.3. Results
3.3.1. NO production rate is independent of the initial state of eNOS coupling for Q supcell ≤ 1
nM.s-1
We analyzed the temporal changes in the eNOS related NO and O2•− production rates,
biopterin ratio and TBP levels at the Qsupcell of 0.01, 0.1, and 1 nM.s-1. These Qsupcell values represent
the normal physiological or basal O2•− production from endothelial cells [199, 207, 220]. The
[BH4]/[TBP] @ t=0 minute was set at 0.99, 0.7, 0.25 and 0.05. The BH4 synthesis was set at QBH4
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= 0.5 nM.s-1. For all simulations, the intracellular concentration of eNOS, L-arginine, O2, CO2 and
initial [TBP] were maintained at 0.097 µM, 100 μM, 140 μM, 1.1 mM and 7 μM, respectively.
The steady state eNOS NO production is independent of initial biopterin ratio and is
constant for Qsupcell between 0.01 and 1 nM.s-1. Figure 7A and C shows the temporal variation in
the eNOS based NO and O2•- production rates at the Qsupcell of 0.01 and 1 nM.s-1. The data for 0.1
nM.s-1 Qsupcell is not shown as the data was similar to that of at the Qsupcell=0.01 nM.s-1. For Qsupcell
at 0.01 and 1 nM.s-1, the NO production rate profiles did not change and reached a steady state
value of 26.5 and 26.4 nM.s-1, respectively. These NO production rate profiles were irrespective
of [BH4]/[TBP] @ t=0 minute set at 0.99, 0.7, 0.25 and 0.05, respectively. However, the O2•production rate initially increased to reach a peak value in less than 9 minutes and later reached a
steady state value equal to the respective Qsupcell.
This temporal change was dependent on the [BH4]/[TBP] @ t=0 minute and reflect the
eNOS related O2•- production above the respective Qsupcell. The peak value of eNOS related O2•production rate was 12 pM.s-1 for the [BH4]/[TBP] @ t=0 minute of 0.05 and Qsupcell between 0.01
and 1 nM.s-1. For Qsupcell between 0.01 and 1 nM.s-1, the [BH4]/[TBP] at steady state was 0.99
(Figure 7B and D). The steady state [TBP] decreased with increasing Qsupcell. The steady state
[TBP] were 5.9, 5.7 and 3.8 µM at the Qsupcell of 0.01, 0.1, and 1 nM.s-1, respectively.
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Figure 7: Temporal variations in eNOS NO and O2•- production rates, [BH4]/[TBP] and
[TBP] for normal physiologic conditions. Panel A and C shows the time dependent variation in
NO and O2•- production rates at Qsupcell = 0.01 and 1 nM.s-1, respectively. Panel B and D
represents the temporal variation in the [BH4]/[TBP] and [TBP] at Qsupcell = 0.01 and 1 nM.s-1,
respectively. The [BH4]/[TBP] @ t=0 minute were set at 0.99, 0.7, 0.25 and 0.05, respectively.
The concentrations of L-arginine, O2, SOD, CO2 and eNOS were set at 100 µM, 140 µM, 10 µM,
1.1 mM and 0.097 µM, respectively. The QBH4 was set at 0.5 nM.s-1. The [TBP] @ t=0 minute was
set at 7 µM for all the cases simulated. The profiles for Qsupcell = 0.1 nM.s-1, which are similar
to that of at 0.01 nM.s-1, are not shown.

3.3.2. Extent of oxidative stress determines eNOS uncoupling in endothelial cells
Persisting oxidative stress renders eNOS uncoupled that can further potentiate cellular
oxidative stress [140]. To understand the effect of cellular oxidative stress levels on eNOS related
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NO and O2•- production, Qsupcell was increased to 10, 100, 1000 and 10000 nM.s-1. The results show
that variation in endothelial cell oxidative stress level increases the extent of eNOS uncoupling
and introduces instabilities in the eNOS based NO production rate. Figure 8A-D shows the
temporal profile of eNOS catalyzed NO production rate. For Qsupcell of 10 nM.s-1 (Figure 8A), the
NO production rate reached a peak value of 23.0-24.0 nM.s-1 in 17-75 minutes for the [BH4]/[TBP]
@ t=0 minute of 0.05-0.99, respectively. The NO production rates subsequently reduced with time
to reach a minimum of 0.45-0.43 nM.s-1 in 876-959 minutes for the [BH4]/[TBP] @ t=0 minute of
0.05-0.99, respectively. Thereafter, the NO production rates exhibited an oscillatory profile with
6.4 nM.s-1 amplitude of the oscillations.
For Qsupcell 100 nM.s-1 (Figure 8B), the NO production rates initially increased to reach
maximum values ranging from 17.0-18.0 nM.s-1 in 8 minutes. The NO production rates
subsequently reduced to a minimum value of 0.005 nM.s-1 within 1893-1952 minutes. Thereafter,
the NO production rates exhibited an oscillatory profile in the time range of 1893-2519 minutes.
After 2519 minutes, the oscillations damped out to reach a new steady state value of 2.0 nM.s-1.
For Qsupcell 1000 and 10000 nM.s-1 (Figure 8C and D), the NO production rate increased to
reach a peak followed by a reduction to a minimum and then demonstrated a step change increase
\to reach a new steady state value. The peak NO production rate ranged from 14.4-16.6 nM.s-1 for
Qsupcell of 1000 nM.s-1 and 13.9-16 nM.s-1 for Qsupcell of 10000 nM.s-1. A minimum NO production
rate of 0.004 nM.s-1 was reached for both the Qsupcell. The steady-state NO production rate of 1.9
nM.s-1 was reached within 1851-2044 minutes for Qsupcell 1000 nM.s-1 and 1.5 nM.s-1 was reached
within 1900-2135 minutes for Qsupcell of 10000 nM.s-1.
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Figure 8: Cellular oxidative stress and eNOS NO production rate. Panels A-D show the
temporal variation in eNOS NO production rate for increase in Qsupcell from 10, 100, 1000 and
10000 nM.s-1, respectively. The concentrations of L-arginine, O2, SOD, CO2 and eNOS were 100
µM, 140 µM, 10 µM, 1.1 mM and 0.097 µM, respectively. QBH4 was 0.5 nM.s-1. The [TBP] @ t=0
minute was 7 µM. The [BH4]/[TBP] @ t=0 minute was 0.99, 0.7, 0.25 and 0.05, respectively. The
inset in Panel B shows the magnified view of the oscillations in the temporal profile of eNOS NO
production rate in the time range of 1850-2650 minutes at Qsupcell = 100 nM.s-1.
The overall endothelial cell O2•- production rates remained the same as the respective
Qsupcell (results not shown). The eNOS based O2•- production ranged from 0.0-0.012 nM.s-1 for the
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oxidative stress conditions simulated in this study. Thus, eNOS uncoupling had minimal effect on
the endothelial cell O2•- production at higher Qsupcell.
3.3.3. Oxidative stress induces temporal perturbations in the biopterin ratio
To understand the oxidative stress dependent variation of the eNOS based NO and O2•production rates, Figure 9A-D shows the temporal variation in [BH4]/[TBP] for Qsupcell 10, 100,
1000 and 10000 nM.s-1, respectively for all values of [BH4]/[TBP] @ t=0 minute.
For Qsupcell of 10 nM.s-1 (Figure 9A), the [BH4]/[TBP] showed oscillatory profile with
similar amplitude and frequency for all values of [BH4]/[TBP] @ t=0 minute. However, there was
a time delay in the oscillation which increased with increasing [BH4]/[TBP] @ t=0 minute values.
The oscillation did not dampen with time. For Qsupcell of 100 nM.s-1 (Figure 9B), the [BH4]/[TBP]
showed an oscillatory behavior that damped with time to reach a steady state value of 0.26 for all
initial [BH4]/[TBP] @ t=0 minute values. However, the oscillation-amplitude were lower and
frequency were higher for Qsupcell at 100 nM.s-1 compared to the oscillation-amplitude and
frequency for Qsupcell at 10 nM.s-1. For Qsupcell of 1000 and 10000 nM.s-1 (Figure 9C and D), we
observed a pulse in the [BH4]/[TBP] profile before reaching a steady state value of 0.25 and 0.2,
respectively for all initial values of [BH4]/[TBP] @ t=0 minute. There was a delay in the pulse
with increasing initial [BH4]/[TBP] @ t=0 minute values.
The [BH4]/[TBP] profiles clearly demonstrates that oxidative stress renders an imbalance
between BH4 synthesis and oxidation and induces temporal perturbations in the biopterin ratio.
The perturbations in the biopterin ratio causes pertubations in eNOS NO production rate (as shown
in Figure 8) and thus leads to eNOS uncoupling.
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Figure 9: Cellular oxidative stress and biopterin ratio ([BH4]/[TBP]). Panels A-D show the
temporal variation in the [BH4]/[TBP] corresponding to Qsupcell values of 10, 100, 1000 and 10000
nM.s-1, respectively. The [BH4]/[TBP] @ t=0 minute were 0.99, 0.7, 0.25 and 0.05, respectively.
The concentrations of L-arginine, O2, SOD, CO2 and eNOS were set at 100 µM, 140 µM, 10 µM,
1.1 mM and 0.097 µM, respectively. The QBH4 was 0.5 nM.s-1 and [TBP] @ t=0 minute was 7 µM.
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3.3.4. Enhancement of BH4 synthesis may restore eNOS coupling under oxidative stress
conditions
In addition to altered expression of GTPCH during oxidative stress condition, de novo
synthesis of BH4 has been targeted as a novel therapeutic approach for the treatment of endothelial
dysfunction [26, 222]. To understand the effect of enhanced BH4 synthesis on eNOS coupling
under oxidative stress conditions, we simulated eNOS based NO production in endothelial cells at
QBH4 values of 0.5, 1, 1.5 and 5 nM.s-1 for increase in Qsupcell from 0.01 to 10000 nM.s-1. For these
simulations, we used initial [BH4]/[TBP] @ t=0 minute of 0.05. For an increase in the QBH4, the
eNOS NO production and biopterin ratio increased at oxidative stress levels above 1 nM.s-1 and
[TBP] increased at all oxidative stress levels (Figure 10 and 6). In addition, the time required for
eNOS NO production to reach steady state reduced in all simulation above Qsupcell of 1 nM.s-1. For
increase in Qsupcell from 0.01 to 1 nM.s-1 (results not shown), the NO production remained constant
at 26.5 nM.s-1 for all QBH4 rates simulated.
For Qsupcell of 10 nM.s-1 (Figure 10A), at QBH4=1.5 nM.s-1 and above, the eNOS NO
production was 25.3 nM.s-1, similar to normal physiologic predictions of eNOS NO production. In
addition, there were oscillations in eNOS NO production at QBH4=0.5 and 1 nM.s-1 that disappeared
at QBH4 ≥1.5 nM.s-1. For Qsupcell of 100 nM.s-1 (Figure 10B), the steady state eNOS NO production
rates were 2.0, 4.1, 6.2 and 20.0 nM.s-1 at QBH4=0.5, 1, 1.5 and 5 nM.s-1, respectively. This
represents a 10-fold increase in eNOS NO production for a 10-fold increase in QBH4. At QBH4 of
0.5, 1, 1.5 and 5 nM.s-1, the steady state eNOS NO production rates were 1.9, 3.8, 5.6 and 16.0
nM.s-1, respectively for Qsupcell of 1000 nM.s-1 (Figure 10C) and were 1.5, 3.0, 4.4 and 12.2 nM.s1

, respectively for Qsupcell of 10000 nM.s-1 (Figure 10D). This represents a maximum of 8-fold

increase in NO production for a 10-fold increase in QBH4 at higher Qsupcell (1000-10000 nM.s-1).
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Figure 10: Effect of increased BH4 synthesis and cellular oxidative stress on eNOS NO
production rate. Panels A-D show the temporal variation in the eNOS NO production rate with
increasing QBH4 corresponding to Qsupcell of 10, 100, 1000 and 10000 nM.s-1, respectively. The
increase in QBH4 were set at 0.5, 1, 1.5 and 5 nM.s-1. The [BH4]/[TBP] @ t=0 minute was 0.05 and
[TBP] @ t=0 minute was 7 µM. The concentrations of L-arginine, O2, SOD, CO2 and eNOS were
set at 100 µM, 140 µM, 10 µM, 1.1 mM and 0.097 µM, respectively.
Even though the [TBP] increased with QBH4, the [TBP] was affected from cellular oxidative
stress (Figure 11A). The [TBP] did not reach to normal levels and remained below 1 µM under

53
oxidative stress conditions except for QBH4 5 nM.s-1 at Qsupcell=10 nM.s-1. For increase in QBH4
from 0.5 to 5 nM.s-1, the [TBP] increased from 5.9 to 59.5 µM for Qsupcell=0.01 nM.s-1; 5.7 to 59.2
µM for Qsupcell=0.1 nM.s-1; 3.75 to 56.6 µM for Qsupcell=1 nM.s-1; 0.002 to 32.8 µM for Qsupcell=10
nM.s-1; 0.002 to 0.02 µM for Qsupcell=100 nM.s-1; 0.001 to 0.03 µM for Qsupcell=1000 nM.s-1 and
0.001 to 0.02 µM for Qsupcell=10000 nM.s-1.
The steady state biopterin ratio remained 0.99 for all simulated QBH4 rates for Qsupcell ≤ 1
nM.s-1 (Figure 11B). For Qsupcell of 10 nM.s-1, the [BH4]/[TBP] were 0.4, 0.7, 0.99, and 0.99 for
QBH4 of 0.5, 1, 1.5 and 5 nM.s-1, respectively. For Qsupcell of 100, 1000 and 10000 nM.s-1, the
[BH4]/[TBP] increased from 0.26 to 0.94, 0.25 to 0.66, and 0.2 to 0.36, respectively for increase
in QBH4 from 0.5 to 5 nM.s-1. For oxidative stress above 100 nM.s-1, the biopterin ratio improved
significantly for 10-fold increase in BH4 synthesis.
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Figure 11: Effect of increased BH4 synthesis and cellular oxidative stress on [TBP] and
biopterin ratio. Panel A shows temporal variation in the [TBP] and Panel B shows temporal
variation in the [BH4]/[TBP] corresponding to the QBH4 of 0.5, 1, 1.5 and 5 nM.s-1 @ t=0 minute
in oxidative stress condition. The Qsupcell were set at 0.01, 0.1, 1, 10, 100, 1000 and 10000 nM.s-1.
The [BH4]/[TBP] @ t=0 minute were set at 0.99, 0.7, 0.25 and 0.05 respectively. The
concentrations of L-arginine, O2, SOD, CO2 and eNOS were set at 100 µM, 140 µM, 10 µM, 1.1
mM and 0.097 µM, respectively. The [TBP] @ t=0 minute was set at 7 µM for all the simulated
cases.
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3.3.5. Sensitivity analysis for eNOS related O2•- production
The maximum eNOS O2•- production rate at Qsupcell of 0.01, 0.1, 1, 10, 100, 1000 and 10000 nM.s1

were 11.769, 11.770, 11.772, 11.793, 11.960 and 12.245 pM.s-1 respectively. As the O2•- production rate

due to eNOS uncoupling stayed near 12 pM.s-1, even though we increased non-eNOS based cellular
oxidative stress, we inferred that eNOS uncoupling contributes negligibly towards endothelial cell oxidative
stress. A sensitivity analysis for the rate constants involved in eNOS O2•- production was performed. The
sensitivity analysis was performed mainly on the forward rate constants involved in the eNOS uncoupling
pathway leading to O2•- production. The rate constants analyzed were kc3, kc4, kc5, kc6, kc8, k38, k17 and k36 at
Qsupcell of 1 and 100 nM.s-1 at initial biopterin ratio of 0.05 and QBH4 of 0.5 nM.s-1 at t=0 minute. The
sensitivity analysis for these rate constants was performed in the range of 50 to 200 % where, 100%
indicates the control value of the respective rate constant. The results from the sensitivity analysis showed
that the decrease in diffusion rate of BH2 (k38) increases the eNOS O2•- production rate at physiologic and
oxidative stress condition (Figure 12). The increase in rate constant kc3, kc4 and kc5 increases the eNOS O2•production rate. The rate constants kc6, kc8 and k36 does not affect the eNOS O2•- production rate. The
increase in the oxidation rate of BH4 (k17) increases the eNOS O2•- production at Qsupcell of 1 nM.s-1 but is
insensitive at Qsupcell of 100 nM.s-1. The range in which the eNOS O2•- production rate changed was 0.5 to 4
x10-6 nM.s-1 for Qsupcell of 1 nM.s-1. This eNOS O2•- production rate further decreased by three orders of
magnitude when Qsupcell increased to 100 nM.s-1.
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Figure 12: Sensitivity analysis for eNOS related O2•- production. Panel A and B represents the
steady state eNOS O2•- production rate for Qsupcell of 1 and 100 nM.s-1, respectively. The % control
values at 100 represents the base value of respective rate constant. The rate constant kc3, kc4, kc5,
kc6 and kc8 are involved in eNOS biochemical pathway for O2•- production. The rate constants k17
and k36 are oxidation rates of BH4 and BH3 respectively and k38 is the diffusion rate of BH2 out of
the cell. The [BH4]/[TBP] was 0.05, QBH4 was 0.5 nM.s-1 and [TBP] was 7 µM @ t=0 minute.
The concentrations of L-arginine, O2, SOD, CO2 and eNOS were set at 100 µM, 140 µM, 10 µM,
1.1 mM and 0.097 µM, respectively.

3.4. Discussions
In this study, we investigated the impact of cellular oxidative stress and BH4 on eNOS NO
production and the biopterin ratio in endothelial cells. We found that oxidative stress reduces
eNOS NO production and sets an oscillatory profile in endothelial NO production and biopterin
ratio. Furthermore, the enhancement of BH4 synthesis may improve eNOS coupling and NO
production under oxidative stress condition.
3.4.1. eNOS remains coupled under normal physiologic conditions with small perturbations
in oxidative stress
Vascular endothelial cells maintains basal levels of BH4 synthesis [180, 223] and ROS
production [27, 181, 223] under normal physiologic conditions. The redox homeostasis of

57
endothelial cells is maintained by a low amount of ROS production [224-226] and the presence of
antioxidant enzymes [170, 227] and/or reducing agents including ASC and GSH [142, 228]. Under
physiologic conditions, endothelial cells maintain its functions such as sustained NO production
rate, BH4 levels, and eNOS remains coupled [25, 229]. Similar observations were found in the
present study. Oxidative stress in the range of 0.01 to 1 nM.s-1 did not affect steady state NO
production rate (~26.5 nM.s-1). The model predicted that the steady state eNOS NO production
and biopterin ratio are independent of the initial-biopterin ratio or state of eNOS coupling for
Qsupcell of 0.01 to 1 nM.s-1. In addition, this NO production rate is in agreement with the
experimental measurements from purified coupled eNOS at 1 µM concentration [221] and from
previous computational models for coupled eNOS catalysis [93, 170, 187]. We can interpret that
0.01 to 1 nM.s-1 represents the physiologic oxidative stress level and small changes in this range
do not affect eNOS NO production. Thus, eNOS remains in coupled state under physiologic
conditions. However, when the cellular oxidative stress was increased above 1 nM.s-1, the eNOS
coupling and NO production transitioned to an oscillatory state.
3.4.2. eNOS uncoupling contributes negligibly towards cellular oxidative stress
Studies have proposed that eNOS uncoupling related transition from NO to O2•- production
may contribute significantly towards cellular oxidative stress [2, 27, 230]. On the other hand, some
studies reported that the eNOS uncoupling does not contribute significantly to cellular oxidative
stress [19, 185]. The major sources of O2•- generation are NADPH oxidase, xanthine oxidase and
mitochondrial electron transport chain in diseases including hypertension, hypercholesterolemia
and diabetes [9]. According to the ‘kindling radical’ hypothesis reactive oxygen and nitrogen
species from ROS sources (e.g. NADPH oxidase) can trigger formation of additional reactive
species including eNOS uncoupling related O2•- formation [2]. Further, the uncoupling of eNOS
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from oxidative depletion of BH4 is proposed [25]. Santhanam et al. [27] reported that an uncoupled
eNOS is the major source of O2•- whereas Landmesser et al. [19] showed that ROS from NADPH
oxidase oxidizes BH4 and leads to eNOS uncoupling.
Our model predictions support the ‘kindling radical’ hypothesis that ROS sources may
contribute to eNOS uncoupling through the oxidative depletion of BH4. The endothelial cell NO
production, TBP levels and biopterin ratio decreased significantly in our study when cellular
oxidative stress was changed from 1 to 100 nM.s-1. The endothelial cell NO production, TBP levels
and biopterin ratio reduced from 26.5 to 2 nM.s-1, 3.8 to 0.002

M and 0.99 to 0.25, respectively

when the Qsupcell increased from 1 to 100 nM.s-1. The NO production and the biopterin ratio
exhibited an oscillatory profile indicating a transition to eNOS uncoupling at higher cellular
oxidative stress. From the sensitivity analysis at Qsupcell from 1 and 100 nM.s-1, we found that the
diffusion rate of BH2 (k38) is important for the eNOS related O2•- production and cellular BH2
levels may affect eNOS related O2•- production. However, the magnitude of eNOS based O2•production was very low (in the range of 10-6 nM.s-1). Furthermore, the eNOS uncoupling related
O2•- production was at least two orders of magnitude lower than the O2•- production from other
sources at all cellular oxidative stress levels.
This indicates that eNOS uncoupling alone may not contribute towards cellular oxidative
stress. However, the ROS generated from other sources may cause eNOS uncoupling, thus
increasing overall oxidative stress.
3.4.3. Cellular biopterin concentration and biopetrin ratio reduces under oxidative stress
conditions
BH4 deficiency is a major cause for eNOS uncoupling in oxidative stress conditions, which
may be a result of increased oxidation of BH4 [190, 231]. Our model results showed that the total

59
[TBP] ranged from 3.8 to 5.9 µM and the biopterin ratio was 0.99 under normal physiologic
conditions. Our model predictions are consistent with the reported [BH4] of 3.9 ± 0.5 pmol/106
cells (i.e. 3.9 µM based on endothelial cell volume of 400 µm3) in human endothelial cells under
normal physiologic conditions by Werner et al. [212]. Our model predicted that the [TBP] and
biopterin ratio reduced under oxidative stress conditions. The [TBP] reduced from 3.8 to 0.0015
µM and the biopterin ratio reduced from 0.99 to 0.25 when oxidative stress increased from 1 to
100 nM.s-1. Jian Xu et al. [232] reported a similar observation of simultaneous decrease in [TBP]
and biopterin ratio in hyperglycemic endothelial cells. They reported [TBP] and [BH4] reduced
from 30 to 25 and 20 to 15 pmol/mg protein, respectively in endothelial cells treated with normal
glucose and high glucose conditions for short period of 2 hours. This corresponds to a decrease in
biopterin ratio from 0.66 to 0.6 in normal to high glucose treated endothelial cells.
3.4.4. Extent of oxidative stress determines the efficacy of BH4 in treating endothelial
dysfunction
In addition to the oxidative depletion of BH4, other mechanisms for the BH4 deficiency
include the downregulation/inhibition of GTPCH [232-234] and the downregulation of enzyme dihydro folate reductase (DHFR), which is responsible for recycling of BH2 back to BH4 [234].
Studies have shown potential for the use of BH4 in cardiovascular therapy [25, 26, 235]. However,
the results from these studies are not consistent for improving the endothelial dysfunction under
oxidative stress [25, 95, 236]. Experimental studies on BH4 supplementation reported a 40-58%
reduction in NO levels, a decrease in biopterin ratio while overall increase in [TBP] levels [95,
237, 238]. Other studies have reported significant (75% and 3 fold) increase in NO production and
an improvement in biopterin ratio ([BH4/BH2]) following the BH4 therapy [236, 239, 240]. Cai et
al. [239] reported a [TBP] of 57 µM under BH4 augmentation through increase in GTPCH
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expression in physiologic conditions, which is similar to our predicted steady state [TBP] range of
32.8 to 59 µM in physiologic conditions with enhanced BH4 synthesis.
Our model predictions suggest that enhancing BH4 synthesis can improve intracellular BH4
levels ([BH4]) in oxidative stress conditions. The [BH4] increased with improved BH4 synthesis at
a given oxidative stress, however [BH4] decreased with the increase in cellular oxidative stress. At
physiological conditions, the intracellular [BH4] was in the range of 3.75 to 5.93 µM, which
increased to 56.6-59.5 µM for a 10 fold increase in BH4 synthesis. For 3-fold increase in BH4
synthesis the [BH4] was 15.18, 1.01, 0.002 µM, while that for 10-fold increase in BH4 synthesis
was 56.61, 32.87 and 0.18 µM, at Qsupcell of 1, 10 and 100 nM.s-1 respectively. The [BH4]
remained below 22 nM for all values of BH4 synthesis at oxidative stress of 1000 and 10000 nM.s1

. This indicates that BH4 oxidizes at higher oxidative stress and supplementation may not increase

intracellular BH4 concentration.
In addition, the NO production rate increased with an increase in BH4 synthesis. The
increase in the NO production like BH4, was also dependent on the extent of cellular oxidative
stress. The NO production and biopterin ratio were less for a 10 fold increase in BH 4 synthesis at
Qsupcell of 100 to 10000 nM.s-1 than the corresponding values at the 3 fold increase in BH4 synthesis
at Qsupcell of 10 nM.s-1. At Qsupcell of 10 nM.s-1, a 3-fold increase in BH4 synthesis resulted in 25.3
nM.s-1 NO production rate and 0.99 biopterin ratio, which were similar to the normal physiologic
predictions of 26.4 nM.s-1 NO production rate and 0.99 biopterin ratio at Qsupcell of 0.01-1 nM.s-1.
For the 10-fold increase in BH4 synthesis, the NO-production rates were 20, 16.1 and 12.2 nM.s-1
and the biopterin ratio were 0.94, 0.66 and 0.36 for Qsupcell of 100, 1000 and 10000 nM.s-1,
respectively.
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The [TBP] increased with improved BH4 synthesis at a given oxidative stress, however
[TBP] decreased with the increase in cellular oxidative stress. The reduction in [TBP] at higher
oxidative stress conditions is attributed to the relative ease with which BH2 can diffuse out of the
endothelial cell [204, 241]. This indicates that at higher oxidative stress conditions, improving BH4
may not restore endothelial cell function.
3.4.5. A combination of BH4 therapy and improvement in oxidative stress condition may
improve endothelial dysfunction
Studies that reported improvement in the endothelial dysfunction have targeted either at
the eNOS biochemical pathway (for improving BH4 levels) [29, 242, 243] or reduction in oxidative
stress by the action of antioxidants [244, 245]. Recently studies have used combination therapy
that targets the eNOS biochemical pathway for increased BH4 synthesis or NO production and
antioxidants to reduce the oxidative stress [246, 247]. Baumgardt et al. [246] reported that the coadministration of the stable precursors of eNOS substrates- sepiapterin (a precursor of BH4) and
L-citrulline, significantly improved BH4 concentrations, eNOS dimerization (thus eNOS activity)
and NO production in the diabetic mice. However, this study targets only the eNOS biochemical
pathway. Coronel et al. [247] reported the protective NO mechanism on the vasoconstrictor effects
of phenylephrine in the kidney is lost in diabetes due to an increase in ROS and a decrease in BH4.
The restoration of this protective NO mechanism was achieved in an efficient manner with the
supplementation of L-arginine which targeted stimulation of NO synthesis and a combination of
antioxidants vitamin C and E, which prevented BH4 oxidation simultaneously.
Our model results indicate that the reduction in cellular oxidative stress along with
enhanced BH4 synthesis is important for restoring eNOS coupling. At Qsupcell of 100 nM.s-1, a 3
fold increase in BH4 synthesis resulted in a 3-fold increase in the NO production rate and 20%
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improvement in the biopterin ratio. But, when the Qsupcell decreased from 100 to 10 nM.s-1, a 3fold increase in BH4 synthesis resulted in a 10 fold increase in NO production rate and 100%
improvement in the biopterin ratio (levels comparable with the normal physiology). [TBP] also
increased as the cellular oxidative stress was reduced at each QBH4. Thus, a combination of
enhanced tetrahydrobiopterin synthesis with a reduction in oxidative stress may result in
significant improvement in endothelial dysfunction and requires further experimental
investigation.
3.4.6. Oscillations in NO production rates under oxidative stress in our simulations
corresponds to unstable eNOS coupling
In many of our results, oscillations in NO production rates and biopterin ratio are observed,
especially at Qsupcell of 10 nM.s-1 and above. As the present study is mathematical study trying to
find solution to a biological problem, the oscillations represented in our results depict the unstable
state of eNOS coupling caused especially due to the instability in biopterin ratio. As seen in Figure
8, the biopterin ratio at start is in completely coupled state, which reduces back to uncoupled state
and there after again increases to higher value and starts to oscillate and where these oscillations
dampen towards the end of the simulation. Depending on the availability of BH4 or BH2, the eNOS
coupling/uncoupling and production NO or O2•- is determined. The oscillations that are seen in the
biopterin ratio are reflected in our other simulations for NO production rate as well as O2•production rates (results not shown).
3.5. Conclusion
In this study, we investigated the interactions of endothelial cell oxidative stress,
tetrahydrobiopterin synthesis and biopterin ratio on the extent of eNOS uncoupling. The model
results indicate that eNOS remains coupled under normal physiologic conditions because of a
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minimal amount of oxidative stress. The eNOS coupling is independent of the initial state of
coupling/uncoupling under normal physiologic conditions. The eNOS uncoupling alone
contributes negligibly towards the cellular oxidative stress. The ROS coming from sources such
as NADPH oxidases, xanthine oxidases and mitochondrial electron transport chain may lead to
eNOS uncoupling. This results in the reduction in NO production rate and biopterin ratio. The
oxidative stress switches eNOS from a coupled state to an uncoupled state by initiating oscillations
in the biopterin ratio and eNOS NO production. These oscillations are initiated due to an imbalance
between BH4 synthesis and oxidation. Furthermore, enhanced BH4 synthesis improves eNOS
coupling. However, the magnitude of improvement in eNOS coupling is determined by the extent
of oxidative stress and BH4 synthesis. We propose a combination therapy of BH4 with a reduction
in oxidative stress for significant improvement in endothelial dysfunction.
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CHAPTER IV
IV.

COMPUTATIONAL INSIGHTS ON THE ROLE OF ASCORBATE IN

TETRAHYDROBIOPTERIN RELATED ENDOTHELIAL DYSFUNCTION2
4.1. Introduction
Vitamin C is an essential dietary nutrient required as a co-factor for many enzymes in low
concentrations. The reduced form of the vitamin C, L-ascorbic acid or ascorbate (ASC), is
considered an effective intracellular circulatory antioxidant due to its high electron-donating power
and converting back to its active reduced form readily [248]. Deficiency in ASC has been
associated with an increased risk of CVDs [33, 249]. Low levels of ASC are observed in several
diseases linked to increased oxidative stress, such as cancer, diabetes mellitus, cataract, sepsis and
in smokers [116]. Endothelium is the most affected organ by ASC deficiency, since it regulates
the distribution of ASC throughout the body [117]. The important functions of ASC in endothelial
cells include increasing the synthesis and deposition of type IV collagen in the basement
membrane, stimulating endothelial proliferation, inhibiting apoptosis, scavenging radical species,
and sparing endothelial cell-derived nitric oxide to help modulate blood flow [117]. Of these, the
role of ASC in increasing the endothelial NO bioavailability is of importance to our study of
endothelial dysfunction in microcirculation. Figure 13 show the putative mechanisms of how ASC
improves vascular health in CVDs as reported in several studies. These includes; (i) ASC
maintaining cofactor BH4 in reduced state [142, 250, 251]; (ii) scavenging of free radicals such as
O2•-, ONOO- by ASC [145] and (iii) increasing eNOS activity by increasing eNOS phosphorylation

2
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[116] and decreasing eNOS S-nitrosylation [252]. However, very little quantitative information
about the interactions of ASC in BH4-dependent endothelial dysfunction is available.

Figure 13: Putative mechanisms of ASC for improving NO bioavailability modeled in the
present paper. The three mechanisms by which ASC improves NO bioavailability, modeled in
this work are depicted as numerics. These includes; 1. ASC reduces oxidized trihydrobiopterin
(•BH3) to BH4, increasing BH4 bioavailability. 2. ASC scavenges O2•- and ONOO- 3. ASC
increases eNOS activity by increasing phosphorylation and decreasing S-nitrosylation. eNOS
biochemical pathway produces NO and O2•- when coupled (left) and uncoupled (right)
respectively. Qsupcell and QBH4 are the rates for non-eNOS based cellular oxidative stress and BH4
synthesis from de novo synthesis pathway respectively. NO and O2•- forms ONOO- and other
downstream reactions. (Intermediate steps in the eNOS biochemical pathway as well as
downstream reactions are not shown in this figure.)
The purpose of the present study was to analyze the role of intracellular ASC in improving
the NO bioavailability under oxidative stress in endothelial cell. We developed a computational
model of interactions of eNOS biochemical pathway and downstream reactions of the products,
biopterin, ASC and GSH, and oxidative stress in endothelial cell. We used this model to analyze
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the biopterin synthesis, level of oxidative stress and ASC on the rate of production of endothelial
NO and O2•- as well as ONOO-. In addition, the model accounts for the interactions of ASC with
total biopterin levels and biopterin ratio. We present results for the effects supplementation of ASC
on i) the eNOS NO and O2•- production rates, ONOO-, total biopterin and biopterin ratio; ii) and
impact of biopterin synthesis on eNOS NO production rate iii) and eNOS protein concentration on
the eNOS NO and O2•- production rate and biopterin ratio. The present work will provide insights
on the protective mechanism of ASC in endothelial dysfunction.
4.2. Materials and Methods
4.2.1. Model Description
We developed an endothelial cell computational model using the known biochemical
pathway of eNOS for NO and O2•- production [187, 190]. We modeled the eNOS biochemical
pathway product and interactions of cellular oxidative stress, BH4 synthesis, ASC, GSH and
reactive species NO, O2•-, ONOO-, H2O2, N2O3, •OH, •NO2, NO2- and others. Figure 1 summarizes
the putative mechanisms of ASC for improving endothelial dysfunction as mentioned in literature.
The eNOS can produce NO and O2•- depending on the availability and oxidative state of its cofactor
BH4 [253]. BH4 is constitutively formed by de novo synthesis pathway [254], which is represented
as QBH4 (M. s−1 ). Apart from the O2•- production from eNOS uncoupling, the significant amount
of cellular oxidative stress comes from the non-eNOS based O2•- sources including NADPH and
xanthine oxidase, and mitochondrial electron transport chain [255]. This is represented by a O2•production rate term, Qsupcell (M. s −1 ). Following ASC interactions are modeled in our current
work and shown in Figure 13. ASC can regenerate BH4 from its oxidized form of trihydrobiopterin
(•BH3) radical, and promote eNOS coupling [144]. ASC is also known to scavenge the O2•- [256]
and ONOO- [257] radicals. ASC is reported to increase eNOS activity by increasing eNOS
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phosphorylation [116] and decreasing eNOS S-nitrosylation [252]. The detailed biochemical
reactions for the eNOS biochemical pathway for the eNOS NO and O2•− production are described
in our previous study Table 2 of Chapter II [255] and summarized in Table 5. These reactions are
classified into two major biochemical pathways of;
i) NO production through eNOS oxidation of L arginine to N-hydroxyl-L-arginine (NHA), when
bound to BH4 and subsequent oxidation of NHA to NO and citrulline.
ii) O2•− production through the inability of BH2 to transfer electron to the eNOS heme, when bound
to L-arginine and O2, results in the dissociation of the eNOS-substrate complex to form O2•−. The
detailed eNOS biochemical pathway for NO and O2•− production was modeled in our previous
work and is not described in the current paper. Please refer to Table 1 from materials and methods
section and reactions from rate constants k c2 to k b−12 from Joshi et. al [255] for more details.
Table 5: Summary of overall reactions involved in the eNOS biochemical pathway for NO
and O2•- production. Please see references [255] for detailed chemical reactions and rate
constants involved in eNOS biochemical pathway.
Overall reactions in eNOS biochemical pathway
eNOS − (FeIII ) + L − Arginine + BH4 + O2 + 2e−
→ eNOS − (FeIII ) − BH4 − NHA
NO
III
−
production eNOS − (Fe ) − BH4 − NHA + O2 + 3e
→ 𝐍𝐎 + Citrulline + eNOS − (FeIII ) − BH4 + eNOS − (FeII )
− BH4
O2•production

eNOS − (FeIII ) + L − Arginine + BH2 + O2 + e−
→ eNOS − (FeIII ) − BH2 − Arginine + 𝐎•−
𝟐

NO and O2•- production from eNOS is dependent on the biopterin ratio ([BH4]/[TBP])
which is defined as the ratio of BH4 to the total biopterins (TBP = BH4 + BH3 + BH2) [93, 95,
255]. The downstream reactions of interactions amongst NO, O2•−, BH4, ASC, GSH, H2O2, N2O3,
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S-Nitrosoglutathion (GSNO) and others with respective rate constants for the reactions are
summarized in Table 6 along with the references.
The important downstream reactions modeled in this work (showed in Table 6) includes;
(i) the reaction between NO and O2•− to form ONOO− (Reaction # 1).
(ii) the oxidation of BH4 by O2•−, ONOO−, •OH, •NO2, CO3•- (Reactions # 4, 5, 6, 8, 19, 20, 21,
22) and subsequent diffusion of BH2 out of the cell (Reaction # 24).
(iii) the dismutation of O2•−, self (Reaction # 14) or SOD catalyzed (Reaction # 3) to form hydrogen
peroxide (H2O2) which is further broken down to H2O by catalase (Reaction # 23).
(iv) the interaction of ASC with oxidized biopterin (•BH3), ONOO−, O2•− (Reactions # 7, 9, 10).
(v) the interaction of GSH with ONOO- and N2O3 (Reactions # 25, 26) to form GSNO which in
turn reacts with O2•− to generate NO (Reaction # 28)
(vi) Formation of N2O3 due to rapid reaction of NO and O2 with intermediate formation of NO2with reported rate constant of 2.4 to 6×106 M-2.s-1 [175, 258] (Reaction # 2) and hydrolysis of N2O3
at the rate of 1.6×103 s-1 [175, 259] (Reaction # 27).

Table 6: Downstream reactions involving NO, ROS, RNS, biopterins, ASC and GSH, rate
expressions and their associated rate constants.
Reaction
#

Reactions

1

−
NO + O•−
2 → ONOO

2

4NO + O2 + 2H2 O → 2NO2−
+ N2 O3 + 2H +

k14

k15

Rate Expressions

Rate constants

(𝐯𝐢 )

𝐤 𝐢 (𝐌. 𝐬−𝟏 )

k14 [NO][O•−
2 ]

6.7
× 109 M −1 . s−1

[199]

4k15 [NO]2 [O2 ]

2.4
× 106 M −2 . s−1

[200, 255]

References
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k16 ,SOD 1

O2•− + H2 O →

2

O2

1
+ H2 O2
2
+ OH −

3

k17

4

2BH4 + O2 → 2BH2 + 2H2 O

5

BH4 + O2•− + H + → BH3
+ H2 O2

6

2BH3 → BH4 + BH2

7

AscH − + BH3 → Asc •−
+ BH4

k18

k19

k16 [SOD][O•−
2 ]

3.85
× 109 M −1 . s−1

[199, 255]

k17 [BH4 ][O2 ]

0.6 M −1 . s −1

[201, 255]

k18 [BH4 ][O•−
2 ]

3.9
× 105 M −1 . s−1

[201, 255]

2k19 [BH3 ]2

4.65
× 104 M −1 . s−1

[201, 255]

k20

8

k22

BH4 + ONOO− → BH3

k 20 [BH3

][AscH −

]

1.7 ×
105 M −1 . s −1

[144]

at pH=9.2
k 22 [BH4 ][ONOO− ]

6
× 103 M −1 . s−1

k 23 [ONOO− ][AscH − ]

361.7 s−1

[257]

−
k 24 [O•−
2 ][AscH ]

5.1
× 105 M −1 . s−1

[256]

k 25 [ONOO− ]

0.981 s−1

[93, 200]

k 26 [ONOO− ]

0.401 s−1

[93, 200]

0.22k 27 [ONOO− ][NO]

9.1
× 104 M −1 . s−1

[199]

0.0025k 28 [O2•− ]2

3.57
× 105 M −1 . s−1

[200]

k 29 [ONOO− ][CO2 ]

3.89
× 104 M −1 . s−1

[200]

k 30 [ONOO− ][CO2 ]

1.91
× 104 M −1 . s−1

[200]

k 31 [CO3•− ][O•−
2 ]

6.65
× 108 M −1 . s−1

[200]

[202, 255]

H + + AscH −
9

k23

+ ONOO− → DHA + NO−
2
+ H2 O
k24

10

H + + AscH − + O2•− → Asc •−
+ H2 O2

11

+
ONOOH → NO−
3 +H

12

ONOOH → • NO2 +• OH

13

k25

k26

ONOOH + NO
k27

→ • NO2 +

NO−
2
k28

14

HO2 + O•−
2 + H2 O → O2
+ H2 O2 + OH −

15

ONOO− + CO2 → NO−
3 + CO2

16

ONOO− + CO2 → • NO2
+ CO3•−

17

•−
−
+
CO•−
3 + O2 + H → HCO3
+ O2

k29

k30

k31
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k32

18

−
−
CO•−
3 + NO + OH → HCO3
+ NO−
2

k 32 [CO3•− ][NO]

5.82
× 109 M −1 . s−1

[200]

k 33 [BH4 ][• OH]

8.8
× 109 M −1 . s−1

[144]

k 34 [BH4 ][• NO2 ]

9.4
× 108 M −1 . s−1

[144]

k 35 [BH4 ][CO•−
3 ]

4.6
× 109 M −1 . s−1

[144]

k 36 [BH3 ][O2 ]

3.2
× 103 M −1 . s−1

[201]

k 37 [CAT][H2 O2 ]

3.4
× 107 M −1 . s−1

[260]

k 38 [BH2 ]

152.5 s−1

[204, 255]

k 39 [ONOO− ][GSH]

1.35
× 103 M −1 . s−1

[175, 261]

k 40 [N2 O3 ][GSH]

6.6
× 107 M −1 . s−1

[175, 262]

k 41 [N2 O3 ]

1.6 × 103 s −1

[175, 259]

k 42 [GSNO]2 [O•−
2 ]

9
× 108 M −2 . s−1

k33

19

BH4 +• OH → OH − + H +
+ BH3

20

BH4 +• NO2 → NO2− + H +
+ BH3

21

2−
+
BH4 + CO•−
3 → CO3 + H
+ BH3

22

BH3 + O2 → BH2 + HO•2

23

2H2 O2 →

24

BH2 (Diffusion out of cell)

25

ONOO− + GSH → GSNO
+ GSSG

26

N2 O3 + GSH → GSNO + H +
+ NO−
2

27

N2 O3 + H2 O → 2H + + NO−
2

k34

k35

k36

k37 ,CAT

2H2 O + O2

k39

k40

k41

O2•− + 2GSNO
28

k42

+ H2 O → GSSG + NO2−
+ NO3− + 2H +

[263]

𝐴𝑠𝑐𝐻− = Ascorbate ion
4.2.2. Model development
The NO production rate is considered independent of the geometric location of eNOS and
all the chemical species involved in eNOS biochemical pathway are considered in uniform
concentrations inside the endothelial cell [170, 187, 255]. By applying the law of mass action
kinetics to each chemical species of interest involved in the eNOS biochemical pathways and its
downstream reactions, the model equations were developed. A total of 39 chemical species were
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involved in the model and their rate equations with respect to time were in the form of ordinary
differential equations and mathematically represented as:
d[Si ]
= ∑ vi
dt

(1)

where, [Si ] (M) represents the concentration of the ith chemical species and vi (M. s −1 ) represents
the production/consumption terms of the ith species.
In addition, to simplify our kinetic model we applied mass conservation eNOS protein and
glutathione disulfide (GSSG), oxidized GSH. It was set in the algebraic form as follows:
[eNOS] = [E] + [E−1 ] + ∑[Eai ] + ∑[Ebi ] + ∑[Eci ]

(2)

where, [E] and [E−1 ] represents different forms of native eNOS and [Eai ], [Ebi ] and [Eci ]
represents different forms of the eNOS-substrate complexes. [eNOS] represents the total eNOS
concentration.
[GSSG] = [GSH]0 − [GSH] − [GSNO]

(3)

where, [GSSG] represents total GSSG concentration which is conserved always. [GSH]0 represents
initial GSH concentration provided in the system at time, t=0 mins, while [GSH],
[GSNO] and [GSSG] vary with time. (GSNO, S-Nitrosoglutathion)
The rate equations for production of NO (R NO ) and O2•- (R O2•− ) are written separately that
includes summation of the generation terms for the respective species. Total of 39 rate expressions
were modeled. The details of 21 rate expressions, out of total 39 rate equations used in this study,
are for modeling eNOS biochemical pathway. These rate expressions including all eNOS and
eNOS-substrate complexes, citrulline and NHA used in this work can be found in our previous
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modeling paper Joshi et al. [255], Table 2. The rate expressions for the remaining 16 chemical
species model equations involved in downstream reactions are illustrated in Table 7.
Table 7: Rate expression of different species for the downstream reactions involving
products of eNOS biochemical pathways - NO and O2•-, other ROS and RNS, biopterins,
ASC and GSH.
Rate equations
∑ 𝐯𝐢

d[Si ]
dt

d[NO]
dt

k b7 [eNOS − (FeIII ) − NO − BH4 ]
+ k b10 [eNOS − (FeII ) − NO − BH4 ]
− k b−7 [NO][eNOS − (FeIII ) − BH4 ]
− k b−10 [NO][eNOS − (FeII ) − BH4 ] − k14 [NO][O•−
2 ]
2
−
− 4k15 [NO] [O2 ] − 0.22k 27 [ONOO ][NO]
2 •−
− k 32 [CO•−
3 ][NO] + k 42 [GSNO] [O2 ]

d[O•−
2 ]
dt

•−
Qsupcell + k c8 [eNOS − (FeIII − O−
2 ) − BH2 − Arg] − k14 [NO][O2 ]
•−
− k16 [SOD][O•−
2 ] − k18 [BH4 ][O2 ]
•− 2
−
− k 24 [O•−
2 ][AscH ] − 0.0025k 28 [O2 ]
•−
•−
•−
− k 31 [CO3 ][O2 ] − k 42 [GSNO]2 [O2 ]

d[ONOO ]
dt

−
−
−
k14 [NO][O•−
2 ] − k 22 [BH4 ][ONOO ] − k 23 [ONOO ][AscH ]
−
−
− k 25 [ONOO ] − k 26 [ONOO ]
− 0.22k 27 [ONOO− ][NO] − k 29 [ONOO− ][CO2 ]
− k 30 [ONOO− ][CO2 ] − k 39 [ONOO− ][GSH]

d[BH4 ]
dt

QBH4 + k c−2 [eNOS − (FeIII ) − BH4 ] − k c2 [eNOS − (FeIII )][BH4 ]
2
− k17 [BH4 ][O2 ] − k18 [BH4 ][O•−
2 ] + k19 [BH3 ]
+ k 20 [BH3 ][AscH − ] − k 22 [BH4 ][ONOO− ]
− k 33 [BH4 ][• OH] − k 34 [BH4 ][• NO2 ]
− k 35 [BH4 ][CO•−
3 ]

d[BH3 ]
dt

2
−
k18 [BH4 ][O•−
2 ] − 2k19 [BH3 ] − k 20 [BH3 ][AscH ]
−
+ k 22 [BH4 ][ONOO ] + k 33 [BH4 ][• OH]
+ k 34 [BH4 ][• NO2 ] + k 35 [BH4 ][CO•−
3 ]
− k 36 [BH3 ][O2 ]

d[BH2 ]
dt

k c−3 [eNOS − (FeIII ) − BH2 ] − k c3 [BH2 ][eNOS − (FeIII )]
+ k17 [BH4 ][O2 ] + k19 [BH3 ]2 + +k 36 [BH3 ][O2 ]
− k 38 [BH2 ]

d[H2 O2 ]
dt

•−
•− 2
k16 [SOD][O•−
2 ] + k18 [BH4 ][O2 ] + 0.0025k 28 [O2 ]
− k 37 [CAT][H2 O2 ]

−
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d[• OH]
dt

k 26 [ONOO− ] − k 33 [BH4 ][• OH]

d[• NO2 ]
dt

k 26 [ONOO− ] + 0.22k 27 [ONOO− ][NO] + k 30 [ONOO− ][CO2 ]
− k 34 [BH4 ][• NO2 ]

d[CO3•− ]
dt

•−
k 30 [ONOO− ][CO2 ] − k 31 [CO3•− ][O•−
2 ] − k 32 [CO3 ][NO]
− k 35 [BH4 ][CO•−
3 ]

d[NO3− ]
dt

k b9 [eNOS − (FeII ) − NO − BH4 ] + k 25 [ONOO− ]
+ k 29 [ONOO− ][CO2 ]

d[NO2− ]
dt

2k15 [NO]2 [O2 ] + 0.22k 27 [ONOO− ][NO] + k 32 [CO3•− ][NO]
+ k 34 [BH4 ][• NO2 ] + k 40 [N2 O3 ][GSH] + k 41 [N2 O3 ]

d[GSH]
dt

[

vm [GSSG]
] − k 39 [ONOO− ][GSH] − k 40 [N2 O3 ][GSH]
K m + [GSSG]

d[GSNO]
dt

k 39 [ONOO− ][GSH] + k 40 [N2 O3 ][GSH] − k 42 [GSNO]2 [O•−
2 ]

d[N2 O3 ]
dt

4k15 [NO]2 [O2 ] − k 40 [N2 O3 ][GSH] − k 41 [N2 O3 ]

d[GSSG]
dt

[GSH]0 − [GSH] − [GSNO] − [GSSG]

R NO
(NO production)
R O•−
2
(O•−
2

production)

k b7 [eNOS − (FeIII ) − NO − BH4 ]
+ k b10 [eNOS − (FeII ) − NO − BH4 ]
+ k 42 [GSNO]2 [O•−
2 ]
Qsupcell + k c8 [eNOS − (FeIII − O2− ) − BH2 − Arg]
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4.2.3. Model parameters
The important parameters used in this study include calculating/using;
(i) the initial concentrations of; eNOS protein, TBP, L-Arginine, O2, CO2, superoxide dismutase
(SOD) and catalase enzymes, biopterin ratio, ASC and GSH
(ii) rate constants for all the reactions, as well as calculation of QBH4 and Qsupcell
(iii) calculation of rate constants for scavenging of O2•- and ONOO- by ASC using Arrhenius
equation.
Table 8 provides the model parameters, initial concentrations and rates for QBH4 and
Qsupcell used in this study. The initial condition for species is assumed zero otherwise mentioned
in the figure legends. We used the eNOS protein concentration of 0.097 µM, based on
experimentally reported values of eNOS protein concentration of 5137 pg/106 cells and single
endothelial cell volume of 400 µM3 for HUVEC’s, [187]. The effect of ASC on eNOS activity due
to increasing eNOS phosphorylation or decreasing eNOS S-nitrosylation was modeled by varying
eNOS protein concentration from 0.097 µM to ± 50% [116, 252]. The role of cellular oxidative
stress on endothelial cell function was assessed by using the term, Qsupcell . Various studies have
been performed to report endothelial O2•- production rate in the range of 0.016 nM.s-1 to 6000
nM.s-1 [183, 199, 207]. In Chapter II, we used a range of 0.01 to 10000 nM.s-1 for Qsupcell and
determined that Qsupcell of 1 nM.s-1 and below represents normal physiological state, maximum
damage to the endothelial function is caused under the oxidative stress range of 1-100 nM.s-1 and
no significant change in species was observed above Qsupcell of 1000 nM.s-1 [255]. Thus, in the
present study we used Qsupcell values of 1, 10, 100 and 1000 nM.s-1 to represent the cellular
oxidative stress conditions progressing from physiological to pathophysiological state. Under
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physiological conditions, the activity for guanosine triphosphate cyclohydrolase I (GTPCH), rate
limiting enzyme of de novo synthesis pathway was reported to be 7 pmol.mg protein-1.h-1 [206].
Based on endothelial cell volume of 400 µm3 and assuming the total protein content of protein
content to be 0.1 mg protein/106 endothelial cells [187], we calculated the QBH4 of 0.5 nM.s-1 for
all simulated cases. From our previous work [255], we found that the initial state of eNOS
coupling/uncoupling does not significantly contribute towards cellular oxidative stress. Also the
NO production rate was independent of initial state eNOS coupling or uncoupling at higher
oxidative stress conditions. Thus, the [BH4]/[TBP] was set at 0.05 at t=0 min, which represents
initial state of eNOS uncoupling for all the simulated cases. We adopted the initial concentrations
for [TBP]0 , [L − Arginine]0 , [O2 ]0 , [CO2 ]0 and [SOD]0 as 7 µM, 100 µM, 140 µM, 1.1 µM and
10 µM from our previous modeling work [255]. Based on in vitro studies by Aebi et al. [260], we
used the catalase concentration of 0.9 µM and the rate constant for hydrolysis of H2O2 is 3.4×107
M-1.s-1. To investigate the optimal concentrations of ASC required for increasing NO
bioavailability, we used [ASC] in the range of 0 to 200 µM in this study. This range was based on
the reported ASC levels in organs and tissues as reviewed in Li et al. [264], mean plasma levels
of ASC between 50 and 60 μM for healthy individuals [146]; low levels of plasma ASC of 3–5
µM observed in individuals linked to diseases with increased oxidative stress [116] and
concentration-dependent saturation for ASC above 100 μM reported by Heller et al. [250] for 24h
pretreated endothelial cells with [ASC] in the range 1 μM to 1 mM. Based on the rate constants
for the interaction of O2•- with ASC determined by chemiluminescence method measured at 25ºC
and pH 7.8 is 3.3x105 M-1.s-1 [256] and that of ONOO- with ASC is 236 M.s-1 [257] respectively,
we calculated the rate constants for the reaction of ASC with O2•- and ONOO- at 37 ºC to be
5.1×105 M-1.s-1 and 361.7 M.s-1 respectively, using Arrhenius equation, as shown in Table 2. GSH
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concentration is present in the range of 0.5 to 10 mM and exceeds by one order of magnitude than
ASC under physiological conditions in endothelial cells [265, 266]. The effect of GSH levels was
analyzed by using [GSH] of 0.1, 1 and 10 mM in the present study. The enzymatic kinetic
parameters related to the enzyme glutathione reductase including Vm,GR and Km,GR were used to
model GSH and are also shown in Table 8.
4.2.4. Model solution
The rate equations, coupled with appropriate initial conditions, were solved using
MATLAB R2017b (Mathworks, Natick, MA, USA) ordinary differential solver ode 15s, which is
a variable multistep solver based on the numerical differentiation formulae. The relative and
absolute error tolerance values were set at 1 × 10−10 and 1 × 10−15 , respectively. However, for
some simulation to get the numerical simulations the tolerance was increased to 1 × 10−4
(relative) and 1 × 10−7 (absolute). The simulations were run for 500,000s (approximately 8333
mins) to obtain the steady-state values.
Table 8: Model parameters used in ASC related endothelial dysfunction model
Variable/Constant

Values

Units

[eNOS]0

0.048 ,0.097, 0.144

Qsupcell

1, 10, 100, 1000

nM. s−1

Text, [255]

0.5, 1, 1.5, 5

nM. s−1

Text, [206, 255]

QBH4
[BH4 ]/[TBP]
[TBP]0

0.05

μM

References

-

Text, [93, 170, 187, 255]

[255]

7

μM

[93, 255]

[L − Arginine]0

100

μM

[93, 255]

[O2 ]0

140

μM

[93, 255, 267]

[CO2 ]0

1.1

mM

[93, 255, 267]
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[SOD]0

10

μM

[93, 255, 267]

[CAT]0

0.9

μM

[260]

[ASC]0

0, 5, 10, 25, 50, 100,
200

μM

[GSH]0

0.01, 0.1, 1, 10, 100

mM

Vm,GR

3.2 × 10−4

M. s−1

[93, 175]

μM

[93, 175]

K m,GR

50

Text, [53, 115, 268, 269]
Text, [270]

4.3. Results
4.3.1. Ascorbate supplementation improves NO production and biopterin bioavailability
To gain quantitative understanding for the role of ASC in endothelial dysfunction, we
analyzed the effect of ASC supplementation, under cellular oxidative stress, on the temporal
profiles of eNOS NO production rate, biopterin ratio and concentration profiles of TBP, O 2•- an
ONOO-. Figure 14 show the temporal profiles of species as a function of ASC supplementation.
Our model results showed that the eNOS NO production rate increased with ASC supplementation
in oxidative stress conditions. Under basal oxidative stress condition (Qsupcell of 1 nM.s-1), ASC
supplementation had no effect on eNOS NO production rate (Figure 2A). Increasing oxidative
stress introduced instability in eNOS when no ASC was present in the system, as seen by the
oscillations at Qsupcell of 10 nM.s-1 (Figure 14B - control). ASC supplementation stabilized eNOS
and improved the NO production level by almost 85-90%.
Under excessive oxidative stress condition, more ASC was required to maximize NO
production rate (Figure 14C and D). ASC supplementation also improved TBP levels and biopterin
ratio in a dose dependent manner in all simulated oxidative stress conditions (Figure 14E-H). The
instability observed in eNOS can be attributed to the instability in biopterin ratio (Figure 14I-L).
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ASC is involved in reducing oxidized biopterin (BH3) back to it reduced state (BH4). Thus, ASC
supplementation is responsible for improving TBP levels as well as maintaining biopterin ratio.
We further analyzed the role of ASC in scavenging O2•- and ONOO- under oxidative stress
conditions. ASC supplementation reduced O2•- concentration (Figure 14M-P) at respective Qsupcell,
however, increased the ONOO- concentration by almost 90% under excessive oxidative stress as
compared to when no ASC was present in the system (Figure 14S and T). The increase in ONOOconcentration can be attributed to increase in NO levels with ASC supplementation. Our results
suggest that the chief mechanism by which ASC improves NO production rate is by increasing
BH4 bioavailability and stabilizing eNOS.
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Figure 14: Temporal profile of species as a function of ASC supplementation under
increasing cellular oxidative stress conditions. Panels A–T show ASC dependent the temporal
variation in various species for the Qsupcell of 1, 10, 100 and 1000 nM·s−1, where Qsupcell of 1 nM.s-
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1

indicates physiological conditions. The [ASC] was varied from control, 5, 10, 25, 50, 100 and
200 µM, where control being no ASC introduced in the system. QBH4 was set at 0.5 nM.s−1. The
[TBP] and biopterin ratio was set at 7 μM and 0.05 @ t = 0 min, respectively. The initial
concentration of GSH, eNOS, L-arginine, O2, SOD and CO2 was 1 mM, 0.097 μM, 100 μM, 140
μM, 10 μM and 1.1 mM, respectively.

4.4.2. Effect of simultaneous increase in tetrahydrobiopterin synthesis and ascorbate on
eNOS NO production
Individual studies have reported that both ASC [271] and BH4 [272] supplementation can
offer therapeutic potential by modulating oxidative stress and providing endothelial protection. In
this study, we analyzed the effect of combination therapy of ASC and BH4 supplementation, under
excessive oxidative stress condition (at Qsupcell of 100 nM.s-1), on eNOS NO production rate and
biopterin ratio. We augmented the QBH4 from physiologic levels of 0.5 nM.S-1 by 2, 3 and 10 orders
of magnitude, represented by QBH4 of 1, 1.5 and 5 nM.s-1 and increased ASC supplementation from
control, 10 and 50 µM in the system. Control being no ASC introduced in the system.
Our results show that increasing QBH4 increased the eNOS NO production rate as well as
improved the biopterin ratio. As observed in our previous results (Figure 14), ASC
supplementation removed the instability in eNOS uncoupling maintained biopterin ratio. As seen
from Figure 15A, when there was no ASC in the system, higher QBH4 was required to maintain
elevated NO production rates. However, with the introduction of ASC, even at low QBH4 the higher
NO production rates were attained (compare Figure 15B and C). Thus, combination therapy of
ASC and BH4 supplementation can considerably improve eNOS NO production rate and biopterin
ratio. Our results suggest that ASC supplementation would be effective in cases of BH4 deficiency
or impaired BH4 synthesis.
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Figure 15: Effect of enhanced BH4 synthesis and ASC supplementation on NO production
rate and biopterin ratio under cellular oxidative stress. Panels A–C and Panels D-F show QBH4
dependent temporal variation in eNOS NO production rate and biopterin ratio, respectively for
[ASC] supplementation of control, 10 and 50 µM. The Qsupcell was 100 nM·s−1 to represent
oxidative stress conditions. The BH4 synthesis rate (QBH4) was varied from 0.5, 1, 1.5 and 5 nM.s1
. The [TBP] and biopterin ratio were set at 7 μM and 0.05 @ t = 0 min. The initial concentration
of GSH, L-arginine, O2, SOD, CO2 and eNOS was 1 Mm, 100 μM, 140 μM, 10 μM, 1.1 mM and
0.097 μM, respectively.

4.4.3. Effect of eNOS on NO production in the presence of ascorbate
In this study, we examined the effect of eNOS concentration and ASC supplementation on
the NO production rate under oxidative stress conditions. Figure 16A-I show the temporal
variations in NO production rate for ASC supplementation under and eNOS concentrations of
0.048, 0.097 (physiologic) and 0.144 µM and increasing oxidative stress.
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As shown in Figure 16, increasing eNOS concentration increased NO production rate.
However, as the oxidative stress level increased the NO production rate was lowered at respective
[eNOS]. ASC supplementation helped to maintain higher NO production rate and was more
effective at higher oxidative stress conditions. When there was no ASC in the system, the eNOS
NO production rate decreased by 55% at physiologic conditions and by 4% under oxidative stress
conditions, with the decrease in [eNOS]. After introducing ASC in the system, 75 – 90% increase
in eNOS NO production rate was observed at respective [eNOS] and Qsupcell. Thus, for improving
NO production rate ASC supplementation as well as increased [eNOS] is required.
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Figure 16: Effect of eNOS concentration NO production rates in the presence of ASC. Panels
A–I show eNOS and ASC dependent temporal variation in in eNOS NO production rate for the
Qsupcell of 1, 10 and 100 nM·s−1. The [eNOS] was set at 0.048, 0.097 and 0.144 µM @ t= 0 min.
The [ASC] was varied from control, 5, 10, 25, 50, 100 and 200 µM, where control being no ASC
introduced in the system. QBH4 was set at 0.5 nM·s−1. The [TBP] was set at 7 μM and [BH4]/[TBP]
was set at 0.05 at t = 0 min. The initial concentrations of GSH, L-arginine, O2, SOD and CO2 were
1 mM, 100 μM, 140 μM, 10 μM and 1.1 mM, respectively.
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4.4.4. Effect of GSH and ASC on NO production
We analyzed the effect of physiological GSH concentration and ASC supplementation on
the NO production rate under oxidative stress conditions. Figure 17 show that, GSH at higher
millimolar concentration can slightly improve NO production rate. However, enhanced NO
production rate, under oxidative stress conditions, was observed only in the presence of ASC. This
slight increase in NO production rate can be attributed to the NO coming from the reaction between
GSNO and O2•-.

Figure 17: Steady state concentrations of NO production rate as a function of GSH and ASC.
The steady state NO production rate was analyzed for varied [GSH] at t=0 min at 0.1, 1 and 10
mM. The [ASC] was control and 50 µM, where control being no ASC introduced in the system.
The Qsupcell was 1 and 100 nM·s−1. QBH4 was set at 0.5 nM.s−1. The [TBP] and biopterin ratio was
set at 7 μM and 0.05 @ t = 0 min, respectively. The initial concentration of eNOS, L-arginine, O2,
SOD and CO2 was 0.097 μM, 100 μM, 140 μM, 10 μM and 1.1 mM, respectively.
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4.4.5. Effect of GPX and Prx on the role of ASC in oxidative stress
Our earlier results in this study show that ASC supplementation although improves NO
production rate, it also increased ONOO- levels. Glutathione peroxidase (GPX) and peroxiredoxins
(Prx) are reported to detoxify ONOO- as well as H2O2 in endothelial cells [105, 109, 166, 179].
We revised our existing model by adding below 4 reactions for ONOO- and H2O2 clearance by
reduced GPX (GPXr) and reduced Prx (Prx-SH2);
ka

GPXr + ONOO− → GPXo + NO−
2
kb

GPXr+H2 O2 → GPXo + H2 O
kc

ONOOH + Prx-(SH2 ) → NO2 + Prx-SOH +2H +
kd

H2 O2 + Prx-(SH2 ) → H2 O + Prx-SOH
where, the rate constants ka, kb, kc and kd are 2×106 M-1.s-1, 2.1×107 M-1.s-1, 1×107 M-1.s-1 and
1.3×107 M-1.s-1, respectively. The details for these reactions and rate constants can be found in
Chapter V, Table 9. We used the concentrations of GPX and Prx as 5 µM and 20 µM.
Figure 18 shows the temporal profiles of species including NO production rate, TBP,
biopterin ratio and ONOO- levels as a function of GPX and Prx under oxidative stress conditions
and for ASC supplementation. The presence of GPX and Prx, decreased ONOO- levels
considerably (compare Figure 14S and Figure 18H) and improved NO production rate even at ASC
supplementation of as low as 10 µM (compare Figure 14C and Figure 18B). The improvement in
NO production rate in the presence of GPX and Prx can be attributed to the improved TBP levels
and biopterin ratio. Lower ONOO- levels resulted in less oxidation of BH4, thus improving BH4
bioavailability.
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Figure 18: Temporal profile of species as a function of ASC supplementation in the presence
of GPX and Prx under oxidative stress conditions. Panels A–D show ASC dependent the
temporal variation in various species for the Qsupcell of 100 nM·s−1. The [ASC] was varied from
control, 10 and 50 µM, where control being no ASC introduced in the system. QBH4 was set at 0.5
nM.s−1. The [TBP] and biopterin ratio was set at 7 μM and 0.05 @ t = 0 min, respectively. The
initial concentration of GSH, eNOS, L-arginine, O2, SOD and CO2 was 1 mM, 0.097 μM, 100 μM,
140 μM, 10 μM and 1.1 mM, respectively.
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4.4. Discussions
4.4.1. Role of ascorbate in endothelial dysfunction
ASC is shown to improve endothelial function by increasing the bioavailability of NO in
diseases with increased oxidative stress such as hypertension [273], diabetes [274, 275],
hyperhomocysteinemia [276]. A clinical study done by Ceriello et al. [274] showed that during
induced acute hypoglycemia, reduction in the generation of oxidative stress and inflammation and
improvement in endothelial dysfunction is observed by infusion of ASC in type 1 diabetes patients.
Another clinical study done by Grebe et al. [35] showed that ASC supplementation increased flowmediated dilation in patient suffering from obstructive sleep apnea, a condition of endothelial
dysfunction caused due to oxidative stress. ASC supplementation is reported to prevent
oxidative/nitrosative stress by decreasing O2•- levels in DOX-treated wistar rats [147]. Our model
results agree with these in vivo studies. Our results showed that under oxidative stress conditions,
the NO production rate from eNOS are decreased by almost 99% due to reactions with reactive
species. ASC supplementation improved NO production rate by 85% (as seen in Figure 14). ASC
supplementation also decreased O2•- levels, however it was not considerable.
4.4.2. Ascorbate improves NO bioavailability by increasing the tetrahydrobiopterin
bioavailability and stabilizing eNOS
One of the proposed mechanistic roles of ASC in endothelial dysfunction is improved BH4
bioavailability. Baker et al. [251] reported that ASC supplementation increased the intracellular
BH4 content in endothelial cells and subsequently enhanced eNOS activity. Heller et al. [277]
reported, ASC pretreatment in the range of 0.1-100 µM in HUVEC’s led to a 3-fold increase of
the cellular production of NO, when 3 µM of BH4 was added to the cell lysate. They further
reported the effect was saturated at [ASC] of 100 µM and that ASC is involved in either enhancing
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the availability of BH4 or increasing its affinity for the eNOS. Valent et al. [278] in their study of
spectrophotometric analysis of the protective effect of ASC against spontaneous oxidation of BH4
in aqueous solution reported that the half-life time of BH4 was increased by 1.4-fold in the presence
of 100 μM of ASC and ASC maintained BH4 levels. They also reported ASC did not convert
oxidized BH2 to reduced BH4. Kinetic study by Patel et al. [144] reported that ASC protects BH4
indirectly by repairing the •BH3 radical which was determined by studying the decay of the •BH3
radical in the absence and presence of ASC. The study on EPR-kinetic analysis and
characterization of the pteridine radical also showed that ASC is not capable of reducing BH2 to
BH4 [279]. Our model results provide evidence that ASC improves endothelial dysfunction by
increasing total biopterin levels and improving biopterin ratio. ASC supplementation also
stabilized eNOS due to improved biopterin ratio and hence increased NO production rate was
observed in the presence of ASC in oxidative stress conditions. Our model results also showed
saturation effect of ASC around 100 µM, since 90 % improvement in NO production rate, TBP
levels and biopterin ratio was observed ≥ 50 µM. Increase in NO production rate was also observed
at higher physiological concentrations of GSH (Figure 17). This suggests increasing levels of NO
donor, such as GSNO may be a strategy to improve NO bioavailability. Details of interactions of
GSH enzyme system in oxidative and nitrosative stress and the mechanisms of GSNO formation
can be found in Chapter V. Further, our results for combination therapy of BH4 and ASC confirmed
that ASC is efficient for improving the NO levels by stabilizing eNOS and making more BH4
available for eNOS coupling at higher cellular oxidative stress. Our results indicate that ASC
supplementation would be effective in cases of BH4 deficiency or impaired BH4 synthesis.
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4.4.3. Role of ascorbate in scavenging reactive species
Several studies have reported that ASC can improve NO bioavailability by scavenging
reactive species including O2•- and ONOO- [147, 257, 280]. Study by Meade et al. [281] reported
local infusion of ASC augmented NO-dependent cutaneous vasodilation, due to the sensitivity of
ROS to ASC, in patients experiencing increased oxidative stress conditions. Study by Jackson et
al. [145] on isolated rabbit arterial segments reported that ASC is not as effective as using SOD
for scavenging O2•- radical. ASC is reported to decrease cellular ROS by inhibiting expression of
NADPH oxidase subunit p47phox induced by inflammatory insults [282] or by inhibiting the
expression of inducible NOS [283]. However, it is suggested that reduced expression of these
enzymes by ASC most likely results from its modulation of cellular redox signaling [264]. Our
model results confirmed these observation by showing no decrease in [O2•-] at Qsupcell of 1000
nM.s-1 for ASC supplementation of 50 µM and above, while only 17% and 13% decrease in [O2•] at Qsupcell of 10 and 100 nM.s-1 respectively. Further our model results showed that ASC
supplementation under oxidative stress conditions led to 10 – 40 fold increase in [ONOO-] levels.
The increase in ONOO- levels was attributed to increase in NO production rate due to ASC
supplementation. Reaction between increased NO production from eNOS and O2•- from cellular
oxidative stress leads to increased ONOO- levels [284]. When we modeled reactions of GPX and
Prx for ONOO- and H2O2 clearance, considerable decrease in the levels of ONOO- and H2O2, as
well as increased TBP levels were was observed in our system. This was attributed to less oxidation
of BH4 by ONOO-.

90
4.4.4. Increasing eNOS concentration and ascorbate supplementation considerably improves
NO bioavailability
ASC is reported to increase eNOS activity by changing its phosphorylation [116] and Snitrosylation status [116]. Further, studies have reported significant increase in eNOS expression
and protein concentration under oxidative stress conditions [95, 138, 222]. Hink et al. [285]
reported increase in the expression of eNOS and its protein concentration by 3-folds in diabetic
rats at higher oxidative stress conditions. Similarly, study by Dubois et al. [286] reported upregulation in eNOS in the lungs of mice exposed to chronic hypoxia. The increase in eNOS protein
concentration was 2-fold while mRNA expression increased by 300-fold in lungs of mice exposed
to chronic hypoxia up to 21 days. However, this more eNOS led to increase in cellular oxidative
stress due to eNOS uncoupling and significant reduction in NO levels. In our model, we the altered
eNOS protein concentration and studied its effect on eNOS NO production rate under oxidative
stress (Figure 16). Our model results suggest that concentration of eNOS played critical role in
determining the NO bioavailability and higher ASC supplementation concentrations were needed
at higher oxidative stress conditions. However, caution should be taken for the use of enhancing
eNOS strategy, as enhancing eNOS under oxidative stress may also lead to enhanced eNOS
uncoupling.
4.5. Conclusion
We investigated the role of ASC in endothelial dysfunction by integrating the putative
mechanisms of ASC in improving endothelial dysfunction as suggested in individual studies. For
this we extended our computational model developed in Chapter III and analyzed the interactions
of endothelial cell oxidative stress, BH4 synthesis and biopterin ratio in the presence of ASC and
GSH. Our model results showed that ASC supplementation improved NO production rate, TBP
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levels and biopterin ratio in oxidative stress conditions. Our results indicate that the important
mechanisms by which ASC improved NO bioavailability is by improving biopterin ratio and
stabilizing eNOS. Our results further showed that enhancing eNOS with higher ASC
supplementation resulted in considerable increase in NO production rates. The model results
showed the effect of ASC on scavenging of O2•- is not considerable. ASC supplementation also
increased ONOO- levels, which can be kept in control in the presence of physiological GPX and
Prx. Our model results for simultaneous increase in ASC and BH4 synthesis showed that higher
QBH4 was required to maintain elevated NO production rates in the absence of ASC. Higher NO
production rates can be attained with the introduction of ASC even at low QBH4. Our results
indicated that ASC supplementation can be used as an effective strategy in conditions were BH4
is depleted.
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CHAPTER V
V.

INTERACTIONS OF GSH/GPX SYSTEM WITH ROS/RNS3

5.1. Introduction
Glutathione (GSH) is one of the most abundant low molecular weight non-protein thiols
synthesized in cells, functionally involved in variety of cellular antioxidant systems. It is a
tripeptide formed of glutamine, glycine and cysteine amino acids of which the cysteine amino acid
gives GSH its reducing capacity [152, 287]. GSH is considered as a potent antioxidant due to its
ability to reduce reactive species, predominantly present in the reduced form, its abundance inside
the cell and ability to reversibly oxidize. The GSH imbalance of has been reported in many disease
states including atherosclerosis, cancer, neurodegenerative disease, and aging [40, 288, 289]. GSH
depletion can lead to an increase in the ROS and RNS generation, an increase in mitochondrial
complex I activity and NADPH oxidation, a decrease in cell viability, and an impairment of ATP
generation [155-157, 290].
Glutathione peroxidase (GPX) catalyzes consumption of GSH to reduce many oxidative
species including H2O2, organic hydro-peroxides, ONOO-, and lipid hydro-peroxide [105, 158].
However, GPX can remove ROS only in a certain range. When ROS production overtakes the
GPX capability beyond this range, ROS levels would increase [165]. Depletion in GPX has also
been implicated in several pathophysiological conditions [37, 38, 106]. Thus, GSH and GPX play
an important role in modulating ROS and RNS levels in biological systems.

3
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Several experimental and computational studies (as discussed in the literature review
section 2.5.3) have demonstrated that GSH/GPX system interacts with ROS/RNS. However, it is
not clear how this cross talk affects these reactive species and GSH/GPX enzyme system, under
physiologic and oxidative/nitrosative stress conditions. In the present study, we developed a
detailed endothelial cell kinetic model to understand the relationship amongst the key enzyme
systems including GSH, GPX, Prx and reactive species, such as H2O2, ONOO-, and dinitrogen
trioxide (N2O3). The analysis presented in this study would help us interpret the complex
interactions amongst reactive species and enzyme systems under physiologic and
oxidative/nitrosative stress conditions.
5.2. Materials and Method
5.2.1. Model description
Figure 19 shows the schematics of the reaction pathways showing interactions of O2•- and
NO, and their derivative products including H2O2, N2O3, and ONOO- with GSH and GPX system
in an endothelial cell. The reaction rate constants used in building the model are also depicted in
Figure 19 and detailed reactions and rate constants are shown in Table 9. In brief; (i) NO reacts
with O2•- to generate ONOO- (k4); (ii) O2•- undergoes self-dismutation (k18) or by action of
superoxide dismutase (SOD) (k5) into H2O2; (iii) ONOO- (k7) and H2O2 (k14) oxidizes GPXr
(reduced GPX) into GPXo (oxidized GPX); (iv) oxidized GPX is recycled to GPXr by GSH
through two steps: first GSH combines GPXo to form a complex, GSGPX (k15), then a second
GSH converts GSGPX to regenerate GPXr and form GSSG (k16); (v) catalase (k19) and Prx (k20)
hydrolyzes H2O2; (vi) NO reacts with O2 (multiple steps as shown in Table 1) to generate N2O3
(k12), which hydrolyzes (k13) or reacts with GSH to generate GSNO (k11); (vi) GSNO reacts slowly
with O2•- to generate GSSG (k10); (vii) ONOO- reacts with GSH to generate GSNO and a small
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amount of GSSG (k6); (viii) GSNO reacts with GSH to generate NO (k17); (ix) GSSG is reduced
into GSH by NADPH (k9). (x) ONOO- reacts with CO2 (k8) and is dismutated by Prx (k21).

Figure 19: Schematics for reactions pathways showing interactions of O2•-/NO with
GSH/GPX system in endothelial cell. Various species are represented inside round edged boxes,
while the enzymes are represented in oval shaped boxes. Species such as O2 and CO2 are
represented inside circles. The k values represent the rate constants for respective reactions and
are detailed in Table 9.

5.2.2. Model Formulation
We developed a computational model to understand the dynamics of the interaction of
ROS/RNS with GSH/GPX system in an endothelial cell. The modeled reaction kinetics network
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is shown in the Figure 19. The kinetic model consisted of 12 mass balance algebraic-differential
equations 1-12 for NO, O2•-, ONOO-, H2O2, GPXr, GPXo, GSGPX, GSH, GSSG, GSNO, nitrite
(NO2-) and N2O3, respectively, as shown below. The initial condition for these 12 species was set
at zero except or GSH and GPXr, as mentioned in the respective figure legends.
d[NO]
= k1 − k4[NO][O2∙− ] − 4k12[NO]2[O2 ] + k17[GSNO][GSH]
dt

(1)

d[O2∙− ]
2 ∙−
= k2 − k4[NO][O2∙− ] − k5[SOD][O∙−
2 ] − k10 [GSNO] [O2 ]
dt
∙
∙−
− k18[HO∙2 ][O∙−
2 ] (where, [HO2 ] = 0.0025[O2 ])

(2)

d[ONOO− ]
−
−
−
= k4[NO][O∙−
2 ] − k6[GSH][ONOO ] − k7[GPXr][ONOO ] − k8[ONOO ][CO2 ]
dt
− k21 [Prx][ONOOH] (where, [ONOOH]
= 0.5625[ONOO- ])

(3)

d[H2 O2 ]
k5[SOD][O∙−
2 ]
=
− k14[H2 O2 ][GPXr]+k18[HO∙2 ][O∙−
2 ] − 0.01k19 [H2 O2 ][catalase]
dt
2
− k 20 [H2 O2 ][Prx]

(4)

d[GPXr]
= −k7[GPXr][ONOO− ] − k14[H2 O2 ][GPXr] + k16[GSGPX][GSH]
dt

(5)

d[GPXo]
= k7[GPXr][ONOO− ] + k14[H2 O2 ][GPXr] − k15[GSH][ GPXo]
dt

(6)

[GSGPX] = [GPXr]i − [GPXr] − [GPXo]

(7)

d[GSH]
= k3 − k6[GSH][ONOO− ] + 2k9[GSSG][NADPH] − k11[N2 O3 ][GSH] − k15[GSH][GPXo]
dt
− k16[GSH][GSGPX] − k17 [GSNO][GSH]

(8)
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d[GSSG] 0.998k 6 [GSH][ONOO− ]
=
− k9[NADPH][GSSG] + k10 [GSNO]2 [O∙−
2 ]
dt
2
+ k16 [GSGPX][GSH] + k17 [GSNO][GSH]

(9)

[GSNO] = [GSH]i − [GSH] − 2[GSSG] − [GSGPX]

(10)

d[NO2− ]
= k7[GPXr][ONOO− ] + k10 [GSNO]2 [O∙−
2 ] + k11[N2 O3 ][GSH] + k17 [GSNO][GSH] (11)
dt
d[N2 O3 ]
= −k11 [N2 O3 ][GSH] + 2k12[NO]2[O2 ] − k13 [N2 O3 ]
dt

(12)

5.2.3. Model parameters
We assumed a homogeneous reaction model to account for the overall changes in the
species concentration for the interactions of ROS/RNS with GSH/GPX system. The model
parameters for NO and O2•- generation rates and reaction rate constants are summarized in Table
9. The generation rate of NO is denoted by ‘k1’ and the generation rate of O2•- is denoted by ‘k2’.
The value of k1 was obtained from the previous modeling studies [93, 175, 291] and was fixed
either at 1×10-6 M-1.s-1 or 1×10-7 M-1.s-1. The value of k2 was varied such that ratio of generation
rate of O2•- to that of NO (k2/k1) would be in the range of 0.01 to 10 based on the reported
endothelial cell O2•- and NO production rates [93]. A low k2/k1 represents high generation rate of
NO compared to that of O2•-, which may represent nitrosative stress, and a high k2/k1 may represent
oxidative stress.
Table 9: Reactions and rate constant used to develop the GSH/GPX computational model.
Rate
constant

Value

Reaction

Reference
Hu et al. [175]

k1

1×10-6
and
Formation of NO
1×10-7 M.s-1

Kar et al. [93]
Vaughn et al. [291]
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k2

varied M.s-1
-8

1×10 - 10×10

-6

Formation of O2•-

Kar et al. [93, 255]
Assumed

k3

0

Formation of GSH

k4

6.7×109 M-1.s-1

−
O∙−
2 +NO → ONOO

k5

1.6×109 M-1.s-1

H2 O + O∙−
2 →

k6

1.5×103 M-1.s-1

ONOO− + GSH → GSNO + GSSG

k7

2×106 M-1.s-1

GPXr + ONOO− → GPXo + NO2−

k8

5.8×104 M-1.s-1

ONOO− + CO2 → ONOOCO2 −

k9

3.2×106 M-1.s-1

GSSG + NADPH + H + → 2GSH
+ NADP +

k10

9×108 M-2.s-1

−
O•−
2 + 2GSNO + H2 O → GSSG + NO2
+
+ NO−
3 + 2H

k11

6.6×107 M-1.s-1

N2 O3 + GSH →

k4

Huie et al. [292]

1
1
O2 + H2 O2 + OH −
2
2

SOD,k5

k6

k7

k8

k9

k10

k11

GSNO + H + + NO−
2

Fielden et al. [293]
van der Vilet et al.
[294]
Sies et al. [105]
Denicola et al. [295]
Henderson
[118]

et

al.

Jourd’heuil
[263]

et

al.

Keshive et al. [262]

2NO + O2 → 2NO2
k12

6

-2 -1

2.4×10 M .s

NO + NO2 ↔ N2 O3
N2 O3 + H2 O → 2NO2− + 2H +
k12

4NO + O2 + H2 O →
k13

+
4NO−
2 + 4H

k13

1.6×103 M-1.s-1

N2 O3 + H2 O →

k14

2.1×107 M-1.s-1

GPXr+H2 O2 →

k15

4×104 M-1.s-1

GPXo + GSH →

k16

1×107 M-1.s-1

GSGPX + GSH →

k17

5.5×10-3 M-1.s-1

GSNO + GSH → GSSG + NH3 + N2 O
+ NO−
2 + NO

k18

8.0×107 M-1.s-1

HO∙2 + O2∙− +H + →

k19

3.4×107 M-1.s-1

H2 O2 + H2 O2 →

+
2NO−
2 + 2H

Licht et al. [259]

GPXo + H2 O

Antunes et al. [296]

GSGPX + H2 O

Antunes et al. [296]

k14

k15

Potdar et al. [199]

k16

GPXr+GSSG + H +

k17

k18

O2 + H2 O2

catalase,k19

O2 + 2H2 O

Antunes et al. [296]
Hogg et al. [297]
Dicks et al. [298]
Potdar et al. [199]
Aebi et al. [260]
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k20

k20

1.3×107 M-1.s-1

H2 O2 + Prx-(SH2 ) →

k21

1×107 M-1.s-1

ONOOH + Prx-(SH2 ) → NO2
+ Prx-SOH +2H +

H2 O + Prx-SOH

k21

Huang et al. [299],
Winterbourne et al.
[166]
De Armas
[109], Text

et

al.

Table 10 shows the initial concentration of species used in the model. The interaction
between GSH and oxidative stress is complex. GSH depletion can increase oxidative stress and an
increase in oxidative stress can decrease GSH levels [300]. In addition to GSH consumption
through oxidative stress, GSH concentration can also be affected through regulation of GSH
synthesis via r-glutamyl cysteine ligase and glutathione synthetase enzymes [301]. GSH can be
oxidized or nitrosated to GSSG or GSNO by multiple oxidative species or nitrosative species
[302]. Physiological concentrations of GSH range from 0.5 to 10 mM in cells and 2 to 20 µM in
plasma with GSH accounting for ~85-90% of the total glutathione pool [266, 270]. To investigate
the role of GSH in physiologic and pathologic conditions, we varied the initial concentration of
GSH ([GSH]i) from 1 µM to 100 mM [178, 270]. GSH is maintained in its reduced form by
NADPH-dependent glutathione reductase, such that one molecule of GSSG can recycle 2
molecules of GSH by NADPH [118]. We used the NADPH concentration of 30 µM, which was
obtained from a human umbilical vein endothelial cells (HUVECs) [303]. The rate constant for
the reaction used was 3.2×106 M-1s-1 (k9) [118]. GPXr is involved in the removal of H2O2 and
ONOO-. We assumed GPXr concentration of 5 µM [304]. When GPXr concentration is less than
H2O2 concentration, H2O2 removal is dependent on GPX and GSH concentration [176]. GPX
knockout mice have a very short survival time (4 hours) under acute oxidative stress [305]. To
understand the effect of GPX deficiency, the initial concentration of GPXr ([GPXr]i) was varied
from a low level of 5 pM to normal physiologic level of 5 µM and supplementation of upto 50
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µM [176, 305]. The peroxisome volume to the total cell volume ratio is 1%. Based on this we
calculated the removal of H2O2 via catalase at the rate of 3.4×107 M-1 s-1 [260, 303]. Recently, Prx
was reported to be involved in detoxifying H2O2 and ONOO- [130, 179]. We analyzed the presence
of Prx on our model system and Prx concentration of 20 µM was used [166]. The kinetic
parameters for dismutation of H2O2 and ONOO- by Prx are in Table 1. The fraction of total
peroxynitrite (ONOOH+ONOO-) present in anion form (ONOO-) was calculated as described by
Kavdia [226]. The ratio of ONOO- with total peroxynitrite calculated was 0.64 resulting in
[ONOOH] = 0.5625[ONOO-] and is incorporated in equation 3.
Table 10: Species/enzyme concentrations used in GSH/GPX model
Species

Concentration

Reference

SOD

10 µM

Beckman et al. [306]

CO2

1.14 mM

Radi et al. [307]

O2

35 µM

Antunes et al. [296]

Catalase

0.9 µM

Aebi et al. [260]

[GPXr]i

5 µM

Jacobson et al. [304]

[GSH]i

0.1, 1, 10 mM

Griffith et al. [308]

NADPH

30 µM

Adimora [179] and Sasaki [303] et al.

Prx

20 µM

Winterbourne et al. [166]

We simulated two scenarios in our modeling study; i) to provide a wide range of RNS and
ROS and analyze the temporal behavior of the species in the model, we varied the generation rates
of O2•- and NO and ii) to quantitatively understand the significance of interactions of GSH and
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GPX system with ROS and RNS, we explored steady-state concentrations of species at various
k2/k1 ratios, at varying [GSH]i, [GPXr]i and NADPH concentration. For both these scenarios the
NO generation rate (k1) was fixed at either 1×10-6 M.s-1 or 1×10-7 M.s-1 and the O2•- generation rate
was changed to represent the cellular level of oxidative or nitrosative stress. Apart from this, we
also analyzed the presence of Prx on the overall interactions of ROS/RNS with GSH/GPX system.
5.2.4. Numerical Simulations
The system of algebraic- and differential- equations (1 – 12) were solved numerically using
MATLAB 2017b (Mathworks Inc., Natick, MA) stiff solver ode15s. The relative error and
absolute error were set at 1×10-10 and 1×10-15, respectively for all simulated cases. The simulations
were run long enough for all participating species to reach steady state. This was achieved with a
time span of 2000 min.
5.3. Results
5.3.1. N2O3 acts as a mediator of GSH nitrosation and GPXr recycling in nitrosative stress
The simulations were performed for the ratio of generation rate of O2•- to that of NO (k2/k1)
of 0.01, 0.1, 0.5, 1, and 2. The initial concentration of GSH and GPXr was 1 mM and 5 µM,
respectively. Figure 20 and Figure 21 show the species profiles for the NO generation rate of 1×106

and 1×10-7 M.s-1, respectively. As seen in Figure 20, the concentration of NO and N2O3 decreased

whereas the concentration of O2•-, ONOO- and H2O2 increased for the ratio of k2/k1 from 0.01 to
2, (i.e. the O2•- generation rate range of 0.01 to 2 ×10-6 M.s-1, respectively). When k2/k1 ≤1, GSH
was converted into GSNO because of higher concentration of NO and N2O3. The recycling of
GPXr by GSH was affected because of GSH depletion and resulted in higher GPXo (oxidized form
of GPXr) under these conditions. For k2/k1 of 2, the concentration of O2•-, H2O2 and ONOOincreased and the concentration of NO and N2O3 decreased. GSH and GPXr remained in their
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reduced forms for k2/k1 of 2. The recycling capacity of GSH and GPXr improved when the O2•generation rate was greater than the NO generation rate.

Figure 20: Concentration profiles of species for NO generation rate (k1) of 1×10-6 M.s-1.
Panels A-I show temporal concentration profiles for species with a change in the ratio of the
generation rate of O2•- to that of NO (k2/k1). The initial concentration of GSH, GPXr, SOD,
catalase, NADPH, O2 and CO2 concentrations were set at 1mM, 5 µM, 10 µM, 0.9 µM, 30 µM,
35 µM and 1.14 mM respectively.
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Figure 21: Concentration profiles of species for NO generation rate (k1) of 1×10-7 M.s-1.
Panels A-I show temporal concentration profiles for species with a change in the ratio of the
generation rate of O2•- to that of NO (k2/k1). The initial concentration of GSH, GPXr, SOD,
catalase, NADPH, O2 and CO2 concentrations were set at 1mM, 5 µM, 10 µM, 0.9 µM, 30 µM,
35 µM and 1.14 mM respectively.

103
For the NO generation rate of 1×10-7, Figure 21 showed that the NO and N2O3
concentrations decreased by 55-68% and 90%, respectively for k2/k1 of 0.01 – 1. For k2/k1 of 2,
there was no change in the concentration of NO and N2O3 because of low levels of NO. For both
NO generation rates, the concentration of NO and N2O3 were 2.3 µM and 0.1 pM, respectively at
k2/k1 of 2. The concentration of O2•-, ONOO- and H2O2 decreased by almost 71 – 90 % at k1 of
1×10-7 M.s-1 as compared to that of k1 = 1×10-6 M.s-1 (please refer Panels B, C and E in Figure 20
and Figure 21) for all k2/k1 ratios. Most of GSH and GPXr remained in reduced state at k2/k1 of 2
for both NO generation rates.
The above results showed that the GPX recycling is dependent on GSH availability and
can be attributed to N2O3 but not to H2O2 and ONOO- levels under nitrosative stress (i.e. k2/k1 of
<1). N2O3 is the mediating factor for GSH consumption through its nitrosation. A negligible
concentration of N2O3 results in GSH to be maintained in its reduced form, whereas an increase in
the concentration of N2O3 promotes conversion of GSH to GSNO. N2O3 mediation remained
consistent in the presence of Prx, even though the H2O2 and ONOO- levels were reduced
considerably as shown later in the Section 6.3.4. The GSH and GPX may remain in reduced state
due to low availability of NO and N2O3 under oxidative stress conditions (i.e. k2/k1 equal to 2).
5.3.2. Effect of oxidative and nitrosative stress on the steady state concentrations of species
The effect of oxidative and nitrosative stress were simulated by varying the generation rate
of O2•- to provide a range of k2/k1 from 0.001 to 10 for the NO generation rate of 1×10-6 and 1×107

M s-1. The [GSH]i and [GPXr]i was 1 mM and 5 µM, respectively. As seen in Figure 22, the

steady state concentrations of NO and N2O3 decreased for the change in k2/k1 from 0.1 to 3 for k1
of 1×10-6 M.s-1. GSH nitrosation to GSNO occurred for k2/k1 ≤1, which can be attributed to N2O3
for both NO generation rates.
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Figure 22: Steady-state concentrations profiles of species as a function of k2/k1. Panels A-K
show semi log plots of steady state (ss) concentration for different species at NO generation rates
(k1) of 1×10-6 M.s-1 and 1×10-7 M.s-1, respectively with respect to varied k2/k1 ratio on a logarithmic
scale to the base 10. The initial concentration of GSH, GPXr, SOD, catalase, NADPH, O2 and CO2
concentrations were set at 1mM, 5 µM, 10 µM, 0.9 µM, 30 µM, 35 µM and 1.14 mM respectively.
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For k2/k1 above 1, the O2•- and H2O2 increased, the NO and N2O3 became negligible, and
the GSH and GPXr remained in reduced form for both NO generation rates. GPXr remained
primarily in the reduced state for lower NO generation rate (k1 of 1×10-7 M.s-1). These results
indicate that the reducing capacity of GPX was dependent on GSH availability and on the level of
oxidative/nitrosative stress.
5.3.3. Effect of varying GSH and GPXr on the steady state concentrations of species
Figure 23 and Figure 24 shows the species concentration profiles for initial concentrations
of GSH and GPXr from 1 µM to 100 mM and from 5 pM to 50 µM, respectively. The NO
generation rate was 1×10-6 and 1×10-7 M.s-1 and the k2/k1 ratio was kept constant at 1. The results
showed that the steady state (ss) concentrations of NO and O2•- were not affected by increasing
[GSH]i from 0.001 to 1 mM. However, the ss[NO] increased and ss[O2•-] decreased for [GSH]i
above 1 mM. The ss[ONOO-] was 13.4 nM at k1 of 1×10-6 M.s-1 and 1.2 nM for k1 of 1×10-7 M.s1

at all [GSH]i below 0.1mM. The ss[ONOO-] decreased for [GSH]i above 0.1 mM. N2O3

concentration decreased for [GSH]i above 0.3 mM for both NO generation rates. The GSNO
concentration reached a peak and decreased once N2O3 concentration became negligible at higher
[GSH]i. H2O2 concentration decreased considerably (Figure 23E) for [GSH]i below 0.3 and 0.1
mM for k1 of 1×10-6 and 1×10-7 M.s-1, respectively. GPXo reduced to GPXr for [GSH]i above 0.2
and 0.02 mM for k1 of 1×10-6 and 1×10-7 M.s-1, respectively.
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Figure 23: Steady-state concentrations profiles of species as a function of initial GSH
concentration. Panels A-K, except for Panel F, show semi log plots for steady state (ss)
concentration for different species at NO generation rates (k1) of 1×10-6 M.s-1 and 1×10-7 M.s-1,
respectively, with respect to initial concentration of GSH on a logarithmic scale to the base 10.
Panel F shows a log-log plot of ss[GSH] with respect to varied [GSH]i. The NO and O2•- generation
rates were kept equal (i.e. k2/k1 = 1). The GPXr, SOD, catalase, NADPH, O2 and CO2
concentrations were set at 5 µM, 10 µM, 0.9 µM, 30 µM, 35 µM and 1.14 mM respectively.

107

Figure 24: Steady-state concentrations profiles of species as a function of initial GPXr
concentration. Panels A-K, except for Panel H, show semi log plots for steady state (ss)
concentration for different species at NO generation rates (k1) of 1×10-6 M.s-1 and 1×10-7 M.s-1,
respectively with respect to initial concentration of GPXr on a logarithmic scale to the base 10.
Panel H shows a log-log plot of ss[GPXr] with respect to varied [GPXr]i. The NO and O2•generation rates were kept equal (i.e. k2/k1 = 1). The GSH, SOD, catalase, NADPH, O2 and CO2
concentrations were set at 1mM, 10 µM, 0.9 µM, 30 µM, 35 µM and 1.14 mM respectively.
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Increasing GPXr level from 0.005 to 50 µM did not affect the steady state concentration
of NO, O2•-, N2O3, GSH, and GSNO as seen in Figure 24. H2O2 concentration decreased with an
increase in [GPXr]i and deceased considerably for [GPXr]i above 0.3 and 3µM for k1 of 1×10-7
and 1×10-6 M.s-1, respectively (Figure 24E). These results showed that both GSH and GPXr are
critical for removal of H2O2 in the absence of Prx. In the presence of Prx, the removal of H2O2 is
primarily dependent on Prx as described in the next Section.
5.3.4. Effect of presence of Prx
Figure 25 and Figure 26 show the overall species profile in the presence of Prx for the NO
generation rate of 1×10-6 and 1×10-7 M.s-1, respectively. The [GSH]i, [GPXr]i, and Prx was 1 mM,
5 µM and 20 µM, respectively. These results were compared with the respective results in the
absence of Prx that are presented in Section 6.3.1 (Figure 20 and Figure 21). As compared to the
respective levels when Prx was not present, the presence of Prx did not change the levels of NO,
O2•-, N2O3, GSH and GSNO by more than 1 %, whereas the presence of Prx decreased the levels
of ONOO- and H2O2 by 59 – 63 % and 71 – 95 %, respectively for both NO generation rates for
all k2/k1 levels. The presence of Prx increased GPXr levels.
We further analyzed levels of ONOO- and H2O2 in the presence of both GPXr and Prx, and
only GPXr or Prx. The results are summarized in Table 11. The respective concentrations for
ONOO- and H2O2 were provided in the presence of both GPXr and Prx (GPXr + Prx) and %
increase from these levels are presented when only GPXr or only Prx was present. We observed
that ONOO- concentration increased by 5 – 6 %, and H2O2 concentration increased by 38 – 40%
in the case of only Prx, except for k2/k1 of 0.1 for the NO generation rate of 1×10-6 M.s-1. This %
increase indicates GPXr contribution in ONOO- and H2O2 removal. Thus, Prx was more effective
than GPXr to remove ONOO-, whereas GPXr and Prx both contributed towards H2O2 removal.
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Figure 25: Concentration profiles of species with Prx for NO generation rate (k1) of 1×10-6
M.s-1. Panels A-I show temporal concentration profiles for species with a change in the ratio of
the generation rate of O2•- to that of NO (k2/k1). The initial concentration of GSH, GPXr, Prx, SOD,
catalase, NADPH, O2 and CO2 concentrations were set at 1mM, 5 µM, 20 µM, 10 µM, 0.9 µM,
30 µM, 35 µM and 1.14 mM respectively.
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Figure 26: Concentration profiles of species with Prx for NO generation rate (k1) of 1×10-7
M.s-1. Panels A-I show temporal concentration profiles for species with a change in the ratio of
the generation rate of O2•- to that of NO (k2/k1). The initial concentration of GSH, GPXr, Prx, SOD,
catalase, NADPH, O2 and CO2 concentrations were set at 1mM, 5 µM, 20 µM,10 µM, 0.9 µM, 30
µM, 35 µM and 1.14 mM respectively.
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Table 11: Effect of GPXr and Prx on the levels of ONOO- and H2O2
NO generation rate (k1), M.s-1
Simulated cases *

0.1

1

10

0.52

4.69

5.26

0.046

0.41

0.53

, % increase 171 %

151 %

146 %

151 %

147 % 145 %

, % increase 2.6 %

5.3 %

5.5 %

5.4 %

5.6 %

5.6 %

7.1 × 10-3

0.16

12.34

1.7 × 10-3

0.03

1.23

, % increase

1696 %

290 %

254 %

285 %

247 % 247 %

, % increase

19 %

38.4 %

40.1 %

39%

40%

[𝐎𝐍𝐎𝐎− ]𝐨𝐧𝐥𝐲 𝐏𝐫𝐱
[𝐎𝐍𝐎𝐎− ](𝐆𝐏𝐗𝐫+𝐏𝐫𝐱)

[𝐇𝟐 𝐎𝟐 ](𝐆𝐏𝐗𝐫+𝐏𝐫𝐱) , nM

[𝐇𝟐 𝐎𝟐 ](𝐆𝐏𝐗𝐫+𝐏𝐫𝐱)

k2/k1
10

[𝐎𝐍𝐎𝐎− ](𝐆𝐏𝐗𝐫+𝐏𝐫𝐱)

[𝐇𝟐 𝐎𝟐 ]𝐨𝐧𝐥𝐲 𝐏𝐫𝐱

k2/k1
1

[𝐎𝐍𝐎𝐎− ]𝐨𝐧𝐥𝐲 𝐆𝐏𝐗𝐫

[𝐇𝟐 𝐎𝟐 ]𝐨𝐧𝐥𝐲 𝐆𝐏𝐗𝐫

1×10-7

0.1
[𝐎𝐍𝐎𝐎− ](𝐆𝐏𝐗𝐫+𝐏𝐫𝐱) , nM

[𝐇𝟐 𝐎𝟐 ](𝐆𝐏𝐗𝐫+𝐏𝐫𝐱)

1×10-6

40%

* % increase for ONOO- and H2O2 were calculated when only GPXr or only Prx were present with
respect to the concentration when both GPXr and Prx were present in the system.
5.3.5. Effect of NADPH concentration on GSH recycling
Glucose 6-phosphate dehydrogenase (G6PD) deficiency depletes NADPH, which is
essential for recycling GSH from its oxidized product GSSG [309, 310]. As previously seen in
Figure 4J, the majority of GSSG was reduced to GSH for k2/k1 ≥1 because sufficient amount of
NADPH was available for reduction of GSSG. In order to understand the relationship of NADPH
on GSH recycling in oxidative stress conditions, we varied NADPH concentration from 0.00003
to 3.0 µM and k2/k1 of 5.
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Figure 27: Steady-state GSH/GPX concentration profiles as a function of NADPH
concentration. Panels A-F show the semi-log plots for steady state (ss) concentration profiles
for various GSH/GPX species, at the NO generation rates (k1) of 1×10-6 M.s-1 and 1×10-7 M.s-1,
respectively, plotted with respect to varied initial concentration of NADPH on a log scale. Panel
G shows a semi-log plot for [GSH]/[GSSG] ratio (plotted on log scale), with respect to lower
range of [NADPH]i. The ratio of k2/k1 was kept constant at 5. The initial concentrations of GSH,
GPXr, SOD, catalase, O2 and CO2 concentrations were set at 1mM, 5 µM, 10 µM, 0.9 µM, 35
µM and 1.14 mM respectively.
Figure 27 shows that [NADPH] above 0.15 and 0.015 µM reduced GSSG and GPXo for
k1 of 1×10-6 M.s-1 and 1×10-7 M.s-1, respectively and maintained GSH and GPXr levels. GSSG
and GPXo were not reduced below 0.03 µM of [NADPH]. We also calculated the redox ratio,
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[GSH]/[GSSG] and saw that this ratio decreased with a decrease in [NADPH] in Figure 9G. The
[GSH]/[GSSG] ratio decreased below 10 when [NADPH] decreased below 0.009 and 0.0009 µM
for k1 of 1×10-6 M.s-1 and 1×10-7 M.s-1, respectively. These results implicate that the recycling of
GSH and GPX was dependent on NADPH only at low levels.
5.4. Discussions
In this study, we performed interactions of GSH/GPX enzyme system under
oxidative/nitrosative stress using a detailed reaction kinetic computational model in endothelial
cells. Major results from our mechanistic analysis were (i) the oxidative and nitrosative stress
related species were dependent on the ratio of generation rates of O2•- and NO, (ii) N2O3 mediated
depletion of GSH in a switch-like manner, (iii) GSH, GPXr and Prx were critical for the removal
of H2O2, (iv) Prx removed ONOO- effectively than GPXr, however, Prx did not play major role in
the overall cross-talk of ROS/RNS with the GSH/GPX system, and (v) the cellular reduction ability
of GSH/GPX system was independent of physiologic NADPH levels.
5.4.1. The ratio of generation rates of O2•- to NO determines the cellular levels of ROS and
RNS
The alterations in O2•- and NO generation play a critical role under physiological and
pathophysiological conditions [130]. Our results showed that the variation in the generation rate
of O2•- and NO led to a wide range of levels of ROS and RNS. The model results showed that the
NO, N2O3 and ONOO- were high when the NO generation rate was higher than the O2•- generation
rate, whereas the H2O2 was high when the O2•- generation rate was equal to or greater than the NO
generation rate. Low NO levels are protective, whereas high NO levels are cytotoxic [311]. Joshi
et al. [255] reported that oxidative stress led to the uncoupling of endothelial NO synthase (eNOS)
and resulted in the imbalance of NO and O2•- generation. Ali et al. [312] reported that high NO
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levels yield high N2O3 and ONOO- levels. Excess N2O3 is reported to cause S-nitrosylation of
proteins [313]. Excess ONOO- can form toxic NO2 and •OH radicals and may exacerbate the
irreversible nitrosation and nitrosylation of proteins, lipids, and DNA [131]. High intracellular
concentrations of H2O2 leads to cellular apoptosis due to mitochondrial membrane
hyperpolarization and causes membrane lipid peroxidation [314].
5.4.2. N2O3 mediates switch-like depletion in GSH
High fluxes of NO under pathological condition enables N2O3 formation, which in the
presence of thiols such as GSH leads to the formation of S-nitrosylated proteins [315]. Ali et al.
[312] reported that N2O3, and not ONOO-, acts as an intermediate for NO-mediated cytotoxicity
in the presence of GSH. We predict that the depletion of GSH is dependent on the N2O3. Our
modeling results showed that N2O3 mediated GSH depletion in a switch-like manner and a lower
N2O3 maintained GSH levels. These results agree with previous studies [175, 178]. Bagci et al.
[178] suggested that the probable reason for GSH depletion, as seen in NO-mediated toxicity, may
due to the switch-like increase in N2O3 concentration. Hu et al. [175] showed that the N2O3, GSNO
and GSH were sensitive to the initial GSH concentrations. Hu et al. suggested that GSH acts as a
dynamic switch for N2O3 levels and cause a step-like increase in N2O3 when GSH decreased below
a critical value. However, our results showed that the presence of N2O3 depleted GSH, whereas
GSH was maintained when N2O3 was negligible as seen Figure 22D and F. This holds also true
even in the presence of Prx (Figure 25D and F), which reduced levels of ONOO- and H2O2. This
indicates that the depletion in N2O3 would maintain the levels of GSH under nitrosative stress
conditions.
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5.4.3. Mechanism of GSNO formation
GSNO has been widely used in research studies as a NO donor [316, 317]. However, other
studies have reported that GSNO decomposition is a reductive process and is dependent on GSH
and thiols, and NO is a minor product of GSNO decay [318, 319]. Therefore, GSNO cannot be
used as a NO donor. Studies also suggested that the formation of GSNO is dependent on the NO
concentration and GSNO can be formed via the reaction between •NO2, N2O3 and ONOO- and GSH
[320, 321]. Our results showed that the majority of GSNO formation occurred through the
interactions of N2O3 and GSH. This indicates that GSNO formation is related to the nitrosative
stress and suggests that GSNO decomposition leads to only a small fraction of the total NO
generation. Our model included the reaction of GSNO with O2•- to form NO, however, there are
other cysteine residues that may decompose GSNO to form GSSG and GSH, and release NO [322,
323]. Deficiency of GPX is directly linked to endothelial dysfunction due to decrease in NO
availability and increased oxidative stress [38]
5.4.4. Contribution of GSH/GPX and Prx in H2O2 removal
The removal of H2O2 is mainly dependent on GPX, GSH and catalase activity [176, 324].
The GSH/GPX redox system is attributed to 80 to 90% of intracellular H2O2 removal [325, 326].
Recently, Prx is reported to be a dominant clearance pathway for H2O2 [327, 328]. Johnson et al.
[328] reported that both GPX and Prx participated in removing endogenous H2O2. They reported
that the absence of Prx increased the intracellular H2O2 by 400 % (to 1 nM) and the absence of
GPX increased the intracellular H2O2 by 20 % (to 0.32 nM). Our model predictions showed similar
trends. Our model predicted that the absence of Prx increased H2O2 levels by 247 to 290 % (0.1 to
44 nM) whereas the absence of GPX increased H2O2 by 38.4 to 40.3 % (0.04 to 17.3 nM) under
oxidative stress conditions (for k2/k1 of 1 to 10) as compared to when both GPX and Prx were
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present in the system. Further, both GSH and GPX were critical for H2O2 removal in the absence
of Prx. Since, H2O2 levels were high at low levels of GSH and/or GPXr (Figure 23E and Figure
24E) and decreased when levels of GSH and/or GPXr increased above 0.1 mM and 0.5 µM,
respectively. This model results are in agreement with the study by Ng et al. [176] that reported
that the removal of H2O2 is a function of both GSH and GPXr. In our model, Prx and GPXr have
comparable rate constants for their reaction with H2O2, however, the intracellular concentration of
Prx was 4 times more than the concentration of GPXr. Winterbourn et al. [166] suggested that Prx
removes more H2O2 as compared to GPXr, because of its abundance. The relative effectiveness of
Prx versus GPX may also depend on the availability of its reducing equivalent thioredoxin and
GSH, respectively [106, 329].
5.4.5. Contribution of GSH/GPX and Prx in the removal of ONOOGPX and Prx may act as ONOO- reductase thereby modulating ONOO--induced signaling
pathways in vivo [105, 130]. Forgione et al. [38] reported increased ONOO- levels and nitrosative
stress in GPX-/- mice than that of in wild type mice. Increasing GSH concentration reduced ONOOtoxicity in these GPX-/- mice. GSH has been shown to be dependent on GPX to defend against
ONOO- toxicity in vitro [105]. Studies have also reported that endothelial cells were protected
against ONOO--mediated damages because of an increase in Prx expression [110], and cellular
GSH content and GPX activity [330], following exposure to an organic selenium compound. Our
model results showed that Prx removed ONOO- efficiently than GSH/GPX system. As compared
to when both GPX and Prx were present in the system, the ONOO- levels increased 3 – 6 % and
145 – 171 % for only GPXr and only Prx, respectively. GSH and GPXr, above concentrations of
0.1 mM and 0.5 µM, respectively, complemented each other in removing ONOO- in the absence
of Prx.
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5.4.6. Recycling of GSH/GPX system is independent of physiologic NADPH concentration
G6PD deficiency is implicated in vascular diseases [331]. G6PD deficiency has been
shown to deplete NADPH, increase oxidative stress, reduce NO bioactivity, and perturb cellular
redox homeostasis [14, 309, 332] and increasing levels of G6PD showed an improvement in these
conditions [333]. Other studies reported that G6PD derived NADPH may increase NADPH
oxidase activity and lead to an increase in oxidative stress [334]. Our model results showed that
GSH/GPX activity was independent of NADPH concentration under oxidative stress conditions.
The redox ratio, [GSH]/[GSSG], which is used as a measure of the extent of oxidative stress, is
normally greater than 100:1 under physiological conditions and can decrease to as low as 4:1,
under oxidative stress conditions [335]. Enough NADPH was available for GSH recycling in our
model system. Thus, the [GSH]/[GSSG] ratio always remained above 500 in all our model
simulations, except for very low NADPH concentrations. We predict that elevated G6PD does not
affect the cellular reduction ability of GSH/GPX system in NADPH dependent manner.
5.5. Conclusion
In this study, a detailed endothelial cell kinetic model was developed to analyze the
interactions of ROS/RNS with the GSH/GPX system in oxidative/nitrosative stress conditions.
With this computational model, we showed that the ratio of generation rates of O2•- and NO
produced a wide range of outcomes for ROS/RNS levels and determined the cellular levels of
oxidative and nitrosative stress. The nitrosative stress from N2O3 became important for cases
where the NO generation was higher than the O2•- generation. The oxidative stress from H2O2
became important for the generation of O2•- higher than the generation of NO. We observed that
GPX recycling was dependent on GSH availability and can be attributed to N2O3 but not to H2O2
and ONOO- levels under nitrosative stress. Prx removed ONOO- efficiently than GSH/GPX
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system. Prx and GSH/GPX complemented each other for H2O2 detoxification. We propose that a
decrease in N2O3 may maintain GSH levels under nitrosative stress and an increase in the NADPH
levels may not affect the reduction ability of GSH/GPX system.
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CHAPTER VI
VI.

CONCLUSIONS AND FUTURE DIRECTIONS

6.1. Conclusions
The body of work presented in this dissertation thesis advances the knowledge on the
quantitative understanding of the oxidative stress mediated endothelial dysfunction in terms of
therapeutic potential of cofactor BH4 and antioxidants including ASC and GSH enzyme system
for improving endothelial dysfunction. Complex interactions amongst the reactive species and
antioxidant system underlay endothelial cell dysfunction. Since ROS and RNS are thought to cause
or aggravate several pathologies which leads to endothelial dysfunction, a systems perspective
should be employed to study these complex interactions and gain quantitative understanding about
the underlying mechanisms. Computational modeling approaches based on mass balances and
reaction kinetics were used in this study to overcome the limitations of measurements of reactive
species using traditional and still evolving experimental approaches.
Oxidative stress has been reported to cause eNOS uncoupling by decreasing the
bioavailability of BH4. In Chapter III, we were able to develop the most comprehensive
computational model to date of eNOS biochemical pathway and used it to analyze complex
interactions of oxidative stress and essential cofactor for eNOS, BH4. Using this model, we were
able to investigate the dynamic interactions reactive species, antioxidants, oxidative stress coming
from eNOS uncoupling as well as non-eNOS based sources and BH4 synthesis. Our model results
indicated that eNOS remains coupled under normal physiologic conditions because of a minimal
amount of oxidative stress, which is necessary for the normal signaling by ROS. eNOS uncoupling
has been reported in several diseases and targeting this enzyme, in its uncoupled state, has been
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proposed as an attractive therapeutic option [5, 336]. There have been attempts on developing
eNOS-directed pharmaceutical, so-called eNOS enhancers, compounds that up-regulate the
expression of eNOS at the mRNA and protein level [337, 338]. Preclinical studies have provided
quite favorable results; however, no clinical data are available to establish the efficacy of eNOS
enhancers in patients with CVD. Our model results suggest that the eNOS uncoupling alone
contributes negligibly towards the cellular oxidative stress while, the ROS coming from sources
such as NOX, XO and mitochondrial electron transport chain may further worsen the overall
oxidative stress experienced by the cell and may lead to eNOS uncoupling. Further, sole
overexpression of eNOS without up-regulation of its cofactor BH4 (maintained in reduced form)
will ultimately lead to its uncoupling and worsen disease conditions rather than improving them.
Also, to keep BH4 in its reduced state the overall cellular oxidative stress needs to be lessened.
More computational based studies on products used for scavenging ROS and RNS including uric
acid [339], SOD mimetics [340, 341] and others are needed to deepen our understanding on their
beneficial roles.
In Chapter IV, we analyzed the role of ASC in endothelial dysfunction. For this study we
developed a computational model that integrated the proposed mechanisms of ASC for its
beneficial effect in endothelial dysfunction, as suggested in individual studies, and analyzed its
interaction with our model of eNOS biochemical pathway and its downstream reactions (presented
in Chapter III). We also incorporated reaction kinetics of GSH and catalase in this model. From
our analysis we were able to identify the most important mechanism for the protective role of ASC
in endothelial dysfunction - ASC stabilizes eNOS by increasing BH4 bioavailability. Also, based
on our analysis of increasing/decreasing eNOS activity/concentration, we propose increasing
eNOS concentration or activity (using eNOS enhancers) along with combination therapy of BH4
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and ASC supplementation would be beneficial in improving endothelial dysfunction. Our model
results also showed that ASC supplementation increased ONOO- levels. Elevated ONOO- levels
can have deleterious effect on the cells and more nitrosative stress is experienced by the cells.
Presence of GPX and Prx in their physiological range can effectively keep the levels of ONOO- as
well H2O2 in check and ensure decreased BH4 oxidation. Use of ebselen (GPX mimetic) or Prx
mimetic are reported to protect endothelial cells from oxidative damage [119, 342]. More studies
(both experimental and computational) are needed to evaluate the effect of ASC supplementation
on the expression and activity of antioxidant enzymes.
In Chapter V, we developed a detailed endothelial cell kinetic model to analyze the
interactions of ROS/RNS with the GSH/GPX system in oxidative/nitrosative stress conditions.
This is one of the few models developed for NO and O2•- coexisting systems, as researchers most
often focus on either ROS or RNS, but not both. Mathematical modeling studies using reaction
kinetics are often used to evaluate the dynamics of H2O2 [176, 179, 299, 343] or ONOO- [344,
345] generation and clearance in terms of their concentrations. The cross-talk amongst species can
provide the overall behavior of the system, which remain to be evaluated. There is a need to
integrate knowledge from both kinds of studies and move towards models that consider ROS,
RNS, which we were able to perform in the present study. Our model analysis showed that the
ratio of generation rates of O2•- and NO is an important determinant for the cellular levels of
oxidative and nitrosative stress. At higher NO generation rate, higher levels of N2O3 can lead to
nitrosative stress, while at higher O2•- generation rates, higher levels of H2O2 exerts oxidative
stress. The contribution of N2O3 to the NO donor mediated cytotoxicity with respect to Snitrosylation has been proposed recently [312]. Our model results show, Prx removed ONOOefficiently than GSH/GPX system. Prx and GSH/GPX complemented each other for H2O2
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detoxification. Based on our model predictions we propose that a decrease in N2O3 may maintain
GSH levels under nitrosative stress and an increase in the NADPH levels may not affect the
reduction ability of GSH/GPX system. Analyses from computational modeling provides new
insights into the current understanding of endothelial dysfunction and can be used as guidelines
for designing future experiments.
6.2. Future Work Recommendations
(i) Therapeutic potential of L-arginine (substrate of eNOS) and L-citrulline (can be converted to
L-arginine) to increase NO bioavailability has been reported to generate mixed results [346]. The
mathematical modeling of eNOS biochemical pathway and its interactions with oxidative stress
and BH4 synthesis can be modified developed in Chapter II can be modified to understand the
effect of these substrates the NO bioavailability in oxidative stress conditions.
(ii) Computational model developed in Chapter IV to analyze the role of ASC in endothelial
dysfunction does not consider the dynamics of ASC. Introducing the ASC dynamics may provide
useful information on the generation and consumption of ASC and its optimal intracellular
concentrations in endothelial cells in health and disease.
(iii) The homeostasis and health of the brain is maintained by neurovascular units that comprises
of different cell types. Endothelial cells in these neurovascular units are considered to play
commander-in-chief role. Recent findings indicate that oxidative stress and vascular dysfunction
underlies the development of neurodegenerative diseases [44]. The computational modeling
approaches presented in this dissertation can be used to understand the dynamics of ROS/RNS and
antioxidant interactions in the endothelia cells of the neurovascular units.
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APPENDIX - Listings of MATLAB sample codes
A1 - Model to analyze for interactions of oxidative stress and tetrahydrobiopterin synthesis
in eNOS coupling
function enos34
close all
clear all
clc
%--------------------------------------------------------------------%Defining Mass matrix
M=zeros(38,38);
M(1,1)=1;
M(2,2)=1;
M(3,3)=1;
M(4,4)=1;
M(5,5)=1;
M(6,6)=1;
M(7,7)=1;
M(8,8)=1;
M(9,9)=1;
M(10,10)=1;
M(11,11)=0;
M(12,12)=1;
M(13,13)=1;
M(14,14)=1;
M(15,15)=1;
M(16,16)=1;
M(17,17)=1;
M(18,18)=1;
M(19,19)=1;
M(20,20)=1;
M(21,21)=1;
M(22,22)=1;
M(23,23)=1;
M(24,24)=1;
M(25,25)=1;
M(26,26)=1;
M(27,27)=0;
M(28,28)=1;
M(29,29)=1;
M(30,30)=1;
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M(31,31)=1;
M(32,32)=1;
M(33,33)=1;
M(34,34)=1;
M(35,35)=1;
M(36,36)=1;
M(37,37)=1;
M(38,38)=0;
%--------------------------------------------------------------------% Defining the ODE parameters and solver
tspan = [0 10000];
x0=[0.097e-06 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0 0e-8
0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0.035e-6 0.035e-6 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e8 0.1e-3 0e-8];
options=odeset('Mass',M,'MstateDependence','strong','RelTol',1e-10,'AbsTol',[1e-15 1e-15 1e-15
1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15
1e-15],'Vectorized','off');
sol=ode15s(@grant2,tspan,x0,options);
x1=linspace(0,10000,100);
[y,z] = deval(sol,x1);
[y1,z1]=deval(sol,x1,20); % NO
[y2,z2]=deval(sol,x1,24); % Superoxide
[y3,z3]=deval(sol,x1,28); % Peroxynitrite
[y4,z4]=deval(sol,x1,29); % NO Production
[y5,z5]=deval(sol,x1,30); % Superoxide Production
figure (1)
plot(x1,y*1e6) % Concentration profiles all
figure (2)
plot(x1,y1*1e6) % NO Concentration profile
figure (3)
plot(x1,z1*1e6) % NO rate
figure (4)
plot(x1,y2*1e6) % Superoxide Concentration profiles
figure (5)
plot(x1,y3*1e6) % Peroxynitrite Concentration profiles
figure (6)
plot (x1,z4*1e6) % NO Production rate
figure (7)
plot (x1,z5*1e6) % Superoxide Production rate
p=xlswrite('b4DEPGSH.xls',[x1' y' z4' z5' z1']);
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%--------------------------------------------------------------------function dx = grant2(t,x)
dx=zeros(38,1);
% Defining the rate constants
nosi=0.097e-06;
tbpi=7e-6;
GSHi=0.1e-3;
carg=100e-6;
cBH4=6.93e-6; % Introduce BH4 Concentration Here
co2=140e-6; % Oxygen Concentration
cco2=1.1e-3; % Carbon Dioxide concentration
Qsupcell=0;
casc=0e-6;
csod=10e-6;
ka1=1.19e6;
ka_1=3.77;
ka2=0.474;
ka3=8.2e5;
ka_3=48.3;
ka5=7.68;
ka6=7.68;
ka7=6.85;
ka8=3.62;
kb1=0.1;
kb_1=1e5;
kb2=0.474;
kb3=9.19e5;
kb_3=40.5;
kb5=36.6;
kb6=9.45;
kb7=11;
kb9=0.033e6;
kb_7=1.7e6;
kb8=7.8e-3;
kb10=1.76e-3;
kb_10=3.07e6;
kb12=3.77;
kb_12=1.19e6;
k13=1.19e6;
k_13=3.77;
kc2=2.2e4;
kc_2=5e-3;
kc3=2.2e4;
kc_3=4.7e-2;
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kc4=1.19e6;
kc_4=3.77;
kc5=0.474;
kc6=1.73e6;
kc_6=14.2;
kc8=0.375;
k14=6.7e9;
k15=2.40e6;
k16=3.85e9;
k17=0.60;
k18=3.9e5;
k19=4.65e4;
k20=1.7e5;
k21=3.62;
k22=6e3;
k23=364;
k24=5.09e5;
k25=0.981;
k26=0.401;
k27=9.10e4;
k28=3.57e5;
k29=3.89e4;
k30=1.91e4;
k31=6.65e8;
k32=5.82e9;
k33=8.8e9;
k34=9.4e8;
k35=4.6e9;
k36=3.2e3;
k37=6e8;
k38=1.35e3;
k39=6.6e7;
vm1=3.2e-4;
km1=50e-6;
%--------------------------------------------------------------------% Defining the rate equations
%( x1=E-1; x2=Ec1; x3=Ec2; x4=Ec3;
%x5=Ec4; x6=E; x7=Ea1;
%x8=Ea2; x9=Ea3; X10=Ea4;
%x11=Ea5; x12=Ea6, X13=Eb1; X14=Eb2; X15=Eb3; X(16)=Eb4;
%X(17)=Eb5; X(18)=Eb6; X(19)=Eb7; X20=NO; X21=NHA; x22=Citrulline; cBH4=BH4;
x23=NO3-; x24=O2-; x25=H2O2; x26=BH3; x27=BH2; x28=ONOO-; x29=NO Production;
x30=O2- Production;
% x31=NO2-; x32=.OH; x33=.NO2; x34=CO3.-; x35=GSNO; x36=N2O3; x37=GSH;
x38=GSSG )
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dx(1)=kc_3*x(2)+kc_2*x(6)-kc3*x(27)*x(1)-kc2*x(1)*cBH4;
dx(2)=kc_4*x(3)+kc3*x(27)*x(1)-kc4*x(2)*carg-kc_3*x(2);
dx(3)=kc4*x(2)*carg+kc8*x(5)-kc_4*x(3)-kc5*x(3);
dx(4)=kc5*x(3)+kc_6*x(5)-kc6*x(4)*co2;
dx(5)=kc6*x(4)*co2-kc_6*x(5)-kc8*x(5);
dx(6)=kc2*x(1)*cBH4+ka_1*x(7)+kb1*x(13)+kb7*x(17)+kb9*x(18)*co2-kc_2*x(6)ka1*x(6)*carg-kb_1*x(21)*x(6)-kb_7*x(20)*x(6);
dx(7)=ka1*x(6)*carg-ka_1*x(7)-ka2*x(7);
dx(8)=ka2*x(7)+ka_3*x(9)-ka3*x(8)*co2+k13*carg*x(19)-k_13*x(8);
dx(9)=ka3*co2*x(8)-ka_3*x(9)-ka5*x(9);
dx(10)=ka5*x(9)-ka6*x(10);
dx(11)=x(1)+x(2)+x(3)+x(4)+x(5)+x(6)+x(7)+x(8)+x(9)+x(10)+x(11)+x(12)+x(13)+x(14)+x(15
)+x(16)+x(17)+x(18)+x(19)-nosi;
dx(12)=ka7*x(11)-ka8*x(12);
dx(13)=ka8*x(12)+kb_1*x(21)*x(6)-kb2*x(13)-kb1*x(13);
dx(14)=kb2*x(13)+kb_3*x(15)+kb_12*x(19)*x(21)-kb3*x(14)*co2-kb12*x(14);
dx(15)=kb3*x(14)*co2-kb_3*x(15)-kb5*x(15);
dx(16)=kb5*x(15)-kb6*x(16);
dx(17)=kb6*x(16)+kb_7*x(6)*x(20)-kb8*x(17)-kb7*x(17);
dx(18)=kb8*x(17)+kb_10*x(20)*x(19)-kb10*x(18)-kb9*x(18)*co2;
dx(19)=kb10*x(18)+k_13*x(8)+kb12*x(14)-kb_10*x(19)*x(20)-kb_12*x(19)*x(21)k13*x(19)*carg;
dx(20)=kb7*x(17)+kb10*x(18)-kb_7*x(20)*x(6)-kb_10*x(20)*x(19)-(4*k15*((x(20))^2)*co2)k14*x(20)*x(24)-k27*0.22*x(28)*x(20)-k32*x(20)*x(34)+k37*(x(35)^2)*x(24);%ok
dx(21)=kb1*x(13)+kb12*x(14)-kb_1*x(21)*x(6)-kb_12*x(19)*x(21);

128
dx(22)=kb6*x(16);
dx(23)=kb9*x(18)*co2+k25*x(28)+k29*x(28)*cco2;
dx(24)=kc8*x(5)+Qsupcell-k14*x(20)*x(24)-k16*csod*x(24)-k28*0.0025*x(24)*x(24)k31*x(24)*x(34)-k24*casc*x(24)-k18*cBH4*x(24)-k37*(x(35)^2)*x(24);
dx(25)=k16*csod*x(24)+k28*0.0025*x(24)*x(24)+k18*cBH4*x(24);
dx(26)=k33*x(32)*cBH4+k34*x(33)*cBH4+k35*x(34)*cBH4+k22*cBH4*x(28)+k18*cBH4*x
(24)-2*k19*((x(26))^2)-k20*x(26)*casc-k36*x(26)*co2;
dx(27)=tbpi-cBH4-x(26)-x(27);
dx(28)=k14*x(20)*x(24)-k25*x(28)-k26*x(28)-k29*x(28)*cco2-k30*x(28)*cco2k27*0.22*x(28)*x(20)-k23*casc*0.22*x(28)-k22*cBH4*x(28)-k38*x(28)*x(37);
dx(29)=kb7*x(17)+kb10*x(18)+k37*(x(35)^2)*x(24);
dx(30)=kc8*x(5)+Qsupcell;
dx(31)=4*k15*((x(20))^2)*co2+k27*x(20)*0.22*x(28)+k32*x(34)*x(20)+k34*x(33)*cBH4;
dx(32)=k26*x(28)-k33*x(32)*cBH4;
dx(33)=k26*x(28)+k30*x(28)*cco2+k27*0.22*x(28)*x(20)-k34*x(33)*cBH4;
dx(34)=k30*x(28)*cco2-k31*x(34)*x(24)-k32*x(34)*x(20)-k35*x(34)*cBH4;
dx(35)=k38*x(28)*x(37)+k39*x(36)*x(37)-k37*(x(35)^2)*x(24);
dx(36)=(4*k15*((x(20))^2)*co2)-k39*x(36)*x(37);
dx(37)=((vm1*x(38))/(km1+x(38)))-k38*x(28)*x(37)-k39*x(36)*x(37);
dx(38)=-GSHi-(-x(37)-x(35)-x(38));
%---------------------------------------------------------------------
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A-2 Model to analyze role of ascorbate in endothelial dysfunction
function enos34newasc
close all
clear all
clc
%Defining Mass matrix
M=zeros(39,39);
M(1,1)=1;
M(2,2)=1;
M(3,3)=1;
M(4,4)=1;
M(5,5)=1;
M(6,6)=1;
M(7,7)=1;
M(8,8)=1;
M(9,9)=1;
M(10,10)=1;
M(11,11)=0;
M(12,12)=1;
M(13,13)=1;
M(14,14)=1;
M(15,15)=1;
M(16,16)=1;
M(17,17)=1;
M(18,18)=1;
M(19,19)=1;
M(20,20)=1;
M(21,21)=1;
M(22,22)=1;
M(23,23)=1;
M(24,24)=1;
M(25,25)=1;
M(26,26)=1;
M(27,27)=1;
M(28,28)=1;
M(29,29)=1;
M(30,30)=1;
M(31,31)=1;
M(32,32)=1;
M(33,33)=1;
M(34,34)=1;
M(35,35)=1;
M(36,36)=1;
M(37,37)=1;
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M(38,38)=1;
M(39,39)=0;
%--------------------------------------------------------------------% Defining the ODE parameters and solver
tspan = [0 1000000];
%0.05 at TBP = 7 uM
x0=[0.097e-6 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0 0e-8
0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 0e-8 3.325e-6 3.325e-6 0e-8 0e-9 0e-8 0e-8 0e-8 0e-8 0e-8 0.35e-6
0e-8 0e-8 0.01e-3 0e-8];
options=odeset('Mass',M,'MstateDependence','strong','RelTol',1e-10,'AbsTol',[1e-15 1e-15 1e-15
1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15
1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15
1e-15 1e-15 1e-15 1e-15 1e-15 1e-15],'Vectorized','off');
sol=ode15s(@grant2,tspan,x0,options);
x1=linspace(0,1000000,10000);
[y,z] = deval(sol,x1);
[y1,z1]=deval(sol,x1,20); % NO
[y2,z2]=deval(sol,x1,24); % Superoxide
[y3,z3]=deval(sol,x1,28); % Peroxynitrite
[y4,z4]=deval(sol,x1,29); % NO Production
[y5,z5]=deval(sol,x1,30); % Superoxide Production
[y6,z6]=deval(sol,x1,26); % BH3
[y7,z7]=deval(sol,x1,27); % BH2
[y8,z8]=deval(sol,x1,35); % BH4
[y9,z9]=deval(sol,x1,25); % H2O2
figure (1)
plot(x1,y*1e6) % Concentration profiles all
figure (2)
plot(x1,y1*1e6) % NO Concentration profile
figure (3)
plot(x1,z1*1e6) % NO rate
figure (4)
plot(x1,y2*1e6) % Superoxide Concentration profiles
figure (5)
plot(x1,y3*1e6) % Peroxynitrite Concentration profiles
figure (6)
plot (x1,z4*1e6) % NO Production rate
figure (7)
plot (x1,z5*1e6) % Superoxide Production rate
p=xlswrite('ResultsASCnew.xls',[x1' y' z4' z5' z1']);
%--------------------------------------------------------------------function dx = grant2(t,x)
dx=zeros(39,1);
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%--------------------------------------------------------------------% Defining the rate constants
nosi=0.097e-6;
% nosi=0.048e-6;
% nosi=0.144e-6;
tbpi=7e-6;
carg=100e-6;
GSHi=0.01e-3;
co2=140e-6; % Oxygen Concentration
cco2=1.1e-3; % Carbon Dioxide concentration
Qsupcell=1e-9; % Other Sources of Superoxide Production
QBH4=0.5e-9; % BH4 production rate
casc=5e-6; % Ascorbate Concentration
csod=10e-6; % SOD concentration
ccat=9e-7; % Catalase conc. peroxisomes
ka1=1.19e6;
ka_1=3.77;
ka2=0.474;
ka3=8.2e5;
ka_3=48.3;
ka5=7.68;
ka6=7.68;
ka7=6.85;
ka8=3.62;
kb1=0.1;
kb_1=1e5;
kb2=0.474;
kb3=9.19e5;
kb_3=40.5;
kb5=36.6;
kb6=9.45;
kb7=11;
kb9=0.0133e6;
kb_7=1.7e6;
kb8=7.8e-3;
kb10=1.76e-3;
kb_10=3.07e6;
kb12=3.77;
kb_12=1.19e6;
k13=1.19e6;
k_13=3.77;
kc2= 2.2e4;
kc_2=5e-3;
kc3=2.2e4;
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kc_3=4.7e-2;
kc4=1.19e6;
kc_4=3.77;
kc5=0.474;
kc6=1.73e6;
kc_6=14.2;
kc8=0.375;
k14=6.7e9;
k15=2.4e6;
k16=3.85e9;
k17=0.6; % BH4 auto-oxidation
k18=3.9e5;
k19=4.65e4;
k20=1.7e5;
k22=6e3;
k23=361.7;
k24=5.1e5;
k25=0.981;
k26=0.401;
k27=9.1e4;
k28=3.57e5;
k29=3.89e4;
k30=1.91e4;
k31=6.65e8;
k32=5.82e9;
k33=8.8e9;
k34=9.4e8;
k35=4.6e9;
k36=3.2e3;
k37=3.4e7; % rate constanst for catalase
k38=152.5; % BH2 extracellular diffusion rate constant
k39=1.35e3;
k40=6.6e7;
vm1=3.2e-4;
km1=50e-6;
k41=1.6e3;
k42=9e8;
cPer=10e-6; %20e-6;
cGPXR=2.5e-6; %5e-6;
k43=2e6; %Hydrolysis of ONOO- by GPXr
k44=2.1e7; % Hydrolysis of H2O2 by GPXr
k45=1.3e7; % Rate constant for H2O2 hydrolysis with peroxiredoxin
k46=1e7; %Rate constant for ONOO- hydrolysis by peroxyredoxin
%---------------------------------------------------------------------
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% Defining the rate equations
%( x1=E-1; x2=Ec1; x3=Ec2; x4=Ec3; x5=Ec4; x6=E; x7=Ea1; x8=Ea2; x9=Ea3; x10=Ea4;
x11=Ea5; x12=Ea6, x13=Eb1; x14=Eb2; x15=Eb3; x16=Eb4; x17=Eb5; x18=Eb6; x19=Eb7;
x20=NO; x21=NHA; x22=Citrulline; x23=NO3-; x24=O2-; x25=H2O2; x26=BH3; x27=BH2;
x28=ONOO-; x29=NO Production; x30=O2- Production; x31=NO2-; x32=.OH; x33=.NO2;
x34=CO3.-; x35=BH4; x36=GSNO; x37=N2O3; x38=GSH; x39=GSSG) Taken out -->
x40=GS.)
dx(1)=kc_3*x(2)+kc_2*x(6)-kc3*x(27)*x(1)-kc2*x(1)*x(35);
dx(2)=kc_4*x(3)+kc3*x(27)*x(1)-kc4*x(2)*carg-kc_3*x(2);
dx(3)=kc4*x(2)*carg+kc8*x(5)-kc_4*x(3)-kc5*x(3);
dx(4)=kc5*x(3)+kc_6*x(5)-kc6*x(4)*co2;
dx(5)=kc6*x(4)*co2-kc_6*x(5)-kc8*x(5);
dx(6)=kc2*x(1)*x(35)+ka_1*x(7)+kb1*x(13)+kb7*x(17)+kb9*x(18)*co2-kc_2*x(6)ka1*x(6)*carg-kb_1*x(21)*x(6)-kb_7*x(20)*x(6);
dx(7)=ka1*x(6)*carg-ka_1*x(7)-ka2*x(7);
dx(8)=ka2*x(7)+ka_3*x(9)-ka3*x(8)*co2+k13*carg*x(19)-k_13*x(8);
dx(9)=ka3*co2*x(8)-ka_3*x(9)-ka5*x(9);
dx(10)=ka5*x(9)-ka6*x(10);
dx(11)=x(1)+x(2)+x(3)+x(4)+x(5)+x(6)+x(7)+x(8)+x(9)+x(10)+x(11)+x(12)+x(13)+x(14)+x(15
)+x(16)+x(17)+x(18)+x(19)-nosi;
dx(12)=ka7*x(11)-ka8*x(12);
dx(13)=ka8*x(12)+kb_1*x(21)*x(6)-kb2*x(13)-kb1*x(13);
dx(14)=kb2*x(13)+kb_3*x(15)+kb_12*x(19)*x(21)-kb3*x(14)*co2-kb12*x(14);
dx(15)=kb3*x(14)*co2-kb_3*x(15)-kb5*x(15);
dx(16)=kb5*x(15)-kb6*x(16);
dx(17)=kb6*x(16)+kb_7*x(6)*x(20)-kb8*x(17)-kb7*x(17);
dx(18)=kb8*x(17)+kb_10*x(20)*x(19)-kb10*x(18)-kb9*x(18)*co2;
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dx(19)=kb10*x(18)+k_13*x(8)+kb12*x(14)-kb_10*x(19)*x(20)-kb_12*x(19)*x(21)k13*x(19)*carg;
dx(20)=kb7*x(17)+kb10*x(18)-kb_7*x(20)*x(6)-kb_10*x(20)*x(19)-k14*x(20)*x(24)(4*k15*((x(20))^2)*co2)-k27*0.22*x(28)*x(20)-k32*x(20)*x(34)+k42*((x(36))^2)*x(24); %
X20=NO
dx(21)=kb1*x(13)+kb12*x(14)-kb_1*x(21)*x(6)-kb_12*x(19)*x(21);% X21=NHA
dx(22)=kb6*x(16);%x22=Citrulline
dx(23)=kb9*x(18)*co2+k25*x(28)+k29*x(28)*cco2; % x23=NO3dx(24)=Qsupcell+kc8*x(5)-k14*x(20)*x(24)-k16*csod*x(24)-k18*x(35)*x(24)k24*casc*x(24)-k28*0.0025*x(24)*x(24)-k31*x(24)*x(34)-k42*(x(36)^2)*x(24); %x24=O2dx(25)=k16*csod*x(24)+k18*x(35)*x(24)+k28*0.0025*x(24)*x(24)-k37*ccat*x(25)k45*cPer*x(24)-k44*x(24)*cGPXR; %x25=H2O2
dx(26)=k18*x(35)*x(24)-2*k19*((x(26))^2)k20*x(26)*casc+k22*x(35)*x(28)+k33*x(32)*x(35)+k34*x(33)*x(35)+k35*x(34)*x(35)k36*x(26)*co2; %x26=BH3
dx(27)= kc_3*x(2)-kc3*x(27)*x(1)+k17*x(35)*co2+k19*((x(26))^2) +k36*x(26)*co2k38*x(27); %x27=BH2
dx(28)= k14*x(20)*x(24)-k22*x(35)*x(28)-k23*casc*x(28)-k25*x(28)-k26*x(28)k27*0.22*x(28)*x(20)-k29*x(28)*cco2-k30*x(28)*cco2-k39*x(28)*x(38)0.5625*k46*cPer*x(28)-k43*x(28)*cGPXR; %x28=ONOOdx(29)=kb7*x(17)+kb10*x(18)+k42*((x(36))^2)*x(24); %x29=NO Production;
dx(30)=kc8*x(5)+Qsupcell; %x30=O2- Production;
dx(31)=(2*k15*((x(20))^2)*co2)+k27*0.22*x(20)*x(28)+k32*x(34)*x(20)+k34*x(33)*x(35)+k
40*x(37)*x(38)+k41*x(37); %x31=NO2-;
dx(32)=k26*x(28)-k33*x(32)*x(35); % x32=.OH;
dx(33)=k26*x(28)+k27*0.22*x(28)*x(20)+k30*x(28)*cco2-k34*x(33)*x(35); %x33=.NO2;
dx(34)=k30*x(28)*cco2-k31*x(34)*x(24)-k32*x(34)*x(20)-k35*x(34)*x(35); %x34=CO3.-;
dx(35)=QBH4+kc_2*x(6)-kc2*x(35)*x(1)-k17*x(35)*co2k18*x(35)*x(24)+k19*((x(26))^2)+k20*x(26)*casc-k22*x(35)*x(28)-k33*x(32)*x(35)k34*x(33)*x(35)-k35*x(34)*x(35); %x35=BH4;
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dx(36)=k39*x(28)*x(38)+k40*x(37)*x(38)-k42*((x(36))^2)*x(24); % x36=GSNO;
dx(37)=(4*k15*((x(20))^2)*co2)-k40*x(37)*x(38)-k41*x(37); % x37=N2O3;
dx(38)=((vm1*x(39))/(km1+x(39)))-k39*x(28)*x(38)-k40*x(37)*x(38); %x38=GSH;
dx(39)=GSHi-x(38)-x(36)-x(39); %x39=GSSG
%---------------------------------------------------------------------
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A-3 Model to analyze interactions of GSH/GPX with ROS/RNS
function gshuirevisedkper
%Defining Mass matrix because we have al
M=zeros(14,14);
M(1,1)=1;
M(2,2)=1;
M(3,3)=1;
M(4,4)=0;%Mass Balance
M(5,5)=1;
M(6,6)=1;
M(7,7)=1;
M(8,8)=1;
M(9,9)=0;%Mass Balance
M(10,10)=1;
M(11,11)=1;
M(12,12)=1;
M(13,13)=1;
M(14,14)=1;
%--------------------------------------------------------------------% Defining the ODE parameters and solver
tspan = [0 100000];
%Initial Concentration x0=[x1=NO; x2=O2-; x3=ONOO-; x4=GSNO; x5=N2O3; x6=GSH;
x7=H2O2; x8=GPXo; x9=GSGPX; x10=GPXr; x11=ONO-; x12=[GSSG]; x13=NO Production;
x14=O2- Production ]
x0=[0 0 0 0 0 1e-3 0 0 0 5e-6 0 0 0 0];
options=odeset('Mass',M,'MstateDependence','strong','RelTol',1e-10,'AbsTol',[1e-15 1e-15 1e-15
1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15 1e-15],'Vectorized','off');
sol=ode15s(@gshoder,tspan,x0,options);
x1=linspace(0,100000,10000);
[y,z] = deval(sol,x1);
[y1,z1]=deval(sol,x1,6); % gsh conc
[y2,z2]=deval(sol,x1,2); % Superoxide conc
[y3,z3]=deval(sol,x1,5); % N2O3 conc
[y4,z4]=deval(sol,x1,13); % NO Production
[y5,z5]=deval(sol,x1,14); % Superoxide Production
[y6,z6]=deval(sol,x1,1);%NO Concentration
[y7,z7]=deval(sol,x1,7);%H2O2 Conc
[y8,z8]=deval(sol,x1,4);%GSNO Conc
[y9,z9]=deval(sol,x1,3);%ONOO- Conc
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figure (1)
plot(x1,y*1e6) % Concentration profiles all
figure (2)
plot(x1,y1*1e3) % Gsh Concentration
figure (3)
plot(x1,y2*1e6) % O2- Conc
figure (4)
plot(x1,y3*1e6) % N203 Conc
figure (5)
plot (x1,z4*1e6) % NO Production Rate
figure (6)
plot (x1,z5*1e6) % Superoxide Production Rate
figure (7)
plot (x1,y6*1e6) %NO Conc
figure(8)
plot (x1,y8*1e3) %GSNO Conc
figure(9)
plot (x1,y9*1e6) %ONOO- Conc
figure (10)
plot (x1,y7*1e6)%h2o2 conc
p=xlswrite('gsh_valueschanging.xls',[x1' y' z4' z5']);
function dx = gshoder(t,x)
dx=zeros(14,1);
% Defining the rate constants and Concentration Values
cSOD=10e-6;
cco2=1.14e-3;
cO2=35e-6;
cCAT=9e-7;
cPer=20e-6;
cGSHi=1e-3;% introduce initial Gsh here
cGPXRi=5e-6;
cNADPH=30e-6;
k1=1e-6;
k2=10e-6;
k3=0e-5;%Rate constant of gsh formation
k4=6.7e9;
k5=1.6e9;
k6=1.5e3;%k6=1.35e3;
k7=2e6; %Hydrolysis of ONOO- by GPXr
k8=5.8e4;
k9=3.2e6;
k10=9e8;%k10=3e8;
k11=6.6e7;
k12=2.4e6;
k13=1.6e3;
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k14=2.1e7; % Hydrolysis of H2O2 by GPXr
k15=4e4;
k16=1e7;
k17=5.5e-3;
k18=8e7;
k19=3.4e7;
k20=1.3e7; % Rate constant for H2O2 hydrolysis with peroxiredoxin
k21=1e7; %Rate constant for ONOO- hydrolysis by peroxyredoxin
%--------------------------------------------------------------------% Defining the rate equations
dx(1)=k1+k17*x(4)*x(6)-k4*(x(1))*x(2)-4*k12*cO2*((x(1))^2);%Rate of change of NO
dx(2)=k2-k4*x(1)*x(2)-k5*cSOD*x(2)-k10*x(2)*((x(4))^2)-(k18*((x(2))^2)*0.0025);%Rate of
change of O2dx(3)=k4*x(1)*x(2)-k6*x(6)*x(3)-k7*x(10)*x(3)-k8*cco2*x(3)-0.5625*k21*cPer*x(3);%Rate
of Change of ONOOdx(4)=cGSHi-x(6)-2*x(12)-x(9)-x(4);%Rate of Change of GSNO
dx(5)=2*k12*cO2*((x(1))^2)-k11*x(5)*x(6)-k13*x(5);%Rate of Change of N2O3
dx(6)=k3+2*k9*x(12)*cNADPH-k11*x(5)*x(6)-k6*x(6)*x(3)-k15*x(6)*x(8)-k16*x(6)*x(9)k17*x(4)*x(6);%Rate of Change of GSH
dx(7)=k5*(1/2)*cSOD*x(2)-k14*x(7)*x(10)+(k18*((x(2))^2)*0.0025)-(0.01*k19*x(7)*cCAT)k20*cPer*x(7);%Rate of Change of H2O2
dx(8)=k14*x(7)*x(10)-k15*x(6)*x(8)+k7*x(10)*x(3);%Rate of Change of GPXo
dx(9)=cGPXRi-x(10)-x(8)-x(9);
dx(10)=k16*x(9)*x(6)-k14*x(7)*x(10)-k7*x(10)*x(3);%Rate of Change of GPXr
dx(11)=k7*x(3)*x(10)+k10*x(2)*((x(4))^2)+k11*x(5)*x(6)+k17*x(4)*x(6);%Rate of Change
of ONOdx(12)=0.499*k6*x(6)*x(3)+k16*x(9)*x(6)+k17*x(4)*x(6)+k10*((x(4)^2))*x(2)k9*cNADPH*x(12); %Rate of Change of GSSG
dx(13)=k1+k17*x(5)*x(6);%NO production
dx(14)=k2;%O2- Production
%---------------------------------------------------------------------
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ABSTRACT
COMPUTATIONAL ANALYSIS OF OXIDATIVE STRESS MEDIATED ENDOTHELIAL
DYSFUNCTION: INSIGHTS ON THE ROLE OF TETRAHYDROBIOPTERIN, ASCORBATE
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Oxidative stress and endothelial dysfunction are reported in the cardiovascular and
neurovascular diseases. Oxidative stress is caused due to an increase in the generation of reactive
oxygen (ROS) and nitrogen species (RNS) and incapacity of antioxidant systems to eliminate ROS
and RNS. Endothelial dysfunction is characterized by a reduction in nitric oxide (NO)
bioavailability. NO is constitutively produced by enzyme endothelial nitric oxide synthase
(eNOS). A reduction in tetrahydrobiopterin (BH4), which is an essential cofactor of eNOS, can
lead to eNOS uncoupling. There is complex interplay between the ROS/RNS and antioxidant
system underlying pathophysiologies of vascular diseases, however our quantitative understanding
of the oxidative stress and these biochemical species in endothelial cell is not complete. The overall
objective of this dissertation is to investigate mechanistically the complex interactions of eNOS
uncoupling, cellular oxidative stress, BH4 bioavailability and antioxidant levels in endothelial
cells. We developed a series of mathematical models for eNOS biochemical pathway and
downstream reactions involving interactions of ROS/RNS with antioxidant systems. Using these
models, we investigated the effects of BH4 synthesis, ascorbate (ASC) and glutathione (GSH) on

162
cellular ROS and RNS. Our model results showed that variations in the generation rates of
superoxide (O2•-) and NO produces a wide range of outcomes for ROS/RNS levels that determines
the cellular levels of oxidative stress. Variation in endothelial cell oxidative stress levels increases
the extent of eNOS uncoupling and introduces instabilities in the eNOS based NO / O2•- production
rate. ASC supplementation removed these instabilities and resulted in improved NO and BH4

bioavailability. Enhancement of BH4 synthesis also showed improvement in eNOS uncoupling and
NO production rate. ASC supplementation also resulted in increasing RNS level such as peroxynitrite
(ONOO-). The GSH and glutathione peroxidase (GPX) kept in check the levels of ROS/RNS including
ONOO- and hydrogen peroxide (H2O2) and resulted in decreasing cellular oxidative stress.

Collectively, these models provide qualitative information about ROS/RNS levels in endothelial
dysfunction. In addition, the therapeutic potential of cofactors, substrates and antioxidants can be
analyzed using these models for effective treatments as well as earlier intervention in treating
cardiovascular and neurovascular diseases.
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